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ABSTRACT	  The	  vascular	  system	  delivers	  oxygen	  and	  nutrients	   to	   tissues	   throughout	   the	  developing	  organism,	   including	   the	   nervous	   system.	   Vice	   versa,	   the	   nervous	   system	   innervates	  resistance	  arteries	  to	  modulate	  vascular	  function.	  The	  two	  systems	  share	  several	  guidance	  cues	  and	  cell-­‐surface	  receptors.	  One	  receptor	  is	  neuropilin	  1	  (NRP1),	  which	  is	  present	  on	  blood	  vessels	  and	  neurons.	  	  The	   sympathetic	   nervous	   system	   is	   a	   neural	   crest	   cell	   (NCC)-­‐derived	   structure	   that	  innervates	   the	   heart	   and	   blood	   vessels	   to	   modulate	   heart	   rate	   and	   vasoconstriction.	  Semaphorin3A	   (SEMA3A)	   signals	   through	   NRP1	   to	   pattern	   the	   axonal	   projections	   of	  sympathetic	   nerves.	   I	   show	   here	   that	   this	   signalling	   pathway	   also	   controls	   the	   earliest	  stage	  of	  sympathetic	  nervous	  system	  development	   -­‐	  sympathetic	  NCC	  migration	  through	  the	  somites.	  Accordingly,	  sympathetic	  NCCs	  stray	  into	  ectopic	  territories	  and	  differentiate	  into	   sympathetic	   neurons	   in	  mice	  with	   disrupted	  NRP1/SEMA3A	   signalling.	   I	   also	   show	  that	  NRP2/SEMA3F	  signalling	  provides	  a	  backup	  pathway	  for	  NRP1/SEMA3A	  signalling	  in	  sympathetic	  NCC	  guidance.	  I	  further	  show	  defective	  sympathetic	  innervation	  of	  the	  heart	  and	  dorsal	  aorta	  in	  postnatal	  mice	  with	  disrupted	  NRP1/SEMA3A	  signalling	  and	  describe	  a	  previously	   unidentified	   role	   for	   NRP2	   in	   sympathetic	   axon	   guidance.	   I	   found	   that	   the	  recently	  discovered	  SEMA3G	  does	  not	  play	  a	  part	  in	  sympathetic	  axon	  guidance	  to	  target	  arteries,	  despite	  its	  unique	  arterial	  expression.	  	  The	   alternative	   NRP1	   ligand,	   a	   vascular	   endothelial	   growth	   factor	   isoform	   termed	  VEGF164,	   is	   essential	   for	   the	   sprouting	   of	   new	   blood	   vessels	   from	   existing	   ones	   in	   a	  process	   called	   angiogenesis.	   A	   large	   body	   of	   in	   vitro	   evidence	   suggests	   that	   heparan	  sulphate	   proteoglycans	   (HSPGs)	   are	   required	   for	   VEGF164-­‐driven	   angiogenesis	   by	  promoting	   its	   interaction	   with	   its	   receptors	   VEGFR1,	   VEGFR2	   and	   NRP1.	   In	   vivo	   data	  supporting	  the	  idea	  that	  HSPGs	  are	  essential	  for	  angiogenesis,	  however,	  are	  sparse.	  I	  here	  found	   that	   mouse	   embryos	   lacking	   enzymes	   required	   for	   the	   sulphation	   of	   HSPGs,	   or	  lacking	  enzymes	  essential	   for	  HSPG	  production	   in	  specific	  cells,	  had	  no	  obvious	  vascular	  branching	  defects	  in	  the	  hindbrain	  and	  do	  not	  phenocopy	  mutants	  lacking	  VEGF164.	  These	  observations	   suggest	   that	   HSPGs	   are	   not	   essential	   for	   VEGF164-­‐driven	   angiogenesis.	   In	  contrast,	   I	   found	   that	   the	   VEGF164/NRP1	   guided	   migration	   of	   facial	   branchiomotor	  neurons	  was	  dependent	  on	  the	  presence	  of	  HSPGs.	  	  Taken	  together,	  these	  results	  provide	  evidence	   for	   the	   differential	   requirement	   of	   HSPGs	   in	   VEGF164-­‐driven	   neural,	   but	   not	  endothelial	  cell	  patterning	  in	  the	  hindbrain.	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  system	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  VEGF	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  endothelial	  growth	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   VEGF	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CHAPTER	  1.	  INTRODUCTION	  	  The	   vascular	   system	   is	   essential	   for	   development	   of	   the	   vertebrate	   embryo.	   It	   delivers	  oxygen	  and	  nutrients	   to	  allow	  growth	  of	  all	  of	   the	   tissues	   in	   the	  organism,	   including	   the	  nervous	  system.	  Vice	  versa,	  the	  nervous	  system	  innervates	  resistance	  arteries	  to	  modulate	  vasculature	  function.	  In	  this	  thesis,	  I	  have	  firstly	  investigated	  the	  molecular	  control	  of	  the	  development	  of	  the	  sympathetic	  nervous	  system,	  which	  innervates	  the	  heart	  and	  arteries	  of	   the	   vascular	   system.	   I	   have	   paid	   particular	   attention	   to	   the	   neuropilins,	   signalling	  receptors	  involved	  in	  both	  angiogenesis	  and	  neurogenesis	  that	  bind	  both	  semaphorins	  and	  vascular	  endothelial	  growth	  factor	  (VEGF).	  Secondly,	   I	  have	  assessed	  the	  role	  of	  heparan	  sulphate	  proteoglycans	  in	  VEGF-­‐driven	  vascularisation	  and	  motor	  neuron	  migration	  in	  the	  developing	  mouse	  hindbrain.	  	  
	  
1.1	  Molecular	  mechanisms	   controlling	   the	   development	   of	   the	   sympathetic	  
nervous	  system	  	  
	  The	  sympathetic	  nervous	  system	  innervates	  a	  wide	  variety	  of	   targets,	   including	  exocrine	  and	   endocrine	   glands	   and	   ducts,	   smooth	   muscle	   layers	   of	   the	   intestine	   and	   pilomotor	  muscles,	  as	  well	  as	  smooth	  muscle	  layers	  of	  the	  blood	  vessels	  and	  the	  cardiac	  muscles	  and	  nodes	   of	   the	   heart,	   to	   initiate	   changes	   in	   response	   to	   stress.	   It	   consists	   of	   preganglionic	  and	  postganglionic	  neurons	  –	  the	  former	  being	  neuroectoderm-­‐derived	  nerves	  synapsing	  the	   central	   nervous	   system	   (CNS)	   to	   the	   latter.	   From	   here	   on,	   I	   will	   refer	   to	   the	  postganglionic	  sympathetic	  neurons	  simply	  as	  sympathetic	  neurons.	  They	  have	  cell	  bodies	  in	  aggregations	  known	  as	   sympathetic	  ganglia,	   and	  extend	  axons	   to	  distal	   locations.	  The	  paravertebral	  ganglia	   lie	   in	  bilateral	  chain	   formations	   in	   the	   trunk	  region,	  parallel	   to	   the	  vertebral	  column,	  and	  the	  prevertebral	  ganglia,	  forming	  the	  superior	  cervical	  ganglia,	  are	  in	  the	  cranium.	  Also	  part	  of	  the	  sympathetic	  nervous	  system	  are	  the	  chromaffin	  cells	  of	  the	  adrenal	  medulla.	  All	  sympathetic	  neurons	  are	  derived	  from	  neural	  crest	  cells.	  	  	  
1.1.1	  The	  Neural	  Crest	  The	  cells	  of	  the	  neural	  crest	  (NC)	  were	  first	  described	  in	  1868	  by	  the	  Swiss	  embryologist	  Wilhelm	  His,	  who	  initially	  named	  them	  ‘Zwischenstrang’	  –	  the	  intermediate	  cord.	  They	  are	  a	   transient	   population	   of	   multipotent	   cells	   fundamental	   and	   specific	   to	   developing	  vertebrates	  and	  give	  rise	  to	  a	  diverse	  range	  of	  cell	  types.	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Different	   subpopulations	   of	   neural	   crest	   cells	   (NCCs)	   exist,	   which	   are	   classified	   by	   the	  pattern	  of	  their	  emergence	  from	  the	  neural	  tube	  and	  the	  organ	  systems	  they	  contribute	  to:	  
• Cranial	  neural	  crest	  emerge	  from	  the	  hindbrain	  and	  give	  rise	  to	  neurons,	  glia	  and	  melanocytes,	  as	  well	  as	  cranial	  bones	  and	  connective	  tissue,	  of	  the	  head	  
• Cardiac	  neural	   crest	  emerge	  between	   the	  otic	  vesicle	  and	   the	   third	  somite	   in	   the	  mouse	   and	   give	   rise	   to	   autonomic	   neurons	   and	   glia,	   smooth	  muscle	   cells	   of	   the	  great	  vessels	  and	  melanocytes	  
• Trunk	  neural	  crest	  emerge	  from	  the	  spinal	  cord,	  between	  somites	  7	  and	  28	  in	  the	  mouse	  and	  give	  rise	  to	  sensory	  and	  sympathetic	  neurons,	  glia,	  chromaffin	  cells	  and	  melanocytes	  
• Vagal	  neural	  crest	  emerge	  in	  the	  neck,	  between	  somites	  1	  and	  7	  in	  the	  mouse	  and	  give	  rise	  to	  enteric	  neurons	  of	  the	  gut,	  glia	  and	  melanocytes	  
• Sacral	  neural	  crest	  emerge	  from	  the	  spinal	  cord,	  between	  somites	  7	  and	  28	  in	  the	  mouse	  and	  give	  rise	  to	  enteric	  neurons	  of	  the	  hindgut,	  glia	  and	  melanocytes	  	  
1.1.2	  Induction	  of	  Neural	  Crest	  
1.1.2.1	  Neurulation	  




Figure 1.1: Development of the neural tube.  
(A) The ectoderm is flat with defined areas of neural tissue (neuroectoderm, purple), non-neural 
tissue (ectoderm, blue) and neural plate border (green). (B) At the beginning of neural induction, 
the neuroectoderm folds and the neural plate is induced. Paraxial mesoderm is formed. (C) The 
neural folds come together and the neural tube begins to form. (D) The neural tube has closed, 
separated from the overlaying epidermis and aligned with the notochord. NCCs are induced 
from neural folds at dorsal aspect of neural tube, and are shown here delaminating. The 
somites have also formed from paraxial mesoderm (Diagram adapted from (Gammill and 
Bronner-Fraser, 2003)). 	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Signalling	   between	   the	   epidermal	   ectoderm	   and	   the	   newly	   formed	   neural	   tube	   initiates	  NCC	  induction	  soon	  after	  neural	  tube	  closure.	  Signals	  from	  the	  underlying	  mesoderm	  have	  also	  been	  implicated	  in	  the	  process,	  although	  are	  not	  thought	  to	  be	  essential,	  as	  ectoderm	  is	  able	  to	  compensate	  for	  loss	  of	  signals	  in	  the	  absence	  of	  mesoderm,	  shown	  by	  studies	  in	  zebrafish	  (Ragland	  and	  Raible,	  2004).	  Several	  morphogens	  are	  implicated	  in	  NC	  induction,	  including	   WNTs,	   bone	   morphogenetic	   proteins	   (BMPs)	   and	   fibroblast	   growth	   factors	  (FGFs),	  which	  act	  in	  concert.	  
1.1.2.2	  Morphogenetic	  induction	  signals	  WNTs:	  WNTs	  are	  multifunctional	  secreted	  signalling	  proteins	  that	  bind	  to	  receptors	  from	  the	   frizzled	   family	   (see	   (Schmidt,	   2008)	   for	   review)	   and	   are	   involved	   in	   two	   signalling	  pathways.	  The	  first	  is	  the	  canonical	  WNT	  pathway,	  which,	  briefly,	  involves	  activation	  of	  β-­‐catenin	  to	  stimulate	  TCF/LEF	  transcription	  factors.	  The	  second	  is	  the	  non-­‐canonical	  WNT	  pathway,	  which	   is	  β-­‐catenin	   independent.	  WNTs	  are	  expressed	   in	   the	  dorsal	  neural	   tube	  and	  are	  necessary	  and	  sufficient	  for	  NCC	  induction	  (Wu	  et	  al.,	  2003).	  It	  has	  recently	  been	  suggested	  that	  the	  specific	  family	  member	  required	  for	  this	  role	  is	  WNT6	  in	  chick	  (Schmidt	  et	  al.,	  2007).	  BMPs:	   	  BMPs	   are	   multifunctional	   secreted	   proteins	   best	   known	   for	   their	   function	   in	  dorsoventral	   patterning.	   BMP2,	   4	   and	   7,	   are	   expressed	   in	   epidermal	   ectoderm	   and	   are	  involved	   in	  neural	  crest	   formation	  (Liem	  et	  al.,	  1995).	  A	  BMP	  gradient	  develops	   through	  BMP	   interaction	   with	   antagonists,	   such	   as	   noggin,	   in	   the	   ectoderm	   that	   specifies	  dorsoventral	  patterning,	  with	  the	  neural	  plate	  border	  cells,	  NCCs,	  forming	  at	  intermediate	  levels	  of	  BMP	  signalling.	  The	  specific	  role	  for	  BMPs	  in	  NCC	  induction	  itself,	  however,	  is	  still	  debated.	   A	   recent	   study	   provides	   evidence	   for	   the	   interplay	   between	   WNTs	   and	   BMP	  signalling	   in	  neural	  crest	   induction:	  an	  initial	  stage	  of	   induction	  requires	  WNT	  activation	  alongside	  BMP	  inhibition,	  then	  a	  second	  stage	  requires	  the	  activation	  of	  both	  pathways	  for	  the	  maintenance	  of	  the	  process	  (Steventon	  et	  al.,	  2009).	  FGFs:	   	  FGFs	   are	   multifunctional	   secreted	   proteins	   widely	   involved	   in	   embryonic	  development,	   growth	   regulation	   and	  morphogenesis.	   They	   are	   known	   to	   function	   in	   the	  induction	   of	   NCCs,	   albeit	   indirectly	   as	   modifiers	   of	   the	   WNT	   pathway,	   and	   FGF8	   in	  particular	  is	  implicated	  (Monsoro-­‐Burq	  et	  al.,	  2005).	  Notch	   ligands:	  Serrate	  and	  Delta	  protein	   ligands	  bind	   to	  Notch	  receptors	   to	  regulate	  cell	  fate	   decisions.	   In	   contrast	   to	   WNT/BMP/FGF	   signalling,	   Notch	   signalling	   results	   from	  direct	  cell-­‐cell	  contact	  and	  downstream	  signalling	  occurs	  in	  adjacent	  cells	  only.	  The	  Notch	  signalling	   pathway	   has	   two	   suggested	   roles	   in	   NCC	   development;	   firstly	   in	   induction,	  although	   a	   specific	   role	   in	   mouse	   trunk	   NCC	   is	   yet	   to	   be	   shown,	   and	   later	   in	   cell	   fate	  diversification	  (Cornell	  and	  Eisen,	  2005).	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Retinoic	  acid:	  Retinoic	  acid	  has	  also	  been	  suggested	  to	  have	  a	  role	  in	  NCC	  induction	  as	  it	  is	  able	  to	   induce	  NCCs	  from	  neural	   fold	  tissue	   in	  an	   in	  vitro	   induction	  model	  (Villanueva	  et	  al.,	  2002).	  	  
1.1.2.3	  NC-­specifying	  transcription	  factors	  The	   induction	   of	   NCCs	   by	   morphogenetic	   signals	   is	   followed	   by	   expression	   of	   NC-­‐specifying	   transcription	   factors,	   which	   promote	   continuing	   NCC	   generation.	   These	   are	  discussed	  below.	  SNAIL/SLUG:	   SNAIL	   (SNAI1),	   a	   zinc	   finger	   transcription	   factor,	   and	   its	   close	   relative	  SLUG	  (SNAI2)	  are	  involved	  at	  several	  stages	  in	  NCC	  development,	  such	  as	  specification	  and	  induction	  via	  the	  WNT	  pathway.	  They	  are	  expressed	  specifically	  in	  NCCs	  and	  can	  therefore	  be	  utilised	  as	  NC	  markers	  (Hemavathy	  et	  al.,	  2000).	  FOXD3:	  	   FOXD3	  is	  a	  winged-­‐helix	  transcription	  factor	  also	  specific	  to	  NCCs,	  and	  has	  been	   shown	   to	   function	   as	   a	   transcriptional	   activator	   for	   genes	   involved	   in	   cell	  multipotency.	  (Dottori	  et	  al.,	  2001;	  Kos	  et	  al.,	  2001)	  SOX9/SOX10:	   The	  group	  E	  Sox	  proteins,	  SOX8,	  9	  and	  10,	  are	  high-­‐mobility	  group	  (HMG)-­‐domain	   transcriptional	   activators	   with	   multiple	   and	   overlapping	   functions	   in	  development.	   In	   particular,	   SOX9	   is	   required	   for	   NCC	   induction	   and	   delamination	   and	  subsequent	   survival	   (Cheung	   et	   al.,	   2005)	   and	   SOX10	   is	   required	   for	   NCC	   induction,	  specification	   and	  differentiation	   (Carney	  et	   al.,	   2006;	  Kelsh,	   2006;	   Southard-­‐Smith	   et	   al.,	  1998).	   Later,	   SOX9	   and	   SOX10	   synergise	   with	   other	   transcription	   factors	   to	   initiate	  differentiation	  in	  NCCs	  (Cheung	  and	  Briscoe,	  2003).	  PAX:	  	   	   The	   PAX	   transcriptional	   activators	   are	   stimulated	   at	   this	   point,	   although	  they	   are	   not	   NCC-­‐	   specific	   as	   they	   are	   also	   expressed	   in	   the	   neural	   plate	   environment	  (Wang	  et	  al.,	  2008).	  	  ZIC:	  	   	   The	  Zic	   family	  of	  zinc-­‐finger	   transcription	   factors,	  also	  expressed	   in	  NCCs	  and	  the	  neural	  plate,	  are	  thought	  to	  be	  involved	  in	  proliferation	  and	  specification	  of	  NCCs	  (Nakata	  et	  al.,	  1998).	  AP2:	  	   	   There	  are	  some	  additional	  NCC	  markers	  that	  are	  also	  expressed	  in	  the	  non-­‐neural	  ectoderm,	  such	  as	  the	  transcription	  factor	  Ap2	  (Mitchell	  et	  al.,	  1991).	  	  
1.1.3	  Delamination	  Once	   NCCs	   have	   been	   fully	   induced,	   they	   are	   situated	   in	   the	   dorsal	   neural	   tube	   as	  epithelial-­‐like	  cells	  and	  adopt	  a	  regular	  and	  elongated	  shape.	  Delamination	  is	  the	  process	  by	  which	   the	  NCCs	   leave	   the	   dorsal	   neural	   tube	   at	   around	   E8.5	   of	  mouse	   development.	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They	   undergo	   epithelial-­‐to-­‐mesenchymal	   transition	   (EMT),	   literally	   a	   transition	   of	   the	  cells	   from	   a	   two-­‐dimensional	   organisation	   in	   the	   neural	   epithelium	   into	   a	   three-­‐dimensional	   mesenchymal-­‐like	   organisation	   (Nakaya	   and	   Sheng,	   2008).	   EMT	   occurs	   in	  many	  other	  processes,	  both	   in	  normal	  embryogenesis	  and	  adulthood,	   for	  example	   tissue	  repair	  and	  tumour	  metastasis.	  EMT	  in	  delaminating	  NCCs	   is	   tightly	  controlled,	  primarily,	  although	   not	   exclusively,	   by	   SNAIL	   and	   SLUG.	   SOX9	   and	   FOXD3	   are	   involved	   in	   EMT	  activation,	  working	  synergistically	  with	  SNAIL	  and	  SLUG	  (Cheung	  et	  al.,	  2005;	  Sakai	  et	  al.,	  2006).	   BMPs	   also	   take	   part,	   most	   prominently	   BMP4	   in	   chick,	   which	   acts	   through	   the	  upregulation	  of	  RhoB,	  a	  RhoGTPase	  that	  modulates	  cell	  dynamics	  (Groysman	  et	  al.,	  2008).	  Together	   these	   proteins	   bring	   about	   EMT	   by	   breaking	   adherens	   and	   tight	   junctions	  through	  regulation	  of	  adhesion	  proteins	  on	  NCCs.	  Thus,	  a	  switch	  in	  the	  expression	  mixture	  of	   integrins	   and	   cell	   adhesion	   molecules	   on	   the	   NCCs	   takes	   place,	   with	   the	   down-­‐regulation	  of	  N-­‐CAM,	  N-­‐cadherin	   and	  E-­‐cadherin,	   and	   a	   concomitant	   down-­‐regulation	  of	  cadherin-­‐6b	  and	  up-­‐regulation	  of	  cadherin-­‐7	  in	  chick	  (Taneyhill	  et	  al.,	  2007).	  Claudins	  and	  occludin	  are	  also	  repressed,	  according	  to	  cell	  culture	  work	  (Ikenouchi	  et	  al.,	  2003).	  These	  changes	  allow	  the	  NCCs	  to	  completely	  dissociate	  from	  the	  epithelial	  sheet.	  The	  neural	  tube	  epithelium,	   however,	   does	   not	   seem	   to	   be	   disrupted	   by	   EMT;	   it	   remains	   intact,	   which	  further	   demonstrates	   the	   tight	   regulation	   of	   the	   process	   (for	   review	   (Duband,	   2006)).	  During	  delamination,	  the	  morphology	  of	  the	  NCCs	  changes	  dramatically,	  and	  they	  become	  irregular	  in	  shape	  and	  extend	  filopodia	  at	  the	  leading	  edge.	  	  
1.1.4	  Migration	  Once	   trunk	  NCCs	  have	  emerged	   from	   the	  neural	   tube,	   they	  aggregate	   in	  an	  extracellular	  matrix-­‐rich	   area	   called	   the	  migration	   staging	   area,	   located	  between	   the	  neural	   tube,	   the	  dorsal	   somite	   and	   the	   surface	   epithelium	   (Weston,	   1991).	   From	  here	   the	  NCCs	   undergo	  significant	  migratory	  movements,	   commencing	   just	   before	  E9.0	   in	   the	  mouse,	  which	   are	  highly	   directional	   and	   ordered.	   It	   has	   been	   proposed	   that	   NCCs	   migrate	   by	   ‘contact	  inhibition’	   that	   is	   controlled	   by	  WNT	   proteins	   and	   their	   frizzled	   receptors	   via	   the	   non-­‐canonical	  planar	  cell	  polarity	  (PCP)	  pathway,	  in	  which	  PCP	  factors	  polarise	  a	  field	  of	  cells	  along	   an	   axis,	   and	   cause	   cytoskeletal	   changes	   that	   lead	   to	   migration	   through	   the	   small	  GTPases	  RhoA	  and	  Rac	  (for	  review	  (Alfandari	  et	  al.,	  2010)).	  WNT11	  in	  particular	  has	  been	  implicated	   in	   Xenopus	   (De	   Calisto	   et	   al.,	   2005),	   and	   syndecan4,	   a	   heparan	   sulphate	  proteoglycan,	  also	  contributes	  to	  PCP-­‐controlled	  directional	  migration	  by	   influencing	  the	  orientation	  of	  cell	  protrusions	  (Matthews	  et	  al.,	  2008).	  	  By	   this	   stage	   in	   development,	   the	   somites	   have	   formed.	   These	   are	   paired	   masses	   of	  mesoderm	   that	   are	   segmentally	   arranged	   along	   the	   anteroposterior	   axis	   of	   the	   early	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vertebrate	   embryo.	   Somites	   are	   composed	   of	   three	   layers:	   sclerotome,	   which	   forms	  vertebral	  structures,	  myotome,	  which	  forms	  muscle,	  and	  dermotome,	  which	  forms	  dermis.	  	  
1.1.4.1	  Migration	  patterns	  Live	   imaging	   of	   NC	  migration	   (for	   example	   (Kasemeier-­‐Kulesa	   et	   al.,	   2005))	   has	   shown	  that	   NCCs	   initially	   emerge	   from	   the	   neural	   tube	   in	   an	   unsegmented	   manner,	   but	  subsequently	  migrate	   in	  distinct	   streams	  along	  different	  paths	   through	   the	  embryo	   (Fig.	  1.2).	  The	  first	  group	  of	  trunk	  NC	  begins	  migration	  at	  about	  E8.75	  and	  travels	  ventrally	  and	  medially	   along	   a	   ‘ventromedial’	   pathway,	   avoiding	   the	  more	   superficial	   dermotome	   and	  myotome	  (dermomyotome)	  layers.	  These	  are	  referred	  to	  as	  early	  wave	  NCCs,	  and	  move	  between	  adjacent	  somites,	   in	  the	  intersomitic	  boundary,	  following	  the	  intersomitic	  blood	  vessels.	  The	  bulk	  of	  the	  NCCs	  on	  the	  ventromedial	  path	  migrates	  slightly	  later	  and	  travels	  through	  the	  anterior	  half	  of	  the	  sclerotome	  of	  each	  somite,	  avoiding	  the	  posterior	  half	  and	  the	   dermomyotome	   layers	   (Bronner-­‐Fraser,	   1986;	   Rickmann	   et	   al.,	   1985).	   These	   are	  referred	  to	  as	  intermediate	  wave	  NCCs.	  The	  remainder	  of	  the	  cells,	  having	  delaminated	  later	  or	  waited	  in	  the	  migration	  staging	  area	  for	  about	  one	  day	  of	  development,	  form	  the	  




Figure 1.2: Stages and patterns of NCC migration.  
At E8.75, the early wave of NCCs have delaminated from the neural tube (nt; A) into the 
migration staging area along the dorsal neural tube (B). At E9.0, they begin to migrate through 
the ventromedial pathway (as in C), a few along the intersomitic boundary but mostly through 
the anterior half of each somite, with the posterior somite and dermomyotome layers kept NCC-
free (as in D). The earliest of these NCCs arrest migration at the dorsal aorta (da) at E9.5 to 
seed the primary sympathetic ganglia (psg), and differentiate into sympathetic precursors (C,D). 
At E10.5, the sympathetic precursors undergo a secondary migratory movement away from the 
dorsal aorta (E), differentiate into mature sympathetic neurons and form the sympathetic ganglia 
(sg) of the sympathetic chain (sc; F). Other NCCs on the ventromedial pathway arrest further 
dorsally to form the dorsal root ganglia (drg). n, notochord.  	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The	  segmental	  migration	  pattern	  of	  the	  trunk	  NC	  through	  the	  anterior	  sclerotome	  places	  the	  NCCs	  in	  the	  correct	  location	  for	  further	  development	  into	  neurons	  of	  the	  sympathetic	  ganglia	  or	  sensory	  neurons	  of	  the	  DRG.	  Similarly,	  but	  independently	  of	  NCCs,	  once	  motor	  neuron	   axons	   emerge	   from	   the	   neural	   tube,	   they	   enter	   only	   the	   anterior	   half	   of	   each	  somite	  (Keynes	  and	  Stern,	  1984;	  Rickmann	  et	  al.,	  1985).	  The	  significance	  of	  this	  segmental	  migration	   pattern	   on	  DRG	   formation	  was	   initially	   illustrated	   by	   grafting	   experiments	   in	  chick;	   correct	   morphogenesis	   and	   segmentation	   of	   the	   DRG	   does	   not	   occur	   when	   the	  anteroposterior	  migration	  pattern	   is	  disrupted	  by	   transplantation	   (Kalcheim	  and	  Teillet,	  1989).	  
1.1.4.2	  Transcriptional	  control	  A	  complex	  network	  of	  signals	  regulates	  NCC	  migration	  (for	  review	  (Kulesa	  et	  al.,	  2009)).	  Fundamental	  co-­‐ordinators	  for	  NCC	  migration	  are	  the	  previously	  described	  transcription	  factors	  SOX10	  and	  FOXD3.	   In	   the	  mouse,	  whereas	  SOX9	   is	  specific	   to	  pre-­‐migratory	  NCC	  (Cheung	   et	   al.,	   2005),	   SOX10	   is	   expressed	   in	   migratory	   NCC	   as	   it	   is	   required	   for	  multipotency	  and	  specification	  of	  the	  different	  NCC	  fates	  (Carney	  et	  al.,	  2006;	  Cheng	  et	  al.,	  2000;	   Kelsh,	   2006).	   FOXD3	   regulates	   the	   expression	   of	   cell-­‐cell	   adhesion	   molecules	  required	  for	  migration	  (Cheung	  et	  al.,	  2005),	  for	  example	  cadherins	  and	  integrins.	  
1.1.4.3	  Migration	  guidance	  cues	  Both	  permissive	  and	  inhibitory	  signals	  from	  the	  extracellular	  matrix	  guide	  migration,	   for	  example	   fibronectin	   (Rovasio	   et	   al.,	   1983)	   and	   F-­‐spondin	   (Debby-­‐Brafman	   et	   al.,	   1999),	  respectively.	  Additionally,	   a	  host	   of	  mesenchymally-­‐derived	  proteins,	   initially	   known	   for	  their	   axon	   guidance	   functions,	   have	   now	   been	   shown	   to	   provide	   attractive	   or	   repulsive	  cues	  to	  guide	  NCC	  migration	  through	  their	  respective	  receptors	  expressed	  by	  trunk	  NCCs	  (for	  review	  (Kuriyama	  and	  Mayor,	  2008)).	  These	  are	  discussed	  below.	  	  Ephrins/Ephs:	  	  Based	  on	  research	  showing	  the	  action	  of	  ephrins	  and	  their	  Eph	  receptors	  in	  repulsive	  axon	  guidance,	  ephrin	   ligands	  secreted	  by	   the	  caudal	  half	  of	  each	  somite	  were	  found	   to	   repel	   migrating	   trunk	   NCCs	   in	   vitro,	   which	   express	   Eph	   receptors	   (Wang	   and	  Anderson,	   1997).	   In	   vivo	   work	   in	   chick	   demonstrated	   that	   transmembrane	   ephrinB1,	  expressed	  in	  the	  caudal	  sclerotome,	  prevents	  NCCs	  that	  express	  its	  receptor	  Eph-­‐B3	  from	  entering	  the	  caudal	  somite	  (Krull	  et	  al.,	  1997).	  EphrinB	  ligands	  also	  prevent	  early	  ventrally	  migrating	   NCCs	   from	   entering	   the	   dorsolateral	   pathway	   through	   their	   Eph-­‐B	   receptors,	  but	  conversely,	   then	  promote	  migration	  of	  melanocyte-­‐fated	  NCCs	  along	  the	  dorsolateral	  pathway	  (Santiago	  and	  Erickson,	  2002).	  Semaphorins/neuropilins:	   Class	   3	   semaphorins	   are	   well-­‐established	   axonal	   guidance	  molecules.	  Semaphorin3A	  (SEMA3A)	  signalling	  through	  its	  neuropilin	  1	  (NRP1)	  receptor	  has	  been	  implicated	  as	  a	  repulsive	  cue	  in	  NCC	  migration	  in	  in	  vitro	  assays	  (Eickholt	  et	  al.,	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1999),	  and	  SEMA3A/NRP1	  signalling	  acts	  as	  a	  repulsive	  cue	  for	  cranial	  NCC	  migration	  in	  chick	   (McLennan	   and	   Kulesa,	   2007;	   Osborne	   et	   al.,	   2005)	   and	   mouse	   (Schwarz	   et	   al.,	  2008a),	  but	  was	  reported	  to	  have	  no	  effect	  in	  mouse	  trunk	  NCC	  migration	  (Kawasaki	  et	  al.,	  2002).	   SEMA3F,	   expressed	   in	   the	   caudal	   sclerotome,	   prevents	   trunk	   NCCs	   expressing	  NRP2	   from	   entering	   the	   rostral	   somite	   (Gammill	   et	   al.,	   2006).	   Semaphorins	   and	   their	  neuropilin	  receptors	  will	  be	  discussed	  in	  more	  detail	   later	  in	  the	  chapter,	  as	  their	  role	  in	  mouse	  NCC	  migration	  was	  a	  major	  focus	  of	  this	  thesis.	  	  Slits/Robos:	  	   In	  chick,	  Slit2	  is	  produced	  by	  mesenchyme	  surrounding	  the	  gut,	  and	  acts	  as	  a	  chemorepellant,	  preventing	  trunk	  NCCs	  which	  express	  Robo1	  and	  Robo2	  receptors	  from	  entering	  the	  gut	  (De	  Bellard	  et	  al.,	  2003).	  It	  also	  speeds	  up	  their	  migration	  away	  from	  the	  Slit2-­‐positive	   area.	   Vagal	   NCCs	   destined	   for	   the	   enteric	   nervous	   system	   do	   not	   express	  Robo1	   and	   Robo2	   and	   can	   therefore	   penetrate	   the	   gut	   and	  migrate	   its	   entire	   length	   to	  populate	  it	  (De	  Bellard	  et	  al.,	  2003).	  Additionally,	  Slit2	  is	  produced	  in	  the	  dermomyotome	  during	  early	  NCC	  migration,	  and	  predominantly	  through	  the	  Robo1	  receptor	  helps	  confine	  early	  migrating	  NCCs	  to	  their	  ventromedial	  pathway.	  Experiments	   in	  chick	  found	  ectopic	  NCC	   migration	   along	   the	   dorsolateral	   route	   at	   early	   stages	   when	   a	   dominant	   negative	  Robo1	  receptor	  was	  expressed	  in	  early	  NCC	  (Jia	  et	  al.,	  2005).	  	  Stromal	  cell	  derived	  factor	  (SDF)-­‐1/CXCR4:	   The	   chemokine	   SDF-­‐1	   acts	   as	   an	   attractive	  cue	  for	  CXCR4-­‐expressing	  sympathetic	  NCCs	  to	  migrate	  ventrally	  towards	  the	  dorsal	  aorta,	  segregating	   them	   from	   NCCs	   destined	   for	   the	   dorsal	   root	   ganglia	   in	   chick	   (Kasemeier-­‐Kulesa	  et	  al.,	  2010).	  In	  mice,	  CXCR4	  is	  thought	  to	  be	  expressed	  by	  sensory	  NC	  populations	  destined	   for	   the	   DRG,	   and	   DRGs	   in	   mice	   lacking	   CXCR4	   are	   disorganised,	   however	   the	  sympathetic	   ganglia	  were	   not	   examined	   (Belmadani	   et	   al.,	   2005).	   It	   has	   been	   suggested	  that	  in	  vitro	  SDF-­‐1	  also	  modulates	  semaphorin	  signalling	  in	  axons	  (Chalasani	  et	  al.,	  2003),	  which	   may	   provide	   a	   mechanism	   for	   NCC	   migration	   through	   SEMA3A-­‐expressing	  mesenchyme.	  	  Netrins/DCC:	  	   Netrins	   have	   been	   shown	   to	   attract	   migrating	   NCCs	   through	   the	   DCC	  receptor	   in	   vagal	   regions	   of	   the	   chick	   and	  mouse	   (Jiang	   et	   al.,	   2003),	   although	   there	   is	  currently	  no	  evidence	  for	  a	  role	  for	  netrins	  in	  migrating	  NCCs	  in	  the	  trunk	  region.	  	  Neuregulin-­‐1/ErbB2/3:	   Sympathetic-­‐fated	   NCCs	   require	   mesenchymally-­‐expressed	  Neuregulin-­‐1	   signalling	   through	   its	   tyrosine	   kinase	   receptor	   complex	   ErbB2/ErbB3	   for	  correct	  migration	  of	  NCCs	  and	  for	  aggregation	  of	  sufficient	  numbers	  of	  NCCs	  at	  the	  dorsal	  aorta	   (Britsch	   et	   al.,	   1998).	   Mice	   lacking	   neuregulin-­‐1,	   ErbB2	   or	   ErbB3	   therefore	   have	  hypoplasia	  of	  the	  sympathetic	  nervous	  system.	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1.1.5	  Sympathetic	  Nervous	  System	  Development	  
1.1.5.1	  Differentiation	  into	  sympathetic	  precursors	  As	   previously	   mentioned,	   the	   first	   of	   the	   early	   wave	   trunk	   NCCs	   migrating	   along	   the	  ventromedial	   pathway	   are	   destined	   to	   become	   sympathetic	   neurons	   and	   aggregate	  proximal	  to	  the	  dorsal	  aorta.	  Once	  arrived,	  at	  around	  E9.5	  in	  the	  mouse,	  it	  is	  thought	  that	  dorsal	  aorta-­‐derived	  BMP2,	  4	  and	  7	  signalling	   initiates	  differentiation	  of	   these	  NCCs	   into	  sympathetic	  precursors	  (Schneider	  et	  al.,	  1999;	  Shah	  et	  al.,	  1996).	  However,	  studying	  this	  process	  is	  difficult,	  as	  BMP	  knockout	  mice	  die	  early	  in	  development	  (for	  example	  (Luo	  et	  al.,	  1995)).	  In	  mice	  lacking	  ALK3	  in	  NCCs,	  a	  BMP	  receptor,	  sympathetic	  NCCs	  differentiate	  but	   die	   at	   E10,	   providing	   evidence	   for	   BMPs	   not	   inducing	   differentiation,	   but	   being	  survival	   factors	   for	   NCCs	   (Morikawa	   et	   al.,	   2009).	   Consistent	   with	   this,	   CASH1,	   a	  sympathetic	   NCC	   specifier	   in	   chick,	   is	   switched	   on	   in	   NCCs	   before	   BMP4	   in	   chick,	  suggesting	   that	   BMPs	   are	   not	   essential	   for	   differentiation	   into	   a	   sympathetic	   fate	  (McPherson	  et	  al.,	  2000).	  	  NCC	   differentiation	   is	   achieved	   via	   activation	   of	   a	   complex	   interplay	   of	   transcription	  factors	   in	   NCC	   (Huber,	   2006;	   Reissmann	   et	   al.,	   1996;	   Schneider	   et	   al.,	   1999)	   (Fig.	   1.3).	  These	   include	   the	   mammalian	   achaete-­‐scute	   homolog	   1	   (MASH1),	   the	   paired	  homeodomain	   proteins	   PHOX2B	   (Pattyn	   et	   al.,	   1999)	   and	   PHOX2A	   (Morin	   et	   al.,	   1997),	  basic	  helix-­‐loop-­‐helix	  factor	  HAND2	  (Morikawa	  et	  al.,	  2007)	  and	  zinc-­‐finger	  factor	  GATA3	  (Tsarovina	  et	  al.,	  2004).	  MASH1	  and	  PHOX2B	  are	  essential	   for	  autonomic	  differentiation	  and	  are	  markers	  for	  the	  precursory	  sympathetic	  neuronal	  state.	  Briefly,	  it	  is	  thought	  that	  PHOX2B	  activates	  or	  maintains	  MASH1;	  together,	  they	  both	  activate	  PHOX2A,	  and	  through	  separate	  pathways	  also	  aid	  in	  the	  progression	  towards	  a	  sympathetic	  neuronal	  cell	  fate	  via	  HAND2	   and	   GATA3	   (for	   review	   (Huber,	   2006)).	   The	   sympathetic	   precursors	   form	   two	  primary	  sympathetic	  chains,	  loosely	  arranged	  ganglia	  bilaterally	  flanking	  the	  dorsal	  aorta.	  
1.1.5.2	  Further	  migration	  and	  differentiation	  	  After	   induction	   into	   sympathetic	   precursors,	   a	   secondary	  migration	   step	   takes	   place	   in	  which	   the	   precursors	  migrate	   away	   slightly	   from	   the	   dorsal	   aorta	   and	   differentiate	   into	  either	  sympathetic	  neurons	  or	  chromaffin	  cells	  of	  the	  adrenal	  medulla,	  depending	  on	  their	  location	  in	  the	  trunk	  (Anderson	  et	  al.,	  1991;	  Ernsberger	  et	  al.,	  1995)	  (Fig.	  1.3).	  The	  mature	  sympathetic	   neurons	   become	   more	   closely	   associated	   and	   form	   the	   ganglia	   of	   the	  sympathetic	   chain,	   and	   begin	   to	   express	   neuronal	   and	   catecholaminergic	   markers	  (Cochard	  et	  al.,	  1978).	  Tyrosine	  hydroxylase	  (TH),	  an	  enzyme	  required	  for	  the	  synthesis	  of	  noradrenalin	   by	   neurons,	   is	   produced,	   as	   well	   as	   dopamine	   beta-­‐hydroxylase.	   General	  neuronal	   markers	   also	   start	   to	   be	   expressed	   at	   this	   time,	   such	   as	   neurofilaments	   (NF),	  intermediate	   filaments	   specific	   to	   neurons,	   and	   SCG10,	   a	   membrane-­‐bound	   protein	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Figure 1.3: Transcription factors and markers involved in sympathetic neuron 
development from NCCs.  
Sox10 is expressed by sympathetic NCCs once they delaminate from the neural tube at E8.75 
and expression is continued during NCC migration through the somite. Sympathetic NCCs 
arrest migration at the dorsal aorta at E9.5, where they differentiate into primary sympathetic 
anlagen and express Mash1, Phox2b and later Hand2 whilst still expressing Sox10. At E10.5 
the sympathetic anlagen migrate away from the dorsal aorta and mature into sympathetic 
neurons. The Sox10, Mash1, Phox2b and Hand2 transcription factors are switched off and the 
neurons express sympathetic-specific tyrosine hydroxylase (TH) and neuronal markers such as 
neurofilament (NF).  	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1.1.5.3	  Target	  innervation:	  the	  heart	  One	  of	  the	  target	  organs	  innervated	  by	  the	  sympathetic	  nervous	  system	  is	  the	  heart,	  which	  is	   also	   extensively	   innervated	   by	   other	   autonomic	   nerves.	   Surprisingly	   little	   is	   known	  about	   the	   development	   of	   sympathetic	   innervation	   of	   the	   heart.	   It	   is	   thought	   that	  sympathetic	   nerves	   augment	   cardiac	   performance	   by	  modulating	   heart	   rate,	   conduction	  velocity,	  myocardial	  contraction	  and	  relaxation	  in	  response	  to	  stress,	  and	  several	  studies	  have	  suggested	  that	  the	  pattern	  of	  sympathetic	  innervation	  is	  critical	  for	  effective	  cardiac	  performance	   in	  humans	  (for	  example	  (Cao	  et	  al.,	  2000a;	  Cao	  et	  al.,	  2000b)).	  Sympathetic	  axons	   from	   the	   stellate	  ganglia,	   a	  prevertebral	   ganglion,	   extend	   to	   the	  base	  of	   the	  heart,	  descend	  the	  pulmonary	  arteries	  and	  innervate	  the	  left	  and	  right	  atria	  and	  ventricles	  of	  the	  heart,	  which	  was	  elucidated	  by	  studies	  in	  dog	  and	  human	  (Crick	  et	  al.,	  1994;	  Randall	  et	  al.,	  1968).	  Sympathetic	  fibres	  are	  also	  present	  in	  the	  atrioventricular	  and	  sinus	  nodes,	  but	  not	  in	   the	   nerve	   bundles	   of	   the	   human	   conduction	   system	   (Chow	   et	   al.,	   1993).	   Sympathetic	  nerve	   fibres	   reside	   mainly	   in	   the	   epicardial	   surface	   of	   the	   heart,	   with	   fibres	   entering	  deeper	   layers	   of	   myocardium	   in	   decreasing	   numbers.	   During	   mouse	   embryonic	  development,	  sympathetic	  fibres	  remain	  on	  the	  surface	  epicardium.	  At	  birth,	  they	  begin	  to	  penetrate	  the	  endocardium,	  and	  by	  early	  adulthood	  an	  epicardial-­‐to-­‐endocardial	  gradient	  of	  sympathetic	  fibres	  is	  apparent	  (Ieda	  et	  al.,	  2004;	  Ieda	  et	  al.,	  2007).	  SEMA3A	  expression	  in	   the	   subepicardium	   maintains	   this	   gradient	   (Ieda	   et	   al.,	   2007),	   as	   discussed	   later	  (Chapter	  1.1.7.3).	  
	  
1.1.6	  Patterning	  of	  the	  sympathetic	  nervous	  system	  
1.1.6.1	  Vascular	  signals	  	  Axonal	   outgrowth	   from	   the	   sympathetic	   chain	   often	   occurs	   in	   close	   proximity	   to	   blood	  vessels,	  and	  most	  sympathetic	  trunks	  travel	  along	  blood	  vessels	  thereafter	  (Makita	  et	  al.,	  2008).	  This	  has	   led	   to	   the	   suggestion	   that	   cues	   from	  blood	  vessels	   regulate	   sympathetic	  nervous	   system	   growth.	   In	   agreement	   with	   this,	   vascular-­‐derived	   signals	   act	   as	  sympathetic	   axon	   growth	   or	   survival	   factors,	   despite	   not	   being	   required	   for	   initial	  sympathetic	  development.	  	  Endothelins:	   A	  member	  of	   the	   endothelin	   family,	   Edn3,	   released	   from	  external	   carotid	  arteries	   and	   signals	   through	   the	   endothelin	   receptor	   EdnrA	   to	   guide	   a	   subset	   of	  sympathetic	   axons	   expressing	   the	   receptor	   towards	   their	   target	   in	   mice,	   the	   external	  carotid	  arteries	  (Makita	  et	  al.,	  2008).	  	  Glial	  cell	  line-­‐derived	  neurotrophic	  factors	  (GDNF)	  family	  ligands/RET	  receptors:	  Artemin,	  neurturin	   and	   persephin	   are	   vascular-­‐derived	   GDNF	   family	   members.	   Mice	   deficient	   in	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artemin/RET	  signalling	  have	  less	  sympathetic	  proliferation,	  mis-­‐routed	  sympathetic	  axons	  and	   accelerated	   sympathetic	   neuronal	   death	   (Andres	   et	   al.,	   2001;	   Enomoto	   et	   al.,	   2001;	  Honma	  et	  al.,	  2002).	  
1.1.6.2	  Non-­vascular	  derived	  signals:	  Neurotrophins/nerve	  growth	  factor	  (NGF):	   The	   classic	   neurotrophin,	   NGF,	   is	   a	  chemoattractant	  required	  for	  proper	  sympathetic	  innervation	  of	  target	  organs.	  Mice	  with	  deficient	   NGF	   signalling	   have	   no	   sympathetic	   innervation	   of	   heart	   ventricles	   and	  submaxillary	   and	   parotid	   glands,	   although	   proximal	   projections	   are	   preserved	   (Glebova	  and	  Ginty,	  2004).	  Overexpression	  of	  neurotrophin	  3	  increases	  the	  number	  of	  sympathetic	  neurons	  (Albers	  et	  al.,	  1996).	  	  Semaphorins/neuropilins:	   Semaphorins	   are	   implicated	   in	   sympathetic	   nervous	   system	  patterning	  through	  their	  neuropilin	  receptors,	  as	  discussed	  below.	  	  
	  
1.1.7	  Semaphorins	  and	  neuropilins	  
1.1.7.1	  Semaphorins	  Semaphorins	   are	   a	   diverse	   family	   of	   secreted,	   transmembrane	   or	  glycosylphosphatidylinositol	   (GPI)-­‐linked	   signalling	   proteins,	   characterised	   by	   a	   500	  amino	   acid	   sema	   domain.	   There	   are	   over	   20	   known	   semaphorins,	   belonging	   to	   eight	  classes	  according	  to	  classification	  based	  on	  structure	  and	  amino-­‐acid	  sequence	  (for	  review	  (Yazdani	  and	  Terman,	  2006)).	  With	  the	  exception	  of	  class	  2	  semaphorins,	  all	  semaphorins	  bind	   the	   plexin	   family	   of	   transmembrane	   receptors.	   Plexins	   are	   grouped	   into	   four	  categories	   (A-­‐D),	   and	   contain	   a	   sema	   domain	   to	   mediate	   the	   interaction	   with	   SEMAs.	  Relevant	  to	  this	  study	  are	  the	  vertebrate-­‐specific	  secreted	  class	  3	  semaphorins	  (SEMA3s),	  which	  have	  a	  stretch	  of	  highly	  basic	  amino	  acids	  in	  their	  carboxy-­‐terminal	  region.	  To	  date	  seven	  class	  3	  semaphorins	  have	  been	  identified,	  named	  SEMA3A	  to	  SEMA3G.	  SEMA3s	  are	  best	  known	  for	  their	  role	  in	  nervous	  system	  development	  as	  repulsive	  axon	  guidance	  cues,	  due	  to	  their	  ability	  to	  collapse	  growth	  cones	  of	  developing	  neurons	  by	  redistribution	  of	  the	  cytoskeleton	   and	  endocytosis	   of	   the	   growth	   cone	   cell	  membrane,	   hence	   SEMA3A	  was	   in	  fact	  originally	  named	  collapsin-­‐1	   (Luo	  et	  al.,	  1993).	  SEMA3	  molecules	  require	  binding	  of	  neuropilins	  to	  activate	  plexins,	  with	  the	  exception	  of	  SEMA3E,	  which	  can	  bind	  neuropilin	  or	  signal	  directly	  through	  PlexinD1	  (Gu	  et	  al.,	  2005).	  	  
1.1.7.2	  Neuropilins	  The	  two	  neuropilins,	  NRP1	  and	  NRP2,	  are	  single-­‐pass	  transmembrane	  proteins	  consisting	  of	  923	  and	  926	  amino	  acids,	  respectively.	  They	  share	  an	  overall	  amino	  acid	  homology	  of	  only	  44%.	  Their	  large	  extracellular	  domain	  contains	  different	  domains:	  two	  CUB	  domains	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(for	   complement	   proteins	   C1r/C1s,	   UEGF	   and	   BMP1)	   called	   a1/a2,	   two	   factor	   V/VIII	  homology	   domains	   called	   b1/b2,	   and	   a	  MAM	  domain	   (for	  meprin/A-­‐5	   protein/receptor	  protein-­‐tyrosine	   phosphatase	   µ)	   called	   c	   (Fig.	   1.4).	   The	   MAM	   domain	   promotes	  dimerisation	  and	  oligomerisation	  with	  other	  cell	  surface	  receptors.	  Neuropilins	  also	  have	  short	  cytoplasmic	  domains	  containing	  a	  PDZ-­‐binding	  motif.	  This	  mediates	  binding	  to	  GIPC,	  a	  protein	  involved	  in	  protein	  trafficking	  that	  also	  contains	  a	  PDZ-­‐domain	  (De	  Vries	  et	  al.,	  1998)	  and	   is	   identical	   to	  synectin	   (Gao	  et	  al.,	  2000)	  or	  NIP1	  (NRP-­‐interacting	  protein	  1)	  (Cai	  and	  Reed,	  1999)	  (Wang	  et	  al.,	  2006).	  The	  exact	   function	  of	  the	  cytoplasmic	  domains	  remains	   to	   be	   elucidated,	   but	   the	   fact	   that	   they	   are	  highly	   conserved	  between	  mice	   and	  humans	   indicate	   they	   may	   have	   an	   important	   role.	   An	   alternative	   splice	   form	   of	   NRP2	  exists,	   called	   NRP2a,	   which	   also	   contains	   a	   partial	   consensus	   ITAM	   (immuno-­‐receptor	  tyrosine-­‐based	  activation	  motif)	  in	  its	  cytoplasmic	  domain	  that	  is	  not	  present	  in	  NRP1	  or	  NRP2	  (Rossignol	  et	  al.,	  2000).	  	  NRP1,	  initially	  called	  A5,	  was	  identified	  as	  an	  adhesion	  molecule	  in	  the	  nervous	  system	  of	  




Figure 1.4: Structure and ligand binding of NRP1.  
NRP1 binds SEMA3 through its a1/a2 domains in axons and NCCs. It binds VEGF165 through 
its b1/b2 domains, where it also binds heparin, in endothelium and facial branchiomotor (FBM) 
neuron cell bodies. It has a c domain for oligomerisaton, a short transmembrane (tm) domain, 
and a small cytoplasmic domain containing a PDZ-binding motif for binding with GIPC. 
Localisation (i.e. axons/NCCs vs. endothelium) and ligand binding (i.e. SEMA vs. VEGF165) 
dictate its mechanism of action. (Diagram adapted from (Schwarz and Ruhrberg, 2010)). 	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1.1.7.3	  NRP/SEMA	  signalling	  in	  the	  nervous	  system	  Neuropilins	  recruit	  plexins	   to	   form	  a	  receptor	  complex	   in	  which	   the	  NRP	   is	   required	   for	  ligand	   binding	   and	   the	   plexin	   transduces	   signals	   (Kitsukawa	   et	   al.,	   1997).	   NRP1	   is	   best	  known	   for	   binding	   SEMA3A	   to	   aid	   fasciculation	   and	   regulate	   branching	   of	   axons.	   It	   can	  also	  bind	  SEMA3B	  and	  SEMA3C,	  although	  with	  no	  growth	  cone	  collapse	  ability,	  as	  well	  as	  SEMA3D,	  SEMA3E,	  and	  SEMA3F	  with	  much	  lower	  affinity	  (Chen	  et	  al.,	  1997;	  Feiner	  et	  al.,	  1997;	  Takahashi	  et	  al.,	  1998).	  NRP2	  preferentially	  binds	  SEMA3F	  (Giger	  et	  al.,	  2000),	  but	  it	  can	   also	  bind	   SEMA3B,	   SEMA3C	  and	  SEMA3G	   (Chen	   et	   al.,	   1997;	  Takahashi	   et	   al.,	   1998;	  Taniguchi	   et	   al.,	   2005).	   NRP1	   is	   expressed	   on	   particular	   classes	   of	   neurons	   in	   the	  peripheral	   nervous	   system	   (PNS)	   and	   CNS,	   including	   the	   trigeminal,	   facial,	  glossopharyngeal,	  vagus,	  spinal	  sensory	  and	  motor	  neurons	  (Kawakami	  et	  al.,	  1996).	  Mice	  lacking	   SEMA3A	   have	   severely	   disrupted	   nerve	   patterns	   in	   the	   PNS	   (Taniguchi	   et	   al.,	  1997),	  which	  is	  phenocopied	  in	  mice	  lacking	  NRP1	  (Kitsukawa	  et	  al.,	  1997)	  and	  when	  the	  SEMA-­‐binding	   domain	   of	   NRP1	   is	   disrupted	   (Gu	   et	   al.,	   2003).	   NRP2/SEMA3F	   signalling	  aids	  in	  fasciculation	  and	  branching	  of	  cranial	  nerves	  (Giger	  et	  al.,	  2000;	  Sahay	  et	  al.,	  2003),	  and	  also	  in	  patterning,	  for	  example	  of	  the	  olfactory	  nerve	  (Walz	  et	  al.,	  2007).	  Importantly	  for	  this	  thesis,	  NRP1/SEMA3A	  signalling	  is	  required	  for	  correct	  aggregation	  of	  sympathetic	   neurons	   into	   primary	   sympathetic	   ganglia.	   Mice	   lacking	   NRP1	   have	  mislocated	  sympathetic	  neurons	  and	  disorganised	  sympathetic	  chains,	  but	  NCC	  migration	  is	  believed	  to	  be	  normal	  (Kawasaki	  et	  al.,	  2002).	  Another	  study	  showed	  that	  mice	  lacking	  PlexinA4,	  but	  not	  PlexinA3,	  have	  sympathetic	  axon	  guidance	  defects,	  but	  mice	  lacking	  both	  plexins	  have	  defects	  worse	  than	  each	  single	  mutant.	  This	  suggests	  that	  PlexinA4	  conveys	  SEMA3A/NRP1	   signals,	   but	   that	   the	   plexins	   are	   functionally	   redundant	   (Waimey	   et	   al.,	  2008).	   Additionally,	   this	   study	   claims	   that	   NRP2	   is	   not	   required	   for	   sympathetic	  development.	  	  	  As	  previously	  mentioned,	  NRP1/SEMA3A	  signalling	  is	  thought	  to	  be	  a	  repulsive	  guidance	  cue	  for	  cranial	  NCC	  migration	  (McLennan	  and	  Kulesa,	  2007;	  Osborne	  et	  al.,	  2005;	  Schwarz	  et	   al.,	   2008a),	   but	   may	   not	   act	   in	   trunk	   NCC	   migration	   in	   vivo	   (Kawasaki	   et	   al.,	   2002),	  despite	   data	   showing	   that	   SEMA3A	   repels	   trunk	   NCC	   in	   vitro	   (Eickholt	   et	   al.,	   1999).	  However,	   a	   publication	   I	   co-­‐authored	  during	   the	   undertaking	   of	   this	   thesis	   showed	   that	  NRP1/SEMA3A	   signalling	  does	   indeed	   coordinate	   trunk	  NCC	  guidance,	   and	  mice	   lacking	  NRP1	  have	  increased	  NCC	  migration	  along	  the	  intersomitic	  boundary	  between	  the	  somites	  and	  in	  the	  dermomyotome	  layer	  instead	  of	  the	  sclerotome	  (Schwarz	  et	  al.,	  2009b).	  In	  mice	  lacking	   SEMA3F/NRP2	   signalling,	   NCCs	   migrate	   uniformly	   through	   the	   anterior	   and	  posterior	   sclerotome,	   due	   to	   a	   cell-­‐autonomous	   defect	   in	   NCCs,	   not	   defective	   somite	  polarity.	   However,	   normal	   development	   of	   the	   sympathetic	   nervous	   system	   and	   a	  segmented	   peripheral	   nervous	   system	   were	   reported	   (Gammill	   et	   al.,	   2006).	   The	   mice	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Figure 1.5: Semaphorin expression and NCC migration control.  
Schematic of a transverse section through the trunk region of an E9.5 mouse embryo, with 
areas in forelimb, dermomyotome and around the notocord indicated where SEMA3A is 
expressed (light green, A). This contributes to confining NRP1-expressing NCCs to the 
ventromedial migration path. Lateral view of the embryo indicates SEMA3F expression in the 
posterior half of each somite (dark green, B). This contributes to confining NRP2-expressing 
migratory NCCs to the anterior half of each somite.  
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1.1.7.4	  NRP/VEGF	  signalling	  in	  vascular	  system	  Mice	  lacking	  NRP1	  have	  greatly	  reduced	  vessel	  growth,	  particularly	  in	  the	  CNS	  (Kawasaki	  et	   al.,	   1999),	   although	   the	   phenotype	   is	   different	   to	   that	   observed	   in	   mice	   lacking	   the	  VEGF164	   isoform	   (Gerhardt	   et	   al.,	   2004;	   Ruhrberg	   et	   al.,	   2002),	   which	   is	   discussed	   in	  detail	  later	  (Chapter	  1.2.4).	  The	  role	  of	  NRP1	  in	  the	  vasculature	  is	  independent	  of	  any	  form	  of	  SEMA	  signalling	  (Vieira	  et	  al.,	  2007).	  NRP1	  has	  been	  proposed	  to	  act	  as	  a	  co-­‐receptor	  to	  the	  VEGF-­‐A	  receptor	  VEGFR2,	   thereby	  potentiating	  VEGF165	  signalling	   through	  VEGFR2	  (for	   example	   (Soker	   et	   al.,	   1998)).	   However,	   the	   exact	   role	   for	   NRP1	   in	   the	   developing	  vasculature	   remains	   to	  be	  defined,	   as	  discussed	   in	   a	   review	   I	   co-­‐authored	   (Fantin	   et	   al.,	  2009).	   NRP2	   has	   also	   been	   implicated	   in	   VEGF-­‐A	   isoform	   binding,	   as	   it	   binds	   VEGF165	  (although	  with	  lower	  affinity	  than	  NRP1)	  and	  the	  shorter	  isoform	  VEGF145	  (Neufeld	  et	  al.,	  2002).	  
1.1.7.5	  VEGF	  signalling	  in	  the	  sympathetic	  nervous	  system	  Some	   evidence	   for	   a	   potential	   role	   for	   VEGF-­‐A	   in	   sympathetic	   nervous	   system	  development	   exists,	   as	   in	   vitro	   data	   suggests	   that	   VEGF164	   stimulates	   growth	   of	  sympathetic	   axon	   and	   growth	   cone	   spreading	   through	   its	   tyrosine	   kinase	   receptor	  VEGFR1	   (Marko	   and	   Damon,	   2008).	   Moreover,	   VEGF-­‐A	   is	   produced	   by	   sympathetic	  targets,	  such	  as	  carotid	  arteries,	  and	  may	  help	  control	  neurite	  outgrowth	  in	  vivo	  (Long	  et	  al.,	   2009).	   VEGF-­‐A	   also	   patterns	   other	   parts	   of	   the	   nervous	   system,	   such	   as	   the	   facial	  branchiomotor	  neurons,	  and	  this	  will	  be	  discussed	  in	  more	  detail	  later	  (Chapter	  1.2.4.3).	  	  
 37	  
1.2	  The	  role	  of	  HSPGs	  in	  VEGF-­A	  signalling	  In	  this	  part	  of	  the	  thesis,	  I	  will	  explore	  whether	  heparan	  sulphate	  proteoglycans	  (HSPGs)	  are	  involved	  in	  VEGF-­‐A	  driven	  vascularisation	  of	  the	  brain	  and	  neuronal	  migration.	  HSPGs	  are	  membrane-­‐bound	   proteins	   carrying	   sugar	   side	   chains	   that	   are	   related	   to	   heparin,	   a	  highly	  sulphated	  glycosaminoglycan	  made	  in	  granular	  mast	  cells.	  Heparin	  is	  released	  only	  at	  sites	  of	   injury	   in	   the	  vasculature,	  whereas	   the	   lower	  sulphated	  heparan	  sulphate	  (HS)	  chains	   are	   found	  ubiquitously	  on	  all	   animal	   cell	   surfaces	   and	   interact	  with	  a	  plethora	  of	  proteins.	   This	   interaction	   diversity	   is	   made	   possible	   by	   variation	   in	   the	   structure	   and	  sulphation	   patterns	   of	   HS	   chains	   themselves	   and	   also	   by	   variation	   of	   the	   core	   protein.	  Many	  processes	  are	  dependent	  on	  HSPGs,	  such	  as	  growth	  factor	  signalling,	  morphogenesis	  and	  pathology.	  For	  example,	  Drosophila	  HSPGs	  Dally	  and	  Dlp	  help	  establish	  Wingless	  (Wg)	  gradients	  in	  the	  developing	  wing	  bud	  (Han	  et	  al.,	  2005)	  and	  HSPGs	  promote	  FGF	  signalling	  during	  gastrulation	  in	  the	  mouse	  (Garcia-­‐Garcia	  and	  Anderson,	  2003).	  Besides	  WNTs	  and	  FGFs,	  HSPGs	  also	  modulate	  Hedgehog	  and	  BMP	  signalling	  (reviewed	  by	  (Lin,	  2004)).	  I	  will	  therefore	  explore	  the	  hypothesis	  that	  HSPGs	  play	  a	  role	  in	  the	  signalling	  of	  another	  growth	  factor,	  VEGF-­‐A,	  in	  sprouting	  angiogenesis	  and	  neuronal	  patterning.	  	  
	  
1.2.1	  HSPG	  structure	  	  
1.2.1.1	  Core	  proteins	  	  There	   are	   three	   main	   families	   of	   proteoglycan	   core	   proteins	   carrying	   HS	   chains:	   the	  transmembrane	  syndecans	  (syndecan-­‐1	  to	  -­‐4)	  and	  GPI-­‐linked	  glypicans	  (gypican-­‐1	  to	  -­‐6),	  and	   the	   basement	   membrane	   proteins	   perlecan,	   agrin	   and	   collagen	   type	   XVIII.	   Other	  proteins	   that	   can	   associate	   with	   HS	   include	   betaglycan	   and	   a	   CD44	   splice	   variant	   (for	  review	  (Esko	  and	  Selleck,	  2002)).	  The	  core	  proteins	  are	  expressed	   in	  a	  cell	   type	  specific	  manner.	  The	  structure	  of	  HS	  chains	  is	   independent	  of	  expression	  of	  the	  core	  protein,	  but	  depends	  on	  the	  presence	  of	  specific	  enzymes	  that	  are	  also	  expressed	  in	  a	  cell	  type-­‐specific	  fashion.	  Between	  one	  and	  four	  HS	  chains	  are	  attached	  to	  each	  protein	  core.	  
1.2.1.2.Heparan	  sulphate	  chain	  structure	  HS	  belongs	   to	   a	   family	  of	  unbranched	  polysaccharides	   called	  glycosaminoglycans,	  which	  are	  composed	  of	  repeating	  disaccharide	  units	  of	  hexuronic	  acid	  and	  amino	  sugars.	  Other	  members	   of	   the	   glycosaminoglycan	   family	   are	   chondroitin	   sulphate,	   dermatan	   sulphate	  and	   keratan	   sulphate.	   In	   HS,	   the	   hexuronic	   acid	   can	   either	   be	  D-­‐glucuronic	   acid	   (GlcA),	  GlcA	  sulphated	  at	  C-­‐2	  (GlcA2S),	  L-­‐iduronic	  acid	  (IdoA)	  or	  IdoA2S,	  and	  the	  amino	  sugar	  is	  a	  form	  of	  glucosamine;	  N-­‐acetylglucosamine	  (GlcNAc),	  N-­‐sulphated	  glucosamine	  (GlcNS)	  or	  unsubstituted	   glucosamine	   (GlcNH3),	  which	   can	   all	   be	   variably	  O-­‐sulphated.	   From	   these	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components,	   48	  disaccharide	   combinations	   are	  possible,	   but	   only	  23	  disaccharides	  have	  been	   identified	   in	   HS	   in	   vivo	   (Esko	   and	   Selleck,	   2002).	   HS	   chains	   typically	   consist	   of	  domains	   rich	   in	   GlcA/GlcNAc	   disaccharide	   units	   (N-­‐acetylated	   domains)	   and	   domains	  containing	  IdoA/GlcNS	  disaccharide	  units	  (N-­‐sulphated	  domains),	  or	  some	  domains	  with	  alternating	   GlcA/GlcNAc	   and	   IdoA/GlcNS	   disaccharide	   units	   (N-­‐acetylated/N-­‐sulphated	  domains).	   In	   contrast,	   chondroitin	   sulphate	   consists	   of	   repeating	   GlcA	   and	   N-­‐acetylgalactosamine,	   dermatan	   sulphate	   of	   IdoA	   and	  N-­‐acetylgalactosamine	   and	   keratan	  sulphate	  of	  galactose	  and	  N-­acetylgalactosamine.	  	  	  
1.2.2	  HSPG	  biosynthesis	  
1.2.2.1	  HS	  chain	  polymerisation	  HS	  chains	  are	  synthesised	  in	  the	  Golgi	  body	  by	  a	  series	  of	  enzymes	  (Fig.	  1.6)	  (Nuwayhid	  et	  al.,	   1986).	   Synthesis	   commences	   with	   the	   attachment	   of	   a	   xylose	   residue	   to	   a	   specific	  serine	   amino	   acid	   in	   the	   core	   protein	   by	   xylotransferase,	   then	   the	   addition	   of	   two	   D-­‐galactose	   (Gal)	   residues	   by	   galactosyltransferase	   I	   and	   II	   and	   a	   GlcA	   residue	   by	  glucuronosyltransferase	   I.	   This	   forms	   the	   tetrasaccharide	   linkage	   complex	   required	   for	  chain	   elongation	   of	  HS,	   as	  well	   as	   for	   chondroitin,	   dermatan	   and	   keratan	   sulphates	   and	  heparin.	  The	  synthesis	  processes	   for	  different	  glycosaminoglycans	  subsequently	  diverge,	  dependent	  on	  the	  addition	  of	  the	  next	  residue.	  Polymerisation	  of	  HS	  is	  initiated	  by	  addition	  of	  one	  GlcNAc	  residue	  to	  the	  tetrasaccharide	  by	   a	   GlcNAc	   transferase,	   which	   acts	   only	   on	   tetrasaccharides	   destined	   to	   become	   HS.	  Polymerisation	  is	  then	  catalysed	  by	  EXT1	  and	  EXT2.	  These	  enzymes	  are	  two	  members	  of	  the	  exostosin	  gene	  family	  that	  were	  given	  their	  name	  because	  mutations	  in	  either	  the	  Ext1	  or	  Ext2	  gene	  in	  humans	  have	  been	  identified	  in	  the	  skeletal	  dysplasia	  hereditary	  multiple	  exostoses	   (for	   review	   (Nadanaka	   and	  Kitagawa,	   2008)).	   EXT1	   and	  EXT2	   contain	   a	   large	  globular	   luminal	   domain	   (Colley,	   1997)	   with	   two	   catalytic	   sites:	   one	   for	   GlcNAc	  transferase	  and	  another	  for	  Glc	  transferase	  activity	  (Lind	  et	  al.,	  1998),	  enabling	  the	  same	  enzyme	  to	  add	  alternating	  residues	  to	  the	  polysaccharide	  chain.	  EXT1	  and	  EXT2	  have	  very	  low	   activity	   separately,	   but	   form	   a	   heterodimer	   in	   vivo	   that	   has	   substantially	   higher	  glycosyltransferase	   activity	   than	   the	   separate	   monomers.	   This	   results	   in	   the	   loss	   of	  function	  of	  both	  enzymes	  if	  only	  one	  is	  mutated	  (McCormick	  et	  al.,	  2000).	  It	  was	  originally	  thought	  that	  chain	  polymerisation	  occurs	  before	  any	  other	  modifications,	  but	   glycosyltransferase	   activity	   has	   been	   shown	   to	   increase	   with	   concomitant	   N-­‐sulphation	   of	   the	   chain,	   suggesting	   simultaneous	   polymerisation	   by	   EXT	   enzymes	   and	  chain	   modification	   by	   other	   enzymes	   (Lidholt	   and	   Lindahl,	   1992;	   Lindahl	   et	   al.,	   1989).
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Figure 1.6: Biosynthesis of HSPGs.  
Synthesis is initiated in the Golgi body by the binding of the tetrasaccharide linkage complex to 
a serine residue of the core protein. Polymerisation is then catalysed by the EXT enzymes, 
EXT1 and EXT2. The HS chain can be modified by N-deacetylase/N-sulphotransferase (NDST)-
1 and -2, C5-epimerase, 2-O-sulphotransferase (HS2ST / 2OST), 6-O-sulphotransferases 
(HS6ST1-3 / 6OST1-3) and 3-O-sulphotransferases (HS3ST1-4 / 3OST1-4). The enzymes do 
not necessarily act in this order. For example, EXT1/2 and NDST1/2 can work simultaneously, 
but NDST1/2 must act before HS2ST. HSPGs are then transported to the cell surface, where 
sulphatases (SULF) 1 and 2 can act on HSPGs to remove specific 6-O-sulphate groups. In this 
way, a wide variety of HSPGs are produced (diagram adapted from (Hacker et al., 2005)).  	  
 40	  
1.2.2.2	  HS	  chain	  modifications	  The	   first	   HS	   chain	   modification,	   which	   is	   a	   prerequisite	   for	   later	   modifications,	   is	   the	  removal	   of	  N-­‐acetyl	   groups	   from	   selected	  GlcNAc	   residues	   and	   subsequent	   replacement	  with	   sulphate,	   carried	   out	   by	   bi-­‐functional	   N-­‐deacetylase/N-­‐sulphotransferase	   (NDST)	  enzymes.	  There	  are	  four	  mammalian	  NDST	  enzymes	  grouped	  into	  two	  subtypes:	  NDST1/2	  and	   NDST3/4	   (Aikawa	   et	   al.,	   2001).	   NDST1	   and	   2,	   the	   best	   characterised	   NDSTs,	   are	  abundantly	   and	   ubiquitously	   expressed,	   consistent	  with	   being	   involved	   in	  HS	   synthesis,	  and	   exhibit	   distinctive	   functions.	   In	   contrast,	   NDST3	   and	   4	   have	   a	   restricted	   expression	  pattern	  and	  may	  act	  on	  previously	  modified	  HS	  chains	   (Aikawa	  et	  al.,	  2001).	  NDST2	  has	  higher	  N-­‐deacetylase	   than	  N-­‐sulphation	  activity	  compared	  to	  NDST1,	  which	  has	  a	  higher	  
N-­‐sulphation	  activity.	  These	  properties	  and	  the	  relative	  expression	  of	  each	  enzyme	  define	  the	  degree	  of	  N-­‐sulphation	  of	  the	  HS	  chain	  (Pikas	  et	  al.,	  2000).	  	  C5-­‐epimerase	  acts	  on	  GlcA	  residues	  that	  are	  adjacent	  to	  GlcNS,	  turning	  them	  into	  L-­‐IdoA,	  the	   5’	   epimer	   of	  D-­GlcA	   present	   at	   ligand	   binding	   sites	   of	   HS.	   IdoA	   can	   exist	   in	   various	  conformations,	   adding	   flexibility	   to	   the	   chain	   and	   creating	   varying	   ligand	   specificities	  (Raman	   et	   al.,	   2003).	   That	   it	   does	   not	   act	   on	   O-­‐sulphated	   GlcA,	   or	   GlcA	   adjacent	   to	   O-­‐sulphated	   GlcNS,	   suggests	   that	   epimerisation	   comes	   after	  N-­‐deacetylation/N-­‐sulphation,	  but	  before	  any	  O-­‐sulphation	  (Hagner-­‐McWhirter	  et	  al.,	  2000).	  	  2-­‐O-­‐sulphotransferase	   (HS2ST)	   catalyses	   the	   transfer	   of	   a	   sulphate	   group	   to	   C-­‐2	   of	   the	  hexuronic	  acid,	  acting	  preferentially	  on	  IdoA,	  but	  also	  on	  GlcA,	  and	  mainly	  in	  N-­‐sulphated	  domains	   (Kusche	   and	   Lindahl,	   1990).	   2-­‐O-­‐sulphated	   IdoA	   residues	   are	   a	   universal	  component	   of	   HS,	   with	   between	   50	   and	   90%	   of	   IdoA	   residues	   being	   2-­‐O-­‐sulphated	  (Safaiyan	  et	  al.,	  2000).	  	  6-­‐O-­‐sulphotransferases	   (HS6ST)	   catalyse	   the	   addition	   of	   sulphate	   groups	   to	   C-­‐6	   of	  glucosamine	  residues.	  Three	  isozymes	  exist,	  HS6ST1-­‐3,	  which	  have	  differential	  specificity	  for	  the	  hexuronic	  acid	  adjacent	  to	  the	  targeted	  N-­‐sulphated	  glucosamine.	  HS6ST1	  prefers	  IdoA-­‐GlcNS	   units,	   but	   also	   acts	   on	   GlcNAc;	   HS6ST2	   acts	   on	   both	   GlcA-­‐GlcNS	   and	   IdoA-­‐GlcNS	   dependent	   on	   substrate	   concentration;	   and	   HS6ST3	   acts	   on	   either	   with	   no	  preference	  (Habuchi	  et	  al.,	  2000).	  An	  alternative	  splice	  form	  of	  HS6ST2	  has	  been	  described	  (Habuchi	  et	  al.,	  2003).	  Consistent	  with	  the	  idea	  that	  the	  isoforms	  target	  different	  HS	  chains	  for	   varying	   functions	   in	   vivo,	   HS6ST	   enzymes	   exhibit	   differential	   expression	   patterns	  (Sedita	  et	  al.,	  2004).	  3-­‐O-­‐sulphostransferases	   (HS3ST)	   catalyse	   the	   addition	   of	   sulphate	   groups	   to	   C-­‐3	   of	  glucosamine	   residues.	   They	   exist	   in	   at	   least	   six	   forms	   (Shworak	   et	   al.,	   1999;	   Xia	   et	   al.,	  2002).	   The	   best	   characterised	   is	   HS3ST1,	   since	   3-­‐O-­‐sulphation	   of	   GlcA-­‐GlcNS	   and	   GlcA-­‐GlcNS6S	   is	  essential	   for	   the	  binding	  site	  of	  antithrombin	   (Atha	  et	  al.,	  1985).	  HS3ST1	  can	  
 41	  
also	   act	   on	   IdoA-­‐GlcNS	   and	   IdoA-­‐GlcNS6S,	   but	   only	   in	   the	   absence	   of	   2-­‐O-­‐sulphation	   of	  hexuronic	   acid,	   which	   blocks	   HS3ST1	   action.	   HS3ST2	   acts	   on	   GlcNS	   residues	   with	   2-­‐O-­‐sulphated	  hexuronic	  acids.	  HS3ST3A	  and	  B	  act	  on	  IdoA2S-­‐GlcNS	  and	  IdoA2S-­‐GlcNH2.	  	  	  Relatively	  recently	  described	  are	  a	  new	  group	  of	  enzymes,	  the	  sulphatases	  (SULFs),	  which	  are	  active	  on	  the	  cell	  surface	  and	  in	  the	  ECM,	  rather	  than	  intracellularly.	  They	  modulate	  HS	  by	  removal	  of	  6-­‐O-­‐sulphate	  groups	  from	  the	  chain	  (Lamanna	  et	  al.,	  2006).	  	  	  
1.2.3	  Gene	  targeting	  to	  study	  HSPG	  function	  Targeted	   disruption	   of	   genes	   of	   interest	   and	   analysis	   of	   the	   resulting	   developmental	  phenotype	  can	  be	  used	   to	   identify	  essential	  HSPG	   functions.	  One	  possible	  approach	   is	   to	  mutate	  the	  core	  protein	  of	  particular	  HSPGs.	  However,	  other	  HS	  chains	  still	  present	  on	  the	  cell	  surface	  might	  compensate.	  An	  alternative	  approach	  would	  be	  the	  targeted	  disruption	  of	  genes	  encoding	  the	  enzymes	  required	  for	  HSPG	  biosynthesis.	  For	  example,	  mice	  lacking	  EXT	   enzymes	   do	   not	   produce	   HS,	   and	   accordingly	   die	   at	   gastrulation	   due	   to	   failure	   to	  organise	  mesoderm	  or	  extraembryonic	  tissue	  (Lin	  et	  al.,	  2000).	  Disrupting	  the	  expression	  of	   enzymes	   required	   for	  HS	   chain	  modification	   rather	   than	   initial	   polymerisation	  would	  result	  in	  altered	  HS	  fine	  structure	  and	  is	  less	  lethal.	  Below,	  I	  discuss	  various	  findings	  from	  such	  knockout	  studies.	  	  
Ndst1-­‐null	  mice	  have	  severe	  HS	  structural	  defects,	  with	  dramatically	  decreased	  levels	  of	  N-­‐sulphation	  in	  most	  tissues	  (Ringvall	  et	  al.,	  2000).	  Although	  the	  ensuing	  phenotypes	  are	  not	  fully	  penetrant,	  embryos	  die	  perinatally,	  with	  craniofacial	  skeletal	  defects,	  particularly	   in	  mandibular	   development	   (Yasuda	   et	   al.,	   2010).	   Ndst1-­‐null	   mice	   also	   have	   defects	   in	  pericyte	  recruitment	  during	  vascular	  development	  (Abramsson	  et	  al.,	  2007)	  (see	  Chapter	  1.2.4).	   Visual	   inspection	   of	   the	   published	   images	   suggests	   that	   blood	   vessels	   grow	   and	  branch	  properly	  in	  these	  animals.	  Ndst2-­‐null	  mice	  have	  a	  mast	  cell	  defect	  caused	  by	  a	  lack	  of	  sulphated	  heparin,	  although	  no	  structural	  HS	  defects	  are	  observed	  in	  any	  other	  tissues	  (Forsberg	  et	  al.,	  1999).	  The	  observation	  that	  Ndst2,	  3	  and	  4	  are	  upregulated	  in	  the	  lungs	  of	  
Ndst1-­‐null	  mice	  suggests	  functional	  compensation	  (Hu	  et	  al.,	  2009).	  	  A	  mutation	   in	   the	   Hsepi	   gene,	   encoding	   C5-­‐epimerase,	   results	   in	   highly	  N-­sulphated	   HS	  devoid	   of	   IdoA	   residues	   (Li	   et	   al.,	   2003).	  Hsepi-­‐null	  mice	   die	   at	   birth	   due	   to	   respiratory	  failure	   and	   also	   exhibit	   renal	   agenesis	   and	   skeletal	   defects,	   although	   many	   other	  developmental	   processes	   appear	   to	   proceed	   relatively	   normally.	   On	   closer	   inspection,	  IdoA-­‐containing	   HS	   are	   also	   required	   for	   pericyte	   recruitment	   in	   the	   developing	  vasculature	  (Abramsson	  et	  al.,	  2007).	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Mice	  lacking	  HS2ST	  die	  neonatally	  due	  to	  renal	  agenesis,	  and	  also	  exhibit	  eye	  and	  skeletal	  defects,	  such	  as	  decreased	  long	  bone	  size,	  craniofacial	  abnormalities	  and	  polydactyly,	  and	  a	   slight	   decrease	   in	   neural	   progenitor	   proliferation	   (Bullock	   et	   al.,	   1998).	  Despite	   these,	  most	  tissues	  with	  high	  Hs2st	  expression	  develop	  normally.	  This	  may	  be	  because	  Hs2st-­‐null	  mice	  have	  more	  extensively	  6-­‐O-­‐sulphated	  HS,	   suggestive	  of	   compensation	   (Merry	  et	  al.,	  2001).	  	  
Hs6st1-­‐null	  mice	  are	  embryonic	  lethal	  between	  E15.5	  and	  birth	  and	  exhibit	  a	  decrease	  in	  placental	  microvessels,	  smaller	  skeleton	  size	  and	  a	  lung	  morphology	  defect	  (Habuchi	  et	  al.,	  2007).	  A	  very	  slight	  upregulation	  in	  Hs6st3	  and	  Hs2st	  mRNA	  was	  reported	  in	  the	  mutants.	  Mouse	  knockout	  data	  for	  the	  other	  Hs6st2	  and	  Hs6st3	  genes	  have	  not	  yet	  been	  published.	  In	   zebrafish,	  morpholino	  knockdown	  of	  Hs6st2	   decreases	  vessel	  branching	   in	   the	   caudal	  vein	  tail,	  causing	  pooling	  of	  blood	  in	  the	  tail	  (Chen	  et	  al.,	  2005).	  	  
Hs3st1-­‐null	  embryos	  appear	  healthy	  and	  exhibit	  none	  of	  the	  expected	  coagulation	  defects,	  but	   they	   have	   intrauterine	   growth	   retardation	   and	   embryonic	   lethality,	   depending	   on	  genetic	  background	  (HajMohammadi	  et	  al.,	  2003).	  Knockout	  data	  for	  the	  other	  Hs3st	  genes	  have	  not	  yet	  been	  published.	  	  
	  
1.2.4	  VEGFA-­driven	  angiogenesis	  and	  neuronal	  patterning	  




Figure 1.7: Sprouting angiogenesis in the brain.  
New vessels sprout from a pre-existing vasculature. VEGF-A produced by neural progenitor 
cells is retained in a gradient by the extracellular matrix. Endothelial tip cells at the leading edge 
of the vascular plexus extend filopodia into an area of high VEGF-A concentration and migrate 
towards it, leading endothelial stalk cells, which proliferate and form a new vessel.  	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Figure 1.8: The mouse embryonic hindbrain as a model for studying sprouting 
angiogenesis.  
(A) Step-wise process of vessel growth in the developing hindbrain. Vessels invade the 
hindbrain from the pial (P) membrane at E9.5 (1) and grow towards the ventricular (V) zone (2). 
At E10.25 vessels reach the subventricular zone and begin to branch (3) to form the 
subventricular vascular plexus at E12 (4). (B) E12.5 hindbrain viewed from pial (P) side with 
vessels labelled with a Tie2 LacZ reporter to visualise vessel sprouts. (C) The same hindbrain 
viewed from the ventricular (V) side to visualise vessel branches. Either the sprouts on the pial 
side or the branches on the ventricular side can be quantified to study angiogenic processes. * 
indicates the midline (diagram adapted from (Ruhrberg et al., 2002)).  	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Figure 1.9: Isoforms of murine VEGF-A.  
VEGF-A exists as multiple isoforms that arise from alternative splicing of the gene product of 8 
exons. All isoforms contain exons 1-5 and exon 8, with exons 6 and 7 alternatively spliced. 
Exons 6 and 7 are the heparin-binding domains, which confer HS-binding in vitro. The inclusion 
or exclusion of these exons results in the varying heparin-binding efficiency of each isoform. 
(Diagram adapted from (Ruhrberg et al., 2002)).  	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Figure 1.10: Migration of FBM neurons in the hindbrain is disrupted in the absence of 
VEGF164.  
(A) Schematic representation of positioning of the trigeminal, abducens, facial and 
glossopharyngeal motor neuron nuclei in the mouse hindbrain at E12.5, with rhombomere (r)2 
to r6 labelled. Hatched circles represent the position of the exit points for the axons from the 
facial and trigeminal neurons. The facial neurons migrate from r4 tangentially to r6. The top 
cross section represents the ventricular (v) position of the facial neurons at r4, and the bottom 
shows the radial migration of the facial neurons at r6 to the pial (p) side. (B,C) Expression of a 
Vegfa LacZ reporter in E12.5 hindbrain reveals Vegfa is expressed at the site of facial nucleus 
(VIIn) formation on the pial side (B); on the ventricular side, Vegfa is expressed at the midline 
(arrow), in sets of stripes (wavy arrow) and in the area where the hypoglossal nuclei (XIIn) form 
(C). (D-G) E13.25 control hindbrains subjected to in situ hybridisation with Isl1 probe to allow 
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visualisation of migrating FBM somata from r4 on the ventricular side (D, arrowhead) to r6, 
close to the hypoglossal nuclei (XIIn), where they dive down to the pial side and form facial 
nuclei (VIIn, F) posterior to the trigeminal nuclei (Vn). In absence of VEGF164, FBM somata 
migrate in multiple streams (E, arrowheads) further anteriorly from the hypoglossal nuclei than 
in control (compare brackets in D,E). Misshapen facial nuclei form (star in G) closer to the 
trigeminal nuclei than in control hindbrains (compare brackets in F,G). Scale bars: 250 µm. * 
indicates midline. Images and schematic adapted with permission from (Schwarz et al., 2004).  	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1.2.5	  Function	  of	  HSPGs	  in	  angiogenesis	  and	  neural	  development	  It	   is	  hypothesised	   that	  HSPGs	  may	  be	   required	   in	  a	   similar	  way	   to	   the	  well-­‐documented	  FGF	  model,	  in	  which	  basic	  FGF	  (bFGF	  or	  FGF2)	  cannot	  bind	  its	  tyrosine	  kinase	  receptor	  in	  the	  absence	  of	  HSPGs	  (Yayon	  et	  al.,	  1991),	  and	  sequestering	  cell	  surface	  HSPGs	  therefore	  prevents	   FGF-­‐signalling	   (Rapraeger	   et	   al.,	   1991).	   Accordingly,	   mice	   lacking	   an	   enzyme	  required	  to	  synthesise	   the	  hexuronic	  acid	  components	  of	  HS	  cannot	  undergo	  FGF-­‐driven	  gastrulation	  (Garcia-­‐Garcia	  and	  Anderson,	  2003).	  	  
1.2.5.1	  HSPGs	  in	  angiogenesis	  	  The	  theory	  that	  HSPGs	  are	  involved	  in	  VEGF-­‐A	  guided	  angiogenesis	  is	  based	  on	  three	  lines	  of	   evidence.	   Firstly,	   the	   heparin-­‐binding	   affinities	   of	   VEGF165	   and	   VEGF189	   vary	  dependent	   on	   the	   presence	   of	   the	   heparin-­‐binding	   domains,	   shown	   in	   vitro	   (Park	   et	   al.,	  1993).	  This	  was	  supported	  by	   in	  vivo	  studies,	  which	  showed	  that	   loss	  of	  heparin-­‐binding	  VEGF-­‐A	   disrupts	   VEGF-­‐A	   gradients	   in	   the	   ECM	   (Gerhardt	   et	   al.,	   2003;	   Ruhrberg	   et	   al.,	  2002).	  Accordingly,	  mice	   that	  express	  solely	   the	  secreted,	  non	  heparin-­‐binding	  VEGF120	  isoform	   have	   vascular	   defects	   in	   the	   brain,	   with	   impaired	   filopodia	   extension	   from	   tip	  cells,	   leading	  to	   fewer	  branch	  points	  and	   large	   luminal	  diameters	  (Fig.	  1.11).	  Conversely,	  mice	   expressing	   only	   heparin-­‐binding	   VEGF-­‐A,	   i.e.	   VEGF188,	   exhibited	   an	   opposing	  phenotype,	   with	   ectopic	   branching	   and	   formation	   of	   thin	   microvessels.	   A	   model	   was	  proposed	   in	   which	   the	   isoforms	   of	   VEGF-­‐A	   are	   differentially	   localised	   and	   retained	   by	  HSPGs	   in	   a	   gradient	   dependent	   on	   their	   varying	   HS-­‐binding	   abilities,	   to	   control	   blood	  vessel	  branching.	  However,	  it	  was	  never	  directly	  investigated	  if	  HSPGs	  are	  indeed	  essential	  for	  retaining	  VEGF-­‐A	  in	  the	  ECM.	  	  Secondly,	   in	   vitro	   work	   suggests	   that	   HS	   promotes	   VEGF165	   binding	   to	   VEGFR1	   and	  VEGFR2	   (Gitay-­‐Goren	  et	   al.,	   1992;	  Tessler	   et	   al.,	   1994),	   as	  well	   as	   to	  NRP1	   (Soker	   et	   al.,	  1998).	   These	   observations	   suggest	   that	  HSPGs	   play	   a	   role	   in	   presenting	   VEGF165	   to	   its	  receptors.	  Consistent	  with	   this	   idea,	  neither	  VEGFR2-­‐deficient	  stem	  cell	  cultures	  nor	  HS-­‐deficient	   stem	  cell	   cultures	   can	  develop	  a	   vasculature	  upon	  VEGF165	   stimulation	  where	  wildtype	  stem	  cell	  cultures	  can.	  In	  co-­‐cultures,	  however,	  endothelial	  cell	  VEGFR2	  (derived	  from	  HS-­‐deficient	  cells)	  can	  be	  activated	  in	  trans	  by	  HSPGs	  produced	  by	  pericytes	  (derived	  from	   VEGFR2-­‐deficient	   cells)	   (Jakobsson	   et	   al.,	   2006).	   The	   authors	   propose	   a	  model	   by	  which	  cell	  surface	  HSPGs	  also	  modulate	  VEGFR2	  turnover	  by	  trapping	  it	  at	  the	  cell	  surface	  rather	  than	  being	  internalised	  and	  recycled.	  	  Thirdly,	  recent	   in	  vitro	  work	  using	  human	  umbilical	  vein	  endothelial	  cells	  showed	  that	  2-­‐
O-­‐	   and	   6-­‐O-­‐sulphated	   groups	   on	   HS	   are	   required	   for	   VEGF165	   mitogenic	   activity	   and	  endothelial	  tube	  formation	  in	  vitro	  (Ashikari-­‐Hada	  et	  al.,	  2005),	  and	  6-­‐O-­‐sulphation	  seems	  to	  be	  particularly	  important	  (Robinson	  et	  al.,	  2006).	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Yet,	   there	   has	   been	   little	   in	   vivo	   evidence	   supporting	   the	   requirement	   for	   HSPGs	   in	  angiogenesis.	  A	  notable	  example	  is	  a	  zebrafish	  study	  using	  Hs6st2	  morpholino	  knockdown	  that	   resulted	   in	   caudal	   vein	   plexus	   defects	   (Chen	   et	   al.,	   2005).	   However,	   the	   phenotype	  was	  mild	  compared	  to	  VEGF	  or	  VEGF	  receptor	  knockouts	  (for	  example	  (Nasevicius	  et	  al.,	  2000)).	  	  




Figure 1.11: Loss of heparin-binding VEGF164 decreases vessel branching.  
E12.5 hindbrains immunolabelled with the endothelial marker PECAM to visualise the 
developing vasculature. Wildtype hindbrains (A) have a complex network of branched 
microvessels. In embryos producing only the non-heparin-binding isoform of VEGF-A 
(Vegf120/120, B), the hindbrain vessels are less branched, and have larger diameters and bulbous 
vessel ends. Images kindly provided by Joaquim Vieira and Christiana Ruhrberg. Scale bar: 
200µm.  	  
 54	  
1.3	  Aims	  In	   the	   first	   part	   of	   this	   thesis	   I	   examined	   sympathetic	   innervation	   of	   the	   cardiovascular	  system.	  My	  aim	  was	   to	   investigate	  how	  NRP1	  and	  NRP2	  and	   their	  SEMA	   ligands	  control	  the	  early	  steps	   in	  the	  development	  of	   the	  sympathetic	  nervous	  system	  from	  sympathetic	  NCCs	  in	  the	  mouse.	  I	  also	  aimed	  to	  assess	  how	  NRP1	  patterns	  sympathetic	  axon	  extension	  in	   target	   organs	   by	   investigating	   heart	   innervation,	   and	   to	   investigate	   if	   the	   novel	  semaphorin,	  SEMA3G,	  helps	  pattern	  the	  sympathetic	  nervous	  system	  in	  vivo.	  	  In	  the	  second	  part	  of	  my	  thesis,	  I	  studied	  the	  role	  HSPGs	  play	  in	  VEGF164-­‐driven	  vascular	  and	  neuronal	  patterning	  in	  the	  developing	  mouse	  brain.	  I	  first	  assessed	  the	  importance	  of	  HS	   fine	   structure	   on	   vascular	   patterning,	   and	   then	  whether	   the	   elimination	   of	  HSPGs	   in	  specific	   tissues	   affects	   vascular	   patterning.	   Finally,	   I	   investigated	   whether	   HSPGs	   are	  required	  in	  VEGF164-­‐driven	  FBM	  neuronal	  migration.	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2.	  MATERIALS	  AND	  METHODS	  
2.1	  Materials	  
2.1.1	  General	  laboratory	  materials	  All	   reagents	   used	   were	   obtained	   from	   Sigma	   Aldrich,	   except	   where	   indicated.	   Plastic	  consumables	  were	   obtained	   from	   Corning	   or	   Nunc.	   Glassware	  was	   obtained	   from	   VWR	  International.	  	  
2.1.2	  General	  laboratory	  solutions	  Water	   used	   was	   purified	   using	   a	   MiliRo	   15	   Water	   Purification	   System	   (Milipore)	   and	  further	   purified	   where	   necessary	   using	   a	   Mili-­‐Q	   reagent	   Grade	   Water	   Ultrafiltration	  System	   (Milipore).	   RNAse-­‐	   and	   DNAse-­‐free	   water	   was	   obtained	   from	   Sigma.	   Absolute	  ethanol,	  methanol	  and	  isopropanol	  were	  from	  Fischer	  Scientific.	  1	  x	  PBS:	   137mM	  NaCl,	  3mM	  KCl,	  10mM	  Na2HPO4,	  1.8mM	  KH2PO4,	  pH	  7.2	  1	  x	  PBT:	   1	  x	  PBS	  +	  0.1%	  TritonX100	  1	  x	  TE:	   	   10mM	  Tris-­‐HCl,	  1mM	  EDTA,	  pH	  8.0	  1	  x	  TAE:	   40mM	  Tris-­‐acetate,	  1mM	  EDTA,	  pH	  8.0	  1	  x	  TBS:	   10mM	  Tris	  pH	  8,	  150mM	  NaCl	  (for	  immunolabelling)	  1	  x	  TBS:	   25mM	  Tris	  pH	  7.5,	  150mM	  NaCl,	  3mM	  KCl	  (for	  in	  situ	  hybridisation)	  4%	  PFA:	   4%	  formaldehyde,	  made	  freshly	  from	  paraformaldehyde,	  in	  PBS	  	  
2.2	  Methods	  
2.2.1	  Animal	  methods	  
2.2.1.1	  Animal	  Maintenance	  and	  Husbandry	  Mice	  were	  mated	  in	  the	  evening	  and	  the	  females	  checked	  for	  vaginal	  plugs	  in	  the	  morning.	  A	  plug	  found	  in	  the	  morning	  was	  taken	  as	  0.5	  embryonic	  days	  post	  coitum	  (E0.5).	  All	  mice	  were	  on	  mixed	  CD1	  and	  C57Bl/6	  genetic	  backgrounds.	  	  
2.2.1.2	  Genetic	  mouse	  strains	  Please	  see	  Table	  2.1	  for	  details	  of	  mouse	  strains	  used.	  
 56	  
	  
Gene/Mutation Source Reference 
Nrp1 knockout Dr Hajime Fujisawa (Kitsukawa et al., 1997) 
Nrp2 knockout Dr Alex Kolodkin (Giger et al., 2000) 
Nrp1sema knockout Dr David Ginty (Gu et al., 2002) 
Nrp1 “floxed” Dr David Ginty (Gu et al., 2003) 
Nrp1cyto Drs. Quenten Schwarz, Christiana 
Ruhrberg 
Unpublished 
Wnt1Cre  (Chai et al., 2000) 
Tie2Cre Dr David Ginty (Kisanuki et al., 2001) 
Vegf120/120 knockin Drs. David Shima, Peter Carmeliet, 
Patricia D’Amore 
(Ruhrberg et al., 2002) 
Sema3A knockout Dr Masahiko Taniguchi (Taniguchi et al., 1997) 
Sema3F knockout Dr Alex Kolodkin (Sahay et al., 2003) 
Sema3G LacZ 
knockin 
Dr Christer Betsholtz (Kutschera et al., 2011) 
Hs6st1 LacZ knockin Dr Tom Pratt (Leighton et al., 2001; 
Mitchell et al., 2001) 
Hs6st2 LacZ knockin Prof Mike Simons (Lexicon Ltd) Unpublished 
Hs2st LacZ knockin Dr Valerie Wilson (Bullock et al., 1998) 
Ext “floxed” Dr Yu Yamaguchi (Inatani et al., 2003) 
Nes8Cre Dr Weimin Zhong (Petersen et al., 2002) 




2.2.1.3	  Compound	  mutant	  mice	  To	   obtain	   compound	  Nrp1sema/Nrp2	   mutants,	   mice	   heterozygous	   for	   the	  Nrp2	   mutation	  were	   crossed	  with	  mice	   heterozygous	   for	   the	  mutation	   in	   the	   SEMA-­‐binding	   domain	   of	  
Nrp1,	  and	  mice	  heterozygous	  for	  both	  mutations	  were	  crossed	  to	  each	  other.	  The	  resulting	  genotypes	  were	  mixtures	  of	  Nrp1sema	  and	  Nrp2	  heterozygous	  and	  homozygous	  mutations	  and	   wildtypes,	   and	   the	   probability	   of	   getting	   a	   full	   wildtype	   or	   a	   full	   compound	  homozygous	  Nrp1sema/Nrp2	  mutant	  was	  1/16.	  The	  same	  method	  was	  carried	  out	  to	  obtain	  compound	   Sema3a/Sema3f,	   Sema3a/Sema3g,	   Sema3f/Sema3g,	   Nrp1cyto/Nrp2	   and	  
Hs6st1/Hs6st2	  mutants.	  	  
2.2.1.4	  Tissue-­specific	  genetic	  targeting	  I	   utilised	   the	   CRE/LOX	   approach	   to	   achieve	   tissue-­‐specific	   deletion	   of	   certain	   genes	  (reviewed	  by	  (Nagy,	  2000)).	  This	  is	  based	  on	  the	  P1	  phage	  CRE-­‐recombinase,	  an	  enzyme	  that	  recognises	  a	  34bp	  sequence	  called	  LoxP.	  Insertion	  of	  two	  LoxP	  sites	  flanking	  a	  region	  of	   DNA	   enables	   binding	   by	   CRE-­‐recombinase	   and	   either	   inversion	   or	   excision	   of	   the	  sequence,	  depending	  on	  the	  orientation	  of	  the	  LoxP	  sites.	  Specificity	  of	  the	  deletion	  can	  be	  accomplished	   by	   inserting	   the	   CRE-­‐recombinase	   under	   the	   control	   of	   a	   tissue-­‐specific	  promoter.	  In	  a	  developmental	  context,	  this	  results	  in	  genetic	  deletion	  in	  the	  somatic	  cells	  and	  their	  entire	  progeny.	  	  To	   inactivate	   genes	   in	   NCC-­‐derived	   cells,	  mice	   expressing	   CRE	   under	   the	   control	   of	   the	  NCC	  specifying	  Wnt1	  promoter	  were	  used.	  These	  mice	  were	  crossed	  with	  mice	  that	  had	  its	  
Nrp1	  gene	  flanked	  by	  LoxP	  sites,	  i.e.	  homozygous	  “floxed”	  Nrp1	  conditional	  mice	  (Nrp1fl/fl).	  Genetic	  recombination	  results	  in	  Nrp1	  being	  deleted	  in	  cells	  in	  which	  the	  Wnt1	  promoter	  is	  active,	   i.e.	   in	  NCCs,	   in	  Nrp1fl/fl;Wnt1Cre+	  mice.	  A	  similar	  approach	  was	  taken	  with	  mice	  expressing	   CRE	   under	   the	   control	   of	   the	   endothelial	   specific	   Tie2	   promoter	   and	  homozygous	   “floxed”	  Nrp1	   conditional	  mice	   to	   delete	  Nrp1	   in	   endothelial	   cells	   of	   blood	  vessels.	   To	   eliminate	   expression	   of	  Ext	   in	   neural	   progenitors	   and	   endothelial	   cells,	  mice	  expressing	  CRE	  under	  the	  control	  of	  the	  neural	  progenitor	  specific	  Nes8	  promoter	  or	  the	  
Tie2	  promoter	  were	  crossed	  with	  homozygous	  “floxed”	  Ext	  conditional	  mice.	  	  A	   recent	   report	   claimed	   that	   the	   Tie2	   promoter	   is	   able	   to	   drive	   the	   expression	   of	   CRE	  recombinase	   in	   the	   female	   germ	   line	   (de	   Lange	   et	   al.,	   2008).	   This	   would	   result	   in	   the	  “floxed”	  allele	  becoming	  null	  in	  the	  germ	  line	  and	  being	  transmitted	  through	  to	  offspring,	  thereby	  becoming	  a	  deletion	   in	   the	  whole	  embryo	  rather	   than	   in	  endothelial	   cells	  alone.	  Care	  was	  therefore	  taken	  to	  only	  transmit	  the	  CRE	  recombinase	  under	  the	  control	  of	  the	  
Tie2	  promoter	  through	  males.	  	  To	   obtain	   compound	   Nrp1;Wnt1Cre/Nrp2	   mutants,	   mice	   with	   heterozygous	   Nrp2	  mutations	   were	   crossed	   to	   Wnt1Cre-­‐positive	   mice	   with	   a	   heterozygous	   Nrp1	   “floxed”	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mutation	   (Nrp1fl/+	   or	   Nrp1fl/-­),	   and	   resulting	   compound	   heterozygous	  mutant	  mice	  were	  crossed	   to	   each	   other.	   The	   probability	   of	   obtaining	   a	   compound	   Nrp1;Wnt1Cre/Nrp2	  mutant	  was	  1/32.	  To	   increase	   the	   frequency	  of	  mutants,	   the	  offspring	  were	  backcrossed	  for	   one	   more	   generation	   to	   obtain	   mice	   with	   heterozygous	   Nrp2	   mutation	   and	  homozygous	  Nrp1	  “floxed”	  mutation	  positive	  for	  Wnt1Cre	  (Nrp2+/-­/Nrp1fl/fl;Wnt1Cre+).	  	  	  
2.2.1.5	  Genotyping	  All	  genotyping	  was	  carried	  out	  by	  Kathryn	  Davidson	  and	  Laura	  Denti	  in	  the	  Ruhrberg	  lab.	  Tissue	  biopsies	  were	  taken	  from	  mice,	  either	  tail	  snips	  or	  yolk	  sacs	  from	  embryos	  or	  ear	  punches	  from	  pre-­‐weening	  age	  mice.	  Genomic	  DNA	  was	  extracted	  from	  tissue	  biopsies	  by	  incubation	  in	  500	  µl	  lysis	  buffer	  (100mM	  Tris-­‐HCl	  pH	  8.5,	  5mM	  EDTA,	  0.2%	  SDS,	  200mM	  NaCl,	  100µg/ml	  proteinase	  K)	  at	  55°C	  overnight	  with	  agitation	  for	  protein	  digestion.	  DNA	  was	  precipitated	  by	  adding	  1	  ml	  ethanol,	  and	  collected	  by	  centrifugation	  at	  12000	  rpm	  for	  5	  minutes.	  The	  pellet	  was	  washed	  with	  70%	  ethanol,	  centrifuged	  as	  before,	  then	  air	  dried	  for	  30	  minutes	  and	  resuspended	  in	  100	  µl	  TBE	  buffer	  (0.2mM	  EDTA,	  2mM	  Tris	  pH	  8.0).	  Polymerase	  Chain	  Reaction	  (PCR)	  amplification	  was	  performed	  using	  genomic	  DNA	  from	  mouse	   ear	   or	   tail	   biopsies	   on	   a	   MJ	   Research	   PTC-­‐200	   Peltier	   Thermal	   Cycler.	   1	   µl	   of	  genomic	  DNA	  was	  used	  with	  10	  µl	  Megamix	  Blue	  reaction	  mix	  (Microzone,	  containing	  Taq	  polymerase,	   dNTPs,	   buffer,	   loading	   dye)	   and	   1	   µg/µl	   of	   each	   oligonucleotide	   primer	  specific	  for	  the	  gene-­‐targeted	  loci	  (see	  Table	  2.2)	  using	  the	  relevant	  cycles	  (see	  Table	  2.3).	  PCR	   products	   were	   visualised	   by	   electrophoresis	   on	   2%	   agarose	   (BDH	   Electran)	   gels	  containing	  ethidium	  bromide.	  	  
 59	  
	  
Gene Primer Primer sequence 
NPneo 5'-CGTGATATTGCTGAAGAGCTTGGC-3' 
NP-F 5'-CAATGACACTGACCAGGCTTATCATC-3' Nrp1 
NP-R 5'-GATTTTTATGGTCCCGCCACATTTGTC-3' 
Nrp2neo 5’-CAGTGACAACGTCGAGCACAG-3' 
Nrp2 -F 5’-TCAGGACACGAAGTGAGAAGC-3' Nrp2 
Nrp2-R 5’-GCTCAATGTAGCTAAGTGGAGGG-3' 
P1 5'-AGGCCAATCAAAGTCCTGAAAGACAGTCCC-3' Nrp1Sema 
P2 5'-AAACCCCCTCAATTGATGTTAACACAGCCC-3' 
semF 5'-CATTGTCAGCGCGTCTAGTGAGTGTTGG-3' 
semWT2 5'-CTGCAGACGCTGGAGGTCCCTGAG-3' Sema3A 
semR 5'-CTTGTAATGGTTCTGATAGGTGAGGCATGG-3' 
3F-31 5'-GAATGCCCGGGTAAACACCA -3' 
3F-32 5'- TCGAAGCGTACCCTGGCTCT-3' Sema3F 
3F-33 5'- AAGGAGCGCACAGAGGACCA-3' 
WT-F 5’- ATGACGCAGGAAACTACACT-3’ 
WT-R 5’- AGTTCTGGACTCCTCTTTCC-3’ Sema3G 
KOF 5’- TTGCCAAGTTCTAATTCCAT-3’ 
Wnt1cre F 5’-TAAGAGGCCTATAAGAGGCGG -3’ Wnt1Cre 
Wnt1cre 2 5’- GTGGCAGATGGCGCGGCAACACCATT-3’ 
Tie2Cre Cre84 5'-TGCCACGACCAAGTGACAGCAATG-3' 





Cyto F 5’-CCTTTTGATGGACATGTGACCTGTAGC-3’ 
Cyto R 5’-CACCAGGTCTGATTGAAGAGAAGG-3’ Nrp1
cyto 
Cyto Neo 5’-ATGGTACCTTGAGCATCTGACTTCTG-3’ 
6OST-F 5'-ATGGTGACTGTGACCCACAA-3' 
6OST-R 5'-GGGATATAGGGGACCTTGGA-3' 




HS6ST2-34 5'-GTTCGGCCAGGTTTGTACC-3'  
 
Hs6st2 
HS6ST2-35 5'- CAGCTGGTGAGCTCGGTC-3' 
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Burn1-11 5’- AAGGATTCTCGCTGTGACAG-3’ Ext 
Burn1-35 5’- CCAAAACTTGGATACGAGCC-3’ 
Cre1 5'- GCCTGCATTACCGGTCGATGCAACGA -3' Nes8Cre 
Cre2 5'- GTGGCAGATGGCGCGGCAACACCATT-3' 
SRY 1: 5'-TCATGAGACTGCCAACCACAG-3' SRY 
SRY 2: 5'-CATGACCACCACCACCACCAA-3' 
 Table 2.2: Specific oligonucleotide primers used in genotyping, synthesised from 
ordered designs by Sigma. 	  
Gene Hot Start Denaturing Annealing Extension Cycles End 
Nrp1 94°C, 3min 94°C, 40s 66°C, 1min 72°C, 1.5min 35 x 72°C, 5min 
Nrp2 94°C, 2min 94°C, 30s 66°C, 45s 72°C, 1.3min 35 x 72°C, 5min 
Nrp1Sema 93°C, 3min 95°C, 30s 66°C, 30s 72°C, 1min 35 x 72°C, 5min 
Sema3A 94°C, 4min 94°C, 40s 62°C, 1min 72°C, 1.5min 35 x 72°C, 5min 
Sema3F 95°C, 5min 95°C, 1min 60°C, 1min 72°C, 1min 30 x 72°C, 10min 
Sema3G 95°C, 2min 94°C, 1min 57.5°C, 1min 72°C, 1min 32 x 72°C, 5 min 
Wnt1Cre 94°C, 4min 94°C, 40s 62°C, 1min 72°C, 1.5min 35 x 72°C, 5min 
Tie2Cre 94°C, 3 min 94°C, 1min 67°C, 1min 72°C, 1min 32 x 72°C, 3min 
Vegf120/120 94°C, 3min 94°C, 40s 52°C, 1min 72°C, 1.5min 5 x  
  94°C, 40s 60°C, 1min 72°C, 1.5min 28 x 72°C, 5min 
Nrp1cyto 94°C, 2min 94°C, 40s 60°C, 30s 72°C, 1min 35 x 72°C, 10min 
Hs6st1 94°C, 4min 94°C, 20s 58°C, 30s 72°C, 30s 29 x 72°C, 1min 
Hs6st2 94°C, 4min 94°C, 30s 65°C, 1min 72°C, 1min 32 x 72°C, 10min 
Hs2st 94°C, 3min 94°C, 40s 60°C, 45s 72°C, 2min 36 x 72°C, 5min 
Ext 94°C, 2min 94°C, 45s 56°C, 45s 72°C, 2min 32 x 72°C, 5min 
Nes8Cre 94°C, 3min 94°C, 1min 67°C, 1min 72°C, 1min 32 x 72°C, 3min 
SRY 95°C, 5min 95°C, 30s 71.5°C, 45s 72°C, 45s 32 x 72°C, 5min 
Table 2.3: PCR cycling parameters used in genotyping. 	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2.2.1.6	  Tissue	  fixation	  Mice	  pregnant	  with	  embryos	  at	   the	   required	  day	  of	   gestation	  were	   culled	   in	  accordance	  with	  Home	  Office	  Schedule	  1	  regulations.	  Embryos	  were	  dissected	  from	  the	  uterus	  into	  1	  x	  PBS	  solution	  on	  ice.	  Embryos	  were	  either	  kept	  as	  wholemounts,	  or	  the	  internal	  organs	  and	  heads	  removed	  to	  reveal	  sympathetic	  chains,	  or	  the	  hindbrains	  or	  hearts	  dissected	  out	  in	  PBS.	  Samples	  were	   fixed	   in	  4%	  PFA	  at	  4°C	  for	  either	  2	  hours	  or	  overnight	  depending	  on	  method	  to	  be	  used	  (see	  Table	  2.4).	  Mouse	  pups	  at	  postnatal	  day	  (P)	  7	  were	  sacrificed	   in	  accordance	   with	   Home	   Office	   Schedule	   1	   regulation,	   and	   their	   hearts	   and	   aortas	   were	  dissected	  and	  fixed	  overnight	  in	  4%	  PFA	  at	  4°C.	  	  	  
2.2.2	  Sectioning	  
2.2.2.1	  Cryosectioning	  Wholemount	   embryos	   and	   P7	   hearts	   for	   immunolabelling	   were	   cryosectioned	   after	  fixation.	   Embryos	   to	   be	   used	   for	   AP-­‐binding	   assay	   were	   not	   fixed,	   but	   frozen	   fresh.	  Samples	  were	  washed	   twice	   in	  PBT,	  and	   incubated	  at	  4°C	   for	  2	  hours	   (or	  until	   embryos	  sank	   in	   solution)	   in	   20%	   sucrose	   in	   PBT.	   They	  were	   embedded	   in	   OCT	   (Sakura	   Tissue-­‐Tek),	  frozen	  rapidly	  on	  dry	  ice,	  and	  stored	  overnight	  at	  -­‐20°C.	  Samples	  were	  sectioned	  at	  a	  thickness	  of	  20	  µm	  using	  a	  histology	  cryostat	  (Leica	  CM1850)	  and	  collected	  on	  Superfrost	  Plus	  slides	  (VWR	  International).	  	  
2.2.2.2	  Vibratome	  sectioning	  Postnatal	  dorsal	  aortas	  or	  pre-­‐stained	  hindbrains	  were	  washed	  in	  1X	  PBT	  and	  mounted	  in	  molten	   but	   cooled	   3%	   agarose	   in	   water,	   and	   allowed	   to	   set.	   Samples	   were	   sectioned	  immediately	  using	  the	  Vibratome	  1000Plus	  Sectioning	  System.	  Pre-­‐stained	  sections	  were	  collected	  on	  glass	  slides	  and	  mounted	  in	  90%	  glycerol.	  	  	  
2.2.3	  Immunolabelling	  
2.2.3.1	  Immunolabelling	  of	  sections	  Slides	   containing	   cryosections	   were	   air	   dried	   for	   1	   hour	   at	   room	   temperature	   (RT).	  Sections	   for	   immunolabelling	   with	   a	   horseradish	   peroxidase	   (HRP)-­‐tagged	   secondary	  antibody	  were	  bleached	  to	  remove	  endogenous	  peroxidase	  activity	   in	  1:100	  H2O2	   in	  PBT	  for	   30	   minutes	   at	   RT.	   Sections	   to	   be	   immunolabelled	   with	   MASH1	   antibody	   (which	   is	  raised	  in	  mouse)	  were	  first	  incubated	  in	  a	  mouse-­‐on-­‐mouse	  IgG	  blocking	  reagent	  (Vector	  Labs)	  for	  1	  hour	  at	  RT.	  This	  improves	  specificity	  as	  it	  blocks	  endogenous	  IgG	  in	  the	  tissue	  that	  may	  be	  recognised	  by	  the	  secondary	  antibody	  and	  increase	  background	  staining.	  All	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sections	   were	   incubated	   in	   blocking	   solution	   for	   30	   minutes	   at	   RT,	   then	   incubated	   in	  primary	  antibody	  at	  appropriate	  concentration	  in	  blocking	  solution,	  for	  1.5	  hours	  at	  RT	  or	  overnight	   at	   4°C	   (see	   Table	   2.4	   for	   antibody	   dilutions	   and	   blocking	   solutions).	   Samples	  blocked	   with	   Dako	   serum-­‐free	   were	   incubated	   in	   primary	   and	   secondary	   antibodies	   in	  PBS	  with	   one	   drop	   of	   Dako	   serum-­‐free	   block	   added.	   Slides	   were	   washed	   5	   times	   for	   5	  minutes	   each	   at	   RT	   in	   PBS.	   Sections	  were	   incubated	   in	   secondary	   antibody	   in	   blocking	  solution	   for	   1.5	   hours	   at	   RT	   or	   overnight	   at	   4°C,	   in	   the	   dark	   for	   immunofluorescence	  labelling.	  Slides	  were	  washed	  5	  times	  for	  5	  minutes	  each	  at	  RT	  in	  PBS.	  Sections	  labelled	  for	  immunofluorescence	  were	  post-­‐fixed	   in	  4%	  PFA	  for	  5	  minutes.	  Sections	   immunolabelled	  with	  HRP-­‐tagged	  secondary	  antibodies	  were	  subjected	  to	  colour	  development:	  incubation	  with	  diaminobenzidine	   (DAB)	  and	  hydrogen	  peroxide	   (SigmaFast,	   Sigma)	   in	  water	   for	  5	  minutes	  at	  RT	  or	  until	  colour	  developed.	  Development	  was	  stopped	  with	  PBS	  and	  sections	  post-­‐fixed	  with	  4%	  PFA	   for	  5	  minutes.	   Sections	  were	  mounted	   in	  Mowiol	   (CalBiochem).	  Vibratome	   sections	  were	   immunolabelled	   in	   the	   same	  way,	   but	   in	   individual	   wells	   of	   a	  multidish	  24-­‐well	  plate.	  They	  were	  mounted	  on	  glass	  slides	  in	  90%	  glycerol.	  	  












(1:100) or AlexaFluor 
488 or 594 goat anti-





smooth muscle actin  




Rat anti-Endomucin  
(1:50, Santa Cruz) 
AlexaFluor 488 or 633 




Rabbit anti-Tuj1  
(1:250, Milipore) 
AlexaFluor 633 goat 




1 ml NGS, 250 µl 
DMSO, 12.5 µl 
thimerosal 
Mouse anti-MASH1  
(1:50, BD Pharmingen) 
AlexaFluor 488 anti-
mouse Fab fragment 
(1:200) 
2 hours, 4% 
PFA 
Dako serum-free (PBS + 
1 drop Dako serum-free) 
Rabbit anti-NRP1  
(1:100, Epitomics) 
488 donkey anti-rabbit 
Fab fragment (1:200) 
2 hours, 4% 
PFA 
Dako serum-free (PBS + 
1 drop Dako serum-free) 
Goat anti-NRP1  
(1:100, R&D Systems) 
594 rabbit anti-goat Fab 
fragment (1:200) 
2 hours, 4% 
PFA 
Dako serum-free (PBS + 
1 drop Dako serum-free) 
Goat anti-NRP2  
(1:100, R&D Systems) 
594 rabbit anti-goat Fab 
fragment (1:200) 
2 hours, 4% 
PFA 
Dako serum-free (PBS + 
1 drop Dako serum-free) 
Rabbit anti-activated 
Caspase3  
(1:200, R&D Systems) 
AlexaFluor 594 goat 
anti-rabbit IgG (1:200) 
2 hours, 4% 
PFA 
Dako serum-free (PBS + 
1 drop Dako serum-free) 
Rat anti-PECAM (CD31)  










(1:100) or AlexaFluor 
594 Streptavidin (1:200) 
Overnight (or 
2 hours), 4% 
PFA 
10% NGS/PBT 




mouse IgM (1:200) 
2 hours, 4% 
PFA 
10% NGS/PBT 
Table 2.4: Primary antibodies with working dilutions, secondary antibodies and 
appropriate fix and blocking solutions used in immunolabelling protocols. NGS, normal 
goat serum; NRS, normal rabbit serum. AlexaFluor secondary antibodies were from Invitrogen. 
HRP-tagged secondary antibodies were from Dako. 
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2.2.4	  In	  situ	  hybridisation	  Digoxigenin-­‐labelled	  Mash1	   and	   Isl1	   antisense	   RNA	   probes	   were	   synthesised	   for	   in	   situ	  hybridisation	   from	  cDNA	  plasmid	  preparations.	  Mash1-­‐containing	  plasmid	  was	  provided	  by	  Francois	  Guillemot,	  National	  Institute	  for	  Medical	  Research,	  London,	  and	  Isl1	  containing	  plasmid	   was	   provided	   by	   Tom	   Jessel,	   Columbia	   University,	   USA.	   All	   solutions	   for	   this	  protocol	  were	  kept	  RNAse-­‐free.	  	  
2.2.4.1	  Bacterial	  culture	  of	  plasmid	  containing	  probe	  Initially,	   transformation-­‐competent	   cells	   were	   made.	   A	   single	   colony	   of	   DH5a–derived	  electrocompetent	  Escherichia	  coli	  bacterial	  cells	  were	  cultured	  overnight	  at	  37°C	  without	  shaking	  in	  10	  ml	  L-­‐broth	  medium	  (10	  g/l	  Bacto-­‐tryptone,	  5	  g/l	  yeast	  extract,	  5	  g/l	  NaCl).	  100	  ml	  L-­‐broth	  medium	  was	   inoculated	  with	   the	  original	  10	  ml	   and	  grown	  at	  37°C	   in	   a	  shaker	   until	   the	   O.D.600	   (optical	   density)	   reached	   0.4.	   Bacterial	   cells	   were	   pelleted	   by	  centrifugation	  at	  4000	  rpm	  for	  15	  minutes	  at	  4°C,	  and	  resuspended	  gently	  in	  500	  ml	  water	  at	  4°C.	  Cells	  were	  centrifuged	  at	  4200	  rpm	  for	  15	  minutes	  at	  4°C,	  and	  resuspended	  gently	  in	  250	  ml	  4°C	  water.	  Previous	  centrifugation	  was	  repeated,	  and	  cells	  were	  resuspended	  in	  20	  ml	  of	  4°C	  10%	  glycerol	  in	  water.	  Cells	  were	  centrifuged	  at	  4000	  rpm	  for	  10	  minutes	  at	  4°C,	  and	  resuspended	  in	  3	  ml	  of	  4°C	  cold	  10%	  glycerol	  in	  water.	  Competent	  cells	  were	  put	  into	  80	  µl	  aliquots	  and	  stored	  at	  -­‐80°C	  until	  use.	  	  1	  µl	  of	  plasmid	  containing	  cDNA	  for	  Mash1	  or	   Isl1	  was	  gently	  mixed	   into	  40	  µl	  of	  slowly	  thawed	   competent	   cells,	  which	  was	   then	   transferred	   into	   sterile,	   chilled	   electroporation	  cuvette	  and	  electroporated	  by	  briefly	  shocking	  them	  with	  an	  electric	  field	  of	  10-­‐20kV/cm.	  1	   ml	   L-­‐broth	   was	   added	   to	   the	   cuvette	   and	   the	   solution	   was	   transferred	   to	   a	   1.5	   ml	  eppendorf	  and	  incubated	  at	  37°C	  for	  30	  minutes.	  The	  culture	  was	  spread	  onto	  an	  LB	  agar	  plate	   (L-­‐broth	   +	   100	   µg/ml	   ampicilin	   +	   15	   g/l	   agar	   added	   prior	   to	   autoclaving)	   and	  incubated	  overnight	  at	  37°C.	  A	  single	  colony	  was	  picked	  and	  grown	  in	  2	  ml	  L-­‐broth	  (+	  100	  
µg/ml	  ampicilin)	  overnight	  at	  37°C.	  	  
2.2.4.2	  RNA	  probe	  synthesis	  Plasmid	   was	   isolated	   with	   the	   Qiagen	   QIAprep	   Spin	   Miniprep	   kit,	   according	   to	  manufacturer’s	   instructions.	   Briefly,	   bacterial	   cells	   were	   pelleted	   by	   centrifugation	   at	  12000	  rpm	  for	  5	  minutes	  and	  resuspended	  in	  250	  µl	  cold	  Buffer	  P1	  (containing	  RNAse	  A).	  250	  µl	  Buffer	  P2	  (NaOH/SDS-­‐containing	  lysis	  solution)	  was	  added	  and	  the	  solution	  mixed,	  then	   350	   µl	   Buffer	   N3	   (high-­‐salt	   neutralising	   solution)	   was	   added	   and	  mixed,	   then	   the	  solution	   centrifuged	   at	   13000	   rpm	   for	   10	   minutes.	   The	   supernatant	   was	   applied	   to	  QIAprep	   spin	   column,	   which	   was	   centrifuged	   for	   30	   seconds	   and	   washed	   with	   750	   µl	  Buffer	  PE	  followed	  by	  another	  30	  seconds	  centrifugation.	  DNA	  was	  eluted	  from	  the	  column	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by	  applying	  50	  µl	  water,	  centrifuging	  for	  1	  minute	  and	  collecting	  flow-­‐through	  in	  a	  fresh	  tube.	  	  Restriction	   enzyme	   analysis	  was	   initially	   carried	   out	   to	   validate	   the	   plasmids.	   Then,	   the	  plasmid	   DNA	  was	   linearised	   by	   digestion	  with	   an	   appropriate	   restriction	   enzyme	   (New	  England	  Biolabs)	  for	  2.5	  hours	  at	  37°C	  in	  a	  reaction	  mixture	  containing:	  5	  µl	  plasmid	  DNA,	  4	   µl	   buffer,	   4	   µl	   10X	   BSA,	   1	   µl	   enzyme,	   26	   µl	   water.	   DNA	   was	   extracted	   by	   standard	  phenol/chloroform	  extraction	  and	   resuspended	   in	  15	  µl	  water.	  RNA	  was	   synthesised	  by	  reverse	   transcription,	   in	   a	   reaction	   mixture	   containing:	   14.5	   µl	   DNA	   and	   2	   µl	   10X	  transcription	  buffer	  ,	  2	  µ	  10X	  DIG,	  1	  µl	  polymerase	  and	  0.5	  µl	  RNAse	  inhibitor	  (Roche)	  for	  2.5	  hours	  at	  37°C.	  RNA	  was	  precipitated	  by	  adding	  100	  µl	  water,	  8	  µl	  5M	  lithium	  chloride,	  1	  µl	   glycogen	   and	   300	  µl	   ethanol,	   leaving	   the	   tube	   at	   -­‐80°C	   for	   20	  minutes	   followed	   by	  centrifugation	  at	  13000	  rpm	  at	  4°C	  for	  15	  minutes,	  washing	  the	  pellet	  in	  70%	  ethanol	  and	  resuspending	   the	   pellet	   in	   40	   µl	   water.	   For	  Mash1	   probe,	   XbaI	   restriction	   enzyme	   was	  used	  with	  buffer	  B2,	  and	  then	  SP6	  polymerase.	  For	  Isl1	  probe,	  NcoI	  restriction	  enzyme	  was	  used	  with	  buffer	  B4,	  and	  then	  SP6	  polymerase.	  
2.2.4.3	  In	  situ	  hybridisation	  Tissues	   were	   fixed	   overnight	   in	   4%	   PFA	   at	   4°C,	   dehydrated	   and	   stored	   as	   before.	  Wholemount	   samples	   were	   then	   bleached	   in	   6%	   hydrogen	   peroxide	   in	   methanol	   for	   1	  hour	   at	  RT	  before	   rehydrating	   into	  PBT.	   Samples	  were	   incubated	   in	  hybridisation	  block	  (50%	   formamide,	   5X	   SSC	   (sodium	   citrate,	   sodium	   chloride,	   citric	   acid)	   pH4.5,	   50	  µg/ml	  tRNA	   (Roche),	   50	   µg/ml	   heparin	   (Sigma),	   1%	   SDS)	   for	   30	   minutes	   at	   70°C	   and	   then	  incubated	  in	  RNA	  probe	  solution	  (3µl	  probe	  in	  1ml	  hybridisation	  block)	  overnight	  at	  65°C.	  Samples	  were	  then	  washed	  3	  times	  in	  solution	  1	  (50%	  formamide,	  5X	  SSC	  pH4.5,	  1%	  SDS)	  and	  3	   times	   in	   solution	  3	   (50%	   formamide,	  2X	  SCC	  pH4.5)	   for	  30	  minutes	  each	  at	  65°C,	  then	  twice	  briefly	  in	  TBST	  (1	  X	  TBS,	  0.1%	  Tween-­‐20)	  at	  RT.	  Samples	  were	  blocked	  in	  10%	  sheep	   serum	   in	  TBST	   for	  30	  minutes	   at	  RT,	   then	   incubated	   in	   anti-­‐digoxigenin	  antibody	  (Roche)	  at	  1:5000	  in	  1%	  sheep	  serum	  in	  TBST	  overnight	  at	  4°C.	  Samples	  were	  washed	  in	  TBST	  5	  times	  for	  1	  hour	  at	  RT	  and	  once	  overnight	  at	  4°C.	  Samples	  were	  washed	  3	  times	  in	  NTMT	   solution	   (0.1M	  NaCl,	   0.1M	   Tris-­‐HCl	   at	   pH9.5,	   0.05M	  MgCl2,	   1%	   Tween20)	   for	   10	  minutes	  at	  RT,	  then	  incubated	  in	  developing	  solution	  (3.5	  µl	  BCIP	  and	  4.5	  µl	  NBT	  (Roche)	  per	  ml	  NTMT)	  at	  RT	  until	  colour	  developed.	  The	  reaction	  was	  stopped	  by	  washing	  in	  TBST	  and	  fixing	  in	  4%	  PFA	  for	  10	  minutes	  at	  RT.	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2.2.5	  Labelling	  techniques	  
2.2.5.1	  X-­gal	  assay	  X-­‐gal	  staining	  was	  used	  to	  visualise	  β-­‐galactosidase	  activity	  in	  samples	  containing	  the	  gene	  for	  this	  enzyme	  (lacZ)	   inserted	  into	  the	   locus	  of	  a	  specific	  gene.	  Embryos	  were	  dissected	  and	   fixed	   in	  4%	  PFA	   for	  30	  minutes	  at	  4°C.	  Embryos	  washed	   in	  PBS/0.02%	  NP40	   three	  times	  for	  15	  minutes	  at	  RT,	  then	  incubated	  in	  X-­‐gal	  (stored	  at	  1	  mg/ml	  X-­‐Gal	  in	  PBS/0.02%	  NP40)	   added	  1:40	   into	   staining	   solution	   (5	  mM	  K3Fe(CN)6,	   5	  mM	  K4Fe(CN)6xH20,	   2	  mM	  MgCl2,	  0.01%	  sodium	  deoxycholate)	  at	  37°C	  for	  a	  few	  hours	  or	  until	  colour	  developed.	  The	  reaction	  was	  stopped	  by	  washing	  with	  PBS	  and	  post-­‐fixing	  in	  4%	  PFA.	  
2.2.5.2	  Alkaline	  phosphatase	  (AP)-­binding	  assay	  Expression	  vectors	  encoding	  AP	  only,	  AP-­‐SEMA3A	  and	  AP-­‐SEMA3F	  were	  kindly	  provided	  by	   Drs	   Jonathan	   Epstein	   and	   Jonathan	   Raper,	   University	   of	   Pennsylvania,	   Philadelphia,	  USA.	   AP	   expression	   vectors	   were	   transformed	   into	   HEK-­‐293T	   cells,	   the	   fusion	   proteins	  collected	  and	  their	  activity	  tested	  by	  Joaquim	  Vieira.	  	  Cryosections	  of	  freshly	  frozen	  tissue	  were	  kept	  at	  -­‐20°C	  until	  fixation	  in	  methanol	  cooled	  to	  -­‐20°C	  for	  5	  minutes.	  Sections	  were	  then	  washed	  three	  times	  in	  AP	  wash	  buffer	  (1x	  PBS	  +	  4mM	  MgCl2)	  for	  5	  minutes	  at	  RT,	  blocked	  in	  10%	  FBS	  in	  AP	  wash	  buffer	  for	  30	  minutes	  at	  RT,	   then	   incubated	   in	   AP-­‐ligand	   overnight	   at	   4°C	   in	   a	   wet	   chamber.	   After	   washing	   five	  times	  in	  PBS	  for	  5	  minutes	  each	  with	  gentle	  shaking,	  bound	  ligand	  was	  fixed	  using	  4%	  PFA	  for	  5	  minutes	  at	  RT	  and	  sections	  were	  washed	  again	  three	  times	  in	  PBS	  for	  5	  minutes	  each.	  Sections	   were	   incubated	   for	   3	   hours	   in	   a	   wet	   chamber	   at	   65°C	   in	   PBS	   to	   inactivate	  endogenous	  phosphatases.	  After	  washing	  briefly	  twice	  in	  PBS,	  sections	  were	  incubated	  in	  AP	  stain	  buffer	  (100mM	  Tris	  pH	  9.5,	  100mM	  NaCl,	  5mM	  MgCl2)	  for	  5	  minutes	  at	  RT,	  then	  in	  AP	  stain	  solution	  (3.375	  µl	  NBT	  +	  3.5	  µl	  BCIP	  per	  1	  ml	  AP	  stain	  buffer)	   for	  3	  hours	  at	  37°C	  then	  overnight	  at	  RT.	  Staining	  was	  stopped	  with	  PBS	  then	  4%	  PFA	  for	  5	  minutes,	  and	  slides	  were	  mounted	  in	  glycerol.	  	  
	  
2.2.6	  Imaging	  
2.2.6.1	  Imaging	  of	  cryosections	  and	  wholemount	  samples	  Fluorescently	   labelled	   cryosections	   of	   embryos,	   postnatal	   hearts	   or	   dorsal	   aortas	   were	  imaged	   using	   the	   Zeiss	   LSM510	   confocal	   microscope	   with	   Zeiss	   LSM510	   operating	  software.	  	  Cryosections	   of	   embryos	   immunolabelled	  with	  HRP	   for	   TH	   to	   visualise	   the	   sympathetic	  ganglia	  and	  cryosections	  of	  embryos	  labelled	  by	  Mash1	  in	  situ	  hybridisation	  were	  imaged	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using	   a	   stereo	   dissection	   microscope	   (Olympus	   SZX16)	   with	   Hamamatsu	   camera	  controller	  (C4742-­‐95)	  and	  Simple	  PCI	  Version	  6.6	  software.	  Areas	  of	  ganglia	  and	  distances	  between	  ganglia	  were	  calculated	  using	  ImageJ	  Version	  1.39u	  software.	  	  Wholemount	  embryos	   immunolabelled	  with	  HRP	   for	  TH	   for	  visualisation	  of	   sympathetic	  chains	   were	   imaged	   using	   a	   stereo	   dissection	  microscope	   (Leica	  MZ16)	   and	   camera	   (Q	  Imaging	  Micropublisher	  3.3	  RTV)	  with	  Improvision	  OpenLab	  version	  5.5.2	  software.	  	  Wholemount	  hearts	  were	  imaged	  using	  the	  Olympus	  stereo	  dissection	  microscope	  with	  an	  Olympus	   fluorescent	   lamp	   (U-­‐RFL-­‐T)	  with	  Hamamatsu	  camera	  and	  Simple	  PCI	   software,	  as	  above.	  	  
2.2.6.2	  Quantification	  of	  blood	  vessel	  branching	  in	  hindbrains	  Wholemount	   hindbrains	   immunolabelled	   with	   either	   PECAM	   antibodies	   or	   IB4	   were	  flattened	   with	   glass	   coverslips	   onto	   4%	   agarose	   gel	   plates	   and	   imaged	   using	   a	   stereo	  dissection	   microscope	   with	   camera	   and	   software,	   as	   above.	   Images	   were	   taken	   at	   a	  magnification	  of	  11.5x	  in	  four	  areas,	  two	  in	  random	  areas	  on	  each	  side	  of	  the	  midline.	  The	  number	  of	  vessel	  branchpoints	  were	  quantified	  inside	  a	  rectangle	  template	  of	  dimensions	  0.4mm	  x	  0.5mm	  that	  was	  superimposed	  on	  the	  original	  image.	  Wholemount	  hindbrains	  labelled	  with	  immunofluorescence	  were	  mounted	  on	  glass	  slides	  with	  mounts	   using	   Slowfade	   Antifade	  mounting	   kit	   (Invitrogen)	   and	   covered	  with	   glass	  coverslips.	  These	  were	  imaged	  using	  confocal	  microscopy	  on	  the	  Zeiss,	  and	  the	  number	  of	  vessel	   branches	  was	   quantified	   in	   a	  whole	   20X	   image.	   Differences	   in	   numbers	   of	   vessel	  branchpoints	  were	  statistically	  analysed	  using	  paired	  student’s	  t-­‐tests.	  	  
	  
2.2.7	  Genetic	  studies	  
2.2.7.1	  Microarray	  RNA	   isolation	  was	   carried	   out	   by	  Alessandro	  Fantin	   from	   the	  Ruhrberg	   lab	   (see	   section	  2.8.2	   below).	   Affymetrix	   GeneChip	   Technology	  microarray	   and	   RNA	   quality	   control	  was	  carried	  out	  by	  the	  UCL	  Genomics	  department.	  Briefly,	  RNA	  samples	  from	  hindbrains	  of	  6	  E11.5	   wildtype	   embryos	   were	   applied	   to	   Mouse	   Gene	   1.0	   ST	   Array	   microarray	   chips	  containing	  27	  small	  oligonucleotides	  spread	  over	  the	  full	  length	  of	  each	  gene	  in	  the	  mouse	  genome.	   The	   readout	  was	   the	   average	   fluorescent	   signal,	   normalised	   to	   a	   housekeeping	  gene,	  which	  was	  representative	  of	  relative	  expression	  of	  the	  gene.	  	  
2.2.7.2	  q-­PCR	  RNA	  was	  isolated	  from	  two	  litters	  of	  E12.5	  hindbrains.	  The	  tissue	  was	  homogenised	  in	  1	  ml	  Trizol	  in	  a	  1.5	  ml	  eppendorf	  by	  passing	  it	  through	  a	  5/8”	  gauge	  needle	  and	  syringe.	  250	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µl	  chloroform	  was	  added	  per	  tube	  and	  the	  tube	  vortexed	  for	  15	  seconds,	  incubated	  at	  RT	  for	   10	   minutes,	   vortexed	   again	   for	   15	   seconds	   and	   centrifuged	   at	   12000	   rpm	   for	   15	  minutes	   at	   4°C.	   The	   top	   layer	   of	   liquid	   was	   removed	   into	   a	   fresh	   tube	   and	   500	   µl	  isopropanol	  added.	  The	  tube	  was	  then	  mixed	  gently	  and	   incubated	  at	  RT	   for	  10	  minutes	  before	  centrifugation	  at	  12000	  rpm	  for	  10	  minutes	  at	  4°C	  to	  pellet	  the	  RNA.	  The	  pellet	  was	  then	  washed	   in	  70%	  ethanol,	  air	  dried	   for	  30	  minutes	  and	  resuspended	   in	  20	  µl	  RNAse-­‐free	  water.	  RNA	  was	  quantified	  and	  quality	  assessed	  using	  a	  Nanodrop	  Spectrophotometer	  ND-­‐1000	  with	  Nanodrop	  1000	  Version	  3.7.1	  software	  (ThermoScientific).	  	  Single	  stranded	  cDNA	  was	  synthesised	  from	  1	  µg	  RNA,	  firstly	  in	  a	  reaction	  mixture	  with	  1	  
µl	  random	  primers	  and	  2	  µl	  dNTP	  mix	  made	  up	  to	  12	  µl	  with	  RNAse-­‐free	  water,	  which	  was	  heated	  to	  65°C	  for	  5	  minutes	  then	  quickly	  chilled	  on	  ice.	  Next,	  4	  µl	  of	  5x	  First	  Strand	  buffer,	  2	  µl	  0.1M	  DTT	  and	  1	  µl	  RNAse	  OUT	  were	  added	  and	  the	  tube	  mixed	  gently	  and	  incubated	  at	   25°C	   for	   5	   minutes.	   Finally,	   1	   µl	   Superscript	   II	   polymerase	   enzyme	   was	   added	   and	  pipetted	   up	   and	   down	   to	   mix,	   before	   incubation	   at	   25°C	   for	   10	   minutes,	   42°C	   for	   50	  minutes,	   and	   the	   reaction	   inactivated	  at	  70°C	   for	  15	  minutes.	  The	   cDNA	  was	   stored	  at	   -­‐20°C	  until	  q-­‐PCR	  was	  carried	  out	  (all	  reagents	  from	  Invitrogen).	  	  Primers	  for	  Hs6st1,	  Hs6st2,	  Hs6st3	  and	  18s	  were	  made	  to	  order	  by	  Sigma	  (see	  Table	  2.5).	  q-­‐PCR	   was	   carried	   out	   in	   optical	   96-­‐well	   reaction	   plates	   using	   the	   PowerSybr	   system	  (Applied	   Biosystems).	   Each	   sample	   was	   analysed	   in	   triplicate	   for	   each	   primer	   set.	   18s	  amplification	   served	   as	   an	   internal	   control	   to	   normalise	   expression	   levels	   between	  samples.	   Reaction	  mixture	   per	  well	   for	  Hs6st1,	  Hs6st2	   and	  Hs6st3	   primers:	   0.3	  µl	   cDNA,	  12.5	  µl	  PowerSybr,	  0.075	  µl	  each	  primer,	  12.05	  µl	  water.	  For	  18s	  housekeeping	  primers,	  a	  1:10	  dilution	  of	  all	  cDNA	  samples	  was	  used	  to	  account	  for	  the	  large	  amount	  of	  18s	  RNA	  in	  the	   samples,	   0.15	   µl	   each	   primer	   used	   and	   the	   volume	   of	   water	   added	   adjusted	  accordingly	  to	  make	  up	  to	  25	  µl	  total	  volume.	  Plates	  were	  centrifuged	  briefly	  to	  collect	  the	  liquid	   and	   run	   on	   a	   7900HT	   Fast	   Real	   Time	   PCR	   System	   with	   7900HT	   Version	   2.2.2	  Sequence	  Detection	   Systems	   software	   (Applied	  Biosystems).	   Raw	   fluorescence	   data	  was	  analysed	  using	  DART-­‐PCR	  Version	  1.0	   software,	  which	  converts	   it	   to	   relative	  expression	  (Peirson	  et	  al.,	  2003).	  Relative	  expression	  was	  normalised	  to	  the	  internal	  control,	  18s	  RNA,	  and	  final	  data	  was	  presented	  as	  fold	  change	  from	  control	  samples,	  i.e.	  wildtype.	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Gene Primer Primer sequence 
Hs6st1 Hs6st1-F 5’-GTTCGCCCAGAAAGTTCTAC-3’ 
 Hs6st1-R 5’-GGATGAAAGATAGGTTGTAGCAG-3’ 
 Hs6st2 Hs6st2-F 5’-GAGTGGGAAGAACTTCCATTAC-3’ 
  Hs6st2-R 5’-GTTGTAGCATCCCACTAGAG-3’ 
 Hs6st3-F 5’-AGCCACACCAGGAATTTCTA-3’ Hs6st3 
Hs6st3-R 5’-GCTACAATCCATGAACTCCC-3’ 
 
Table 2.5: Primers designed for Hs6st gene amplification in q-PCR. 
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3.	  NEUROPILINS	  IN	  THE	  DEVELOPING	  SYMPATHETIC	  NERVOUS	  SYSTEM	  
3.1	  Introduction	  Mice	   lacking	   NRP1	   have	   disorganised	   sympathetic	   chains	   and	   sympathetic	   axon	  misguidance,	   but	  NCC	  migration	  was	  previously	   reported	   to	  be	  normal	   (Kawasaki	   et	   al.,	  2002).	  In	  contrast,	  other	  work	  showed	  that	  NRP1/SEMA3A	  signalling	  repels	  trunk	  NCCs	  in	  
vitro	   (Eickholt	   et	   al.,	   1999).	   A	   publication	   I	   co-­‐authored	   in	   2009	   showed	   that	  NRP1/SEMA3A	  signalling	  does	  coordinate	  trunk	  NCC	  guidance,	  as	  mice	  lacking	  NRP1	  have	  increased	  NCC	  migration	  along	  the	  intersomitic	  boundary	  and	  in	  the	  dermomyotome	  layer	  instead	  of	  the	  sclerotome	  (Schwarz	  et	  al.,	  2009b).	  I	  therefore	  wanted	  to	  investigate	  more	  thoroughly	   the	   implications	   of	   this	   misguided	   migration	   on	   the	   sympathetic	   nervous	  system.	   In	  mice	   lacking	  SEMA3F/NRP2	  signalling,	   segmental	  NCC	  migration	   is	  disrupted	  (Gammill	   et	   al.,	   2006),	   but	  whether	   this	   affects	   the	   sympathetic	  nervous	   system	  has	  not	  been	  studied.	  SEMA3F	  repels	  sympathetic	  axons	  through	  NRP2	  in	  vitro	  (Giger	  et	  al.,	  2000);	  however	  loss	  of	  NRP2	  reportedly	  does	  not	  affect	  the	  sympathetic	  nervous	  system	   in	  vivo	  (Waimey	  et	  al.,	  2008).	  Therefore	  my	  first	  aim	  in	  this	  chapter	  was	  to	  investigate	  how	  NRP1	  and	   NRP2	   and	   their	   SEMA	   ligands	   control	   the	   early	   steps	   in	   the	   development	   of	   the	  sympathetic	  nervous	  system	  from	  sympathetic	  NCCs	  in	  the	  mouse.	  SEMA3A	  patterns	  sympathetic	   innervation	  of	   the	  heart	   in	  postnatal	  mice	  by	  maintaining	  an	  epicardial-­‐to-­‐endocardial	  gradient	  of	  sympathetic	  fibres	  (Ieda	  et	  al.,	  2007).	  My	  second	  aim	  was	  to	  assess	  whether	  NRP1	  patterns	  sympathetic	  axon	  extension	  in	  target	  organs	  by	  investigating	   postnatal	   heart	   innervation.	   The	   dorsal	   aorta	   is	   another	   target	   of	  sympathetic	  innervation,	  and	  I	  also	  investigated	  if	  this	  was	  affected	  by	  NRP1	  signalling.	  The	  recently	  discovered	  semaphorin,	  SEMA3G,	  binds	  NRP2	  and	  repels	  sympathetic	  axons	  
in	  vitro,	  and	  its	  embryonic	  expression	  is	  mainly	  restricted	  to	  arteries	  and	  sensory	  ganglia	  (Kutschera	  et	  al.,	  2011;	  Taniguchi	  et	  al.,	  2005).	  My	  third	  aim	  was	  to	  attempt	  to	  find	  an	   in	  
vivo	  role	  for	  SEMA3G	  in	  helping	  pattern	  the	  sympathetic	  nervous	  system.	  	  
	  
3.2	  Results	  
3.2.1	  Expression	  of	  the	  neuropilins	  in	  the	  sympathetic	  nervous	  system	  	  
3.2.1.1	  NRP1	  and	  NRP2	  are	  differentially	  expressed	  by	  neural	  crest	  cells	  Initially,	  I	  wanted	  to	  ascertain	  whether	  trunk	  NCCs	  express	  either	  or	  both	  of	  the	  neuropilin	  receptors.	   I	   cut	   transverse	   cryosections	   through	   wildtype	   embryos	   at	   E9.5	   at	   forelimb	  level	  and	  immunolabelled	  these	  with	  antibodies	  against	  NRP1	  and	  NRP2	  (Fig.	  3.1A-­‐C).	  At	  this	   stage	   in	   mouse	   development,	   the	   first	   of	   the	   early	   wave	   NCCs	   destined	   to	   be	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sympathetic	  neurons	  had	  aggregated	  at	  the	  dorsal	  aorta.	  NRP1	  was	  expressed	  in	  recently	  delaminated	  NCCs	  migrating	   through	   the	   dorsal	   somite,	   as	  well	   as	   in	   sympathetic	  NCCs	  aggregated	   at	   the	   dorsal	   aorta	   (Fig.	   3.1A,G).	   NRP1	   was	   also	   strongly	   expressed	   in	   the	  endothelium	  of	  the	  dorsal	  aorta,	  as	  previously	  shown	  at	  this	  stage	  (Kitsukawa	  et	  al.,	  1995).	  The	  sympathetic	  NCCs	  at	  the	  dorsal	  aorta	  did	  not	  express	  NRP2	  (Fig.	  3.1B,C,H).	  A	  subset	  of	  migratory	  NCCs	  in	  the	  dorsal	  somite	  was	  NRP2-­‐positive.	  NRP2	  was	  also	  expressed	  in	  the	  sclerotome	   and	   the	   developing	   posterior	   cardinal	   vein.	   Venous	   expression	   of	   NRP2	   had	  previously	  been	  shown	  in	   the	  cardinal	  veins	  of	  chick	  (Herzog	  et	  al.,	  2001).	  All	  migratory	  NCCs	  expressed	  NRP1	  but	  only	  some	  co-­‐expressed	  NRP1	  and	  NRP2	  (yellow	  in	  Fig.	  3.1C),	  suggesting	  that	  all	  migratory	  NCCs	  are	  NRP1-­‐positive,	  whereas	  only	  a	  subset	  is	  also	  NRP2-­‐positive.	  The	  merged	  image	  confirmed	  that	  the	  sympathetic	  NCCs	  aggregated	  at	  the	  dorsal	  aorta	  were	  NRP1-­‐positive	  and	  NRP2-­‐negative	  (Fig.	  3.1C,I).	  
3.2.1.2	  NRP1	  and	  NRP2	  are	  expressed	  by	  mature	  sympathetic	  neurons	  At	  later	  developmental	  stages,	  transverse	  cryosections	  through	  a	  wildtype	  mouse	  at	  E11.5	  (Fig.	  3.1D-­‐F)	  showed	  that	  the	  dorsal	  aorta	  and	  cardinal	  veins	  continued	  to	  express	  NRP1	  and	   NRP2,	   respectively.	   Several	   non-­‐NC-­‐derived	   neural	   structures,	   such	   as	   the	   dorsal	  funiculus	  and	  radial	  nerves,	  expressed	  NRP1	  (Fig.	  3.1D).	  NRP2	  was	  expressed	  in	  parts	  of	  the	   sclerotome	   and	  myotome,	   and	   in	   the	   lower	   part	   of	   the	   neural	   tube	   (Fig.	   3.1E).	   The	  neurons	   of	   the	   sympathetic	   ganglia	   were	   strongly	   NRP1-­‐positive	   (Fig.	   3.1J),	   and	   the	  sensory	   neurons	   of	   the	   DRG,	   another	   type	   of	   NC-­‐derived	   structure,	   were	   also	   NRP1-­‐positive	  (Fig.	  3.1D,F).	  The	  sympathetic	  neurons	  in	  the	  ganglia	  were	  strongly	  NRP2-­‐positive	  (Fig.	   3.1E,F,K).	   This	   suggested	   that	   sympathetic	   neurons	   expressed	   NRP2	   even	   though	  their	  NC	  precursors	  did	  not.	  These	  findings	  were	  confirmed	  by	  co-­‐labelling	  of	  sympathetic	  neurons	  with	  antibodies	  for	  sympathetic	   markers	   and	   neuropilins.	   Transverse	   cryosections	   through	   E9.5	   and	   E11.5	  wildtype	   embryos	   at	   forelimb	   level	   were	   immunolabelled	   with	   an	   antibody	   against	   the	  sympathetic	  NC	  marker	  MASH1	  or	   the	  mature	  sympathetic	  marker	   tyrosine	  hydroxylase	  (TH)	  and	  NRP1	  or	  NRP2	  (Fig.	  3.2).	  At	  E9.5,	  NRP1	  and	  MASH1	  staining	  co-­‐localised	  in	  the	  sympathetic	  NCCs	  of	   the	  primary	   sympathetic	   ganglia	   at	   the	  dorsal	   aorta	   (yellow	   in	  Fig.	  3.2A,C),	   but	   these	   MASH1-­‐positive	   sympathetic	   NCCs	   were	   not	   NRP2-­‐positive	   (Fig.	  3.2B,D).	  The	  dorsal	  aorta	  was	  NRP1-­‐positive,	  as	  were	  the	  migratory	  NCCs	  in	  the	  somite,	  as	  shown	  above	   (Fig.	  3.2A).	   Some	  migratory	  NCCs	  were	  NRP2-­‐positive,	   and	  NRP2	  was	  also	  expressed	  in	  the	  sclerotome	  and	  the	  posterior	  cardinal	  vein,	  as	  shown	  above	  (Fig.	  3.2B).	  At	  E11.5,	  mature	  sympathetic	  neurons	  in	  the	  ganglia	  co-­‐expressed	  TH	  and	  NRP1	  (Fig.	  3.2E,G-­‐I).	  TH-­‐positive	  sympathetic	  neurons	  of	  the	  ganglia	  also	  expressed	  NRP2	  (Fig.	  3.2F,J-­‐L).	  The	  dorsal	  aorta,	  DRGs	  and	  spinal	  nerves	  were	  NRP1-­‐positive,	  and	  the	  posterior	  cardinal	  veins	  and	   the	  areas	  of	   sclerotome	  and	  myotome	  were	  NRP2-­‐positive,	   as	  observed	  before	   (Fig.	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3.1).	  Taken	   together,	   the	   results	   show	   that	   the	  early	  migratory	  wave	  of	  NCC	  destined	   to	  become	   sympathetic	   neurons	   express	   NRP1	   but	   not	   NRP2,	   and	   once	   they	   have	  differentiated	  into	  mature	  sympathetic	  neurons,	  they	  express	  both	  NRP1	  and	  NRP2.	  These	  observations	   suggest	   that	   the	   neuropilins	   may	   have	   different	   functions	   during	  sympathetic	  development.	  	  
3.2.1.3	  SEMA3A	  binds	  NRP1	  on	  sympathetic	  neurons	  SEMA3A	  and	  SEMA3F	  act	  as	  axon	  guidance	  molecules	  in	  fasciculation	  and	  branching	  of	  the	  developing	  nervous	   system	   through	  NRP1	   and	  NRP2,	   respectively,	   in	   plexin	   co-­‐receptor	  complexes	  (Kitsukawa	  et	  al.,	  1997;	  Sahay	  et	  al.,	  2003;	  Taniguchi	  et	  al.,	  1997).	  An	  alkaline	  phosphatase	   (AP)-­‐binding	   assay	  using	  protein	   constructs	   containing	  AP-­‐tagged	   SEMA3A	  and	   SEMA3F	   or	   AP	   alone	   allowed	   visualisation	   of	   the	   localisation	   of	   SEMA-­‐binding	   in	  wildtype	   embryos	   (Fig	   3.3A,C,E).	   SEMA3A	   bound	   to	   the	   sympathetic	   ganglia	   and	  sympathetic	  axons	  (Fig.	  3.3A,	  inset),	  as	  well	  as	  the	  radial	  nerves	  and	  dorsal	  funiculus	  (Fig.	  3.3A),	  all	  of	  which	  were	  previously	  shown	  to	  express	  NRP1	  (Figs.	  3.1D	  and	  3.2E).	  SEMA3A	  also	   bound	   the	   subepicardial	   layer	   of	   the	   heart	   and	   the	   lungs,	   in	   accordance	   with	   its	  functions	   in	  heart	   innervation	  and	   lung	  development	   (Ieda	  et	   al.,	   2007;	   Ito	   et	   al.,	   2000).	  SEMA3F	   bound	   to	   the	   sympathetic	   ganglia	   and	   axons	   (Fig.	   3.3C,	   inset),	   which	   express	  NRP2	  (Figs.	  3.1E	  and	  3.2F).	  SEMA3F	  also	  bound	  the	  ventral	  neural	  tube	  (Fig.	  3.3C),	  which	  expressed	  NRP2	  (Figs.	  3.1E	  and	  3.2D),	   the	   tissue	  surrounding	  developing	  rib	  bones	  (Fig.	  3.3C),	   perhaps	   consistent	   with	   a	   role	   in	   patterning	   sympathetic	   innervation	   of	   the	  intercostal	   bones	   (Asmus	   et	   al.,	   2000),	   and	  weakly	   in	   lung	   tissue	   (Fig.	   3.3C),	   consistent	  with	   its	   role	   in	   lung	   morphogenesis	   (Kagoshima	   and	   Ito,	   2001).	   The	   control	   AP-­‐only	  construct	  did	  not	  bind	  any	  tissues	  (Fig.	  3.3E).	  Due	  to	  the	  endogenous	  AP	  activity	  of	  blood,	  tissues	   with	   blood	   accumulation,	   such	   as	   the	   dorsal	   aorta	   and	   heart	   ventricles,	   were	  positive	  in	  all	  reactions	  including	  the	  negative	  control	  (Fig.	  3.3A,C,E).	  	  To	   confirm	   that	   SEMA3A	   bound	  NRP1	   in	   the	   sympathetic	   ganglia,	   I	   carried	   out	   the	   AP-­‐binding	   assay	   with	   tissues	   from	   embryos	   with	   point	   mutations	   in	   the	   SEMA-­‐binding	  domain	   of	   the	   Nrp1	   gene	   (termed	   Nrp1Sema	   mutation;	   (Gu	   et	   al.,	   2002))(Fig.	   3.3B,D,F).	  SEMA3A	  did	  not	  bind	  the	  sympathetic	  ganglia,	  sympathetic	  axons	  (Fig.	  3.3B,	  inset),	  axons	  of	  the	  dorsal	   funiculus	  or	  the	  subepicardium	  of	  the	  heart	   in	  Nrp1Sema	  mutants	  (Fig.	  3.3B).	  Since	   these	   were	   all	   bound	   by	   SEMA3A	   in	   wildtype	   tissue,	   this	   indicates	   that	   SEMA3A	  requires	  NRP1	  to	  bind	  these	  tissues.	  Surprisingly,	  lung	  tissue	  was	  still	  bound	  by	  SEMA3A,	  suggesting	  that	  SEMA3A	  can	  bind	  to	  another	  receptor	   in	  this	  tissue.	  There	   is	  precedence	  for	   this	   finding,	   as	   SEMA3A	   binds	   vomeronasal	   axons	   through	   either	   NRP1	   or	   NRP2	  (Cariboni	  et	  al.,	  2011).	  SEMA3F	  bound	  the	  sympathetic	  ganglia	  and	  axons	  (Fig.	  3.3D,	  inset),	  ventral	   neural	   tube	   and	   the	   tissue	   surrounding	   the	   developing	   rib	   bones	   in	   Nrp1Sema	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Figure 3.1: Sympathetic NCCs express NRP1 and mature sympathetic neurons express 
both NRP1 and NRP2.  
Transverse 20µm cryosections at forelimb level through wildtype embryos at E9.5 (A-C; box in 
C magnified in G-I) and E11.5 (D-F; box in F magnified in J-L) immunolabelled for NRP1 (green) 
and NRP2 (red). At E9.5, the first NCCs aggregated at the dorsal aorta (da) to seed the primary 
sympathetic ganglia (psg) expressed NRP1 (A) but not NRP2 (B); accordingly, they appeared 
green, not yellow, in the merged image (C,I). NCCs migrating through the somite were positive 
for both NRP1 and NRP2 (yellow in C). At E11.5, sympathetic neurons forming the sympathetic 
ganglia (sg) were positive for both NRP1 (D) and NRP2 (E), as ganglia appeared yellow in the 
merged image (F,L). nt, neural tube; drg, dorsal root ganglia. Scale bars: A-C – 50 µm; D-F – 
200 µm.  
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Figure 3.2: MASH1-positive NC sympathetic precursors express NRP1, and TH-positive 
sympathetic neurons express both NRP1 and NRP2.  
Transverse 20µm cryosections at forelimb level through wildtype embryos at E9.5 (A-D) and 
E11.5 (E-L) immunolabelled for NRP1 or NRP2 (red) and TH or MASH1 (green). At E9.5, 
sympathetic precursors in the primary sympathetic ganglia (psg) expressed MASH1 and NRP1 
(yellow, A; labelled psg magnified in C) but not NRP2 (B; labelled psg magnified in D). At E11.5, 
sympathetic neurons in the sympathetic ganglia (sg) expressed TH as well as NRP1 (E; labelled 
sg magnified in G-I) and NRP2 (F; labelled sg magnified in J-L). NRPs were localised to the cell 
surface, whereas TH was in the cytoplasm. nt, neural tube; drg, dorsal root ganglia. Scale bars: 




Figure 3.3: SEMA3A and SEMA3F bind sympathetic neurons.  
Transverse cryosections at forelimb level through E14.5 wildtype (A,C,E) and Nrp1sema-/- (B,D,F) 
embryos, with bound AP-tagged SEMA3A, SEMA3F or control AP-only construct. Higher 
magnification of the left sympathetic ganglia (sg) is shown in inset of each panel. In wildtype 
tissue, SEMA3A bound sympathetic ganglia and axons, as well as the dorsal funiculus (df), 
spinal nerves (spn), lung tissue (labelled) and subepicardium (se) of the heart (A). SEMA3A 
binding was abolished in Nrp1sema-/- embryos, except in lung tissue (B). SEMA3F bound 
sympathetic ganglia and axons, the ventral neural tube (nt) and tissue surrounding developing 
rib bones (C). Binding persisted in Nrp1sema-/- embryos (D). Control AP-construct did not bind 
tissue of wildtype or Nrp1sema-/- embryos (E,F). da, dorsal aorta. Scale bar: 500 µm.  
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3.2.2	   Different	   roles	   for	   NRP1	   and	   NRP2	   in	   sympathetic	   nervous	   system	  
development	  
3.2.2.1	  NRP1	  signalling	  controls	  sympathetic	  precursor	  placement	  The	  findings	  so	  far	  suggest	  that	  NRP1	  and	  NRP2	  have	  different	  roles	  in	  the	  development	  of	  the	   sympathetic	   nervous	   system,	   most	   likely	   through	   signalling	   with	   their	   respective	  ligands	   SEMA3A	   and	   SEMA3F.	   Working	   on	   a	   project	   with	   Dr	   Quenten	   Schwarz,	   we	  provided	   evidence	   that	   NRP1	   and	   NRP2	   coordinate	   different	   aspects	   of	   trunk	   NCC	  migration	   (Schwarz	   et	   al.,	   2009a).	   To	   clarify	   the	   role	   of	   NRP1	   in	   sympathetic	   nervous	  system	  development,	  I	  subjected	  E9.5	  embryos	  lacking	  NRP1	  and	  wildtype	  littermates	  to	  
in	  situ	  hybridisation	  using	  an	  RNA	  probe	  for	  Mash1,	  the	  early	  sympathetic	  marker.	  I	  then	  immunolabelled	   transverse	   cryosections	   of	   these	   embryos	  with	   endomucin	   to	  mark	   the	  vasculature	   and	   smooth	  muscle	   actin	   to	  mark	   the	   dorsal	   aorta	   (Fig.	   3.4).	   Two	   bilateral	  
Mash1-­‐positive	  primary	   sympathetic	   ganglia	  were	  visible	   adjacent	   to	   the	  dorsal	   aorta	   in	  wildtype	   embryos	   (Fig.	   3.4A).	   Primary	   sympathetic	   ganglia	   were	   also	   present	   in	   4/4	  embryos	  lacking	  NRP1,	  however,	  they	  all	  had	  sympathetic	  precursors	  in	  ectopic	  locations,	  and	   1/4	   had	   small	   clusters	   of	   Mash1-­‐positive	   sympathetic	   precursors	   lateral	   to	   the	  posterior	  cardinal	  veins	  (Fig.	  3.4B).	  	  Immunolabelling	   of	   cryosections	   from	   E11.5	   wildtype	   embryos	   with	   endomucin,	   the	  sympathetic	   marker	   TH	   and	   the	   neuronal	   marker	   Tuj1	   revealed	   TH-­‐	   and	   Tuj1-­‐positive	  sympathetic	   neurons	   in	   compact	   sympathetic	   ganglia	   between	   the	   dorsal	   aorta	   and	  posterior	   cardinal	   veins	   (Fig.	   3.5A,C,E).	   In	   mutants,	   the	   sympathetic	   ganglia	   were	  dispersed	   (Fig.	   3.5B),	   and	   some	   neurons	   were	   seen	   in	   ectopic	   locations	   lateral	   to	   the	  posterior	   cardinal	   veins	   (Fig.	   3.5D,F),	   similar	   to	   the	   phenotype	   observed	   in	   earlier	   ages	  (Fig.	   3.4B).	   The	   sympathetic	   neurons	   in	   all	   positions	   were	   TH-­‐	   and	   Tuj1-­‐positive,	  indicating	   that	   despite	   their	   aberrant	   location,	   sympathetic	   differentiation	   proceeded.	  Interestingly,	  ectopic	  neurons	  often	  seemed	  to	  be	  positioned	   in	  close	  proximity	   to	  blood	  vessels,	   perhaps	   because	   blood	   vessels	   are	   surrounded	   by	   a	   fibronectin-­‐rich	   ECM	  favourable	  to	  migratory	  NCCs	  (Francis	  et	  al.,	  2002;	  Newgreen	  et	  al.,	  1982).	  DRGs	  were	  also	  misshapen	  in	  the	  Nrp1-­‐null	  mutant,	  confirming	  previous	  observations	  that	  NRP1	  regulates	  migration	  or	  differentiation	  of	  sensory	  NCC	  populations	  (Schwarz	  et	  al.,	  2009b).	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Figure 3.4: Ectopic sympathetic precursors in NRP1 mutants.  
E9.5 wildtype and Nrp1-null mutant embryos labelled by wholemount in situ hybridisation with 
Mash1 probe (alkaline phosphatase reaction product pseudocoloured in red), transverse 
sections at forelimb level were immunolabelled for endomucin (endm, green) and smooth 
muscle actin (sma, blue). In wildtype embryos (A; n=3), Mash1-positive sympathetic precursors 
aggregated into primary sympathetic ganglia (psg), in between the dorsal aorta (da) and the 
posterior cardinal veins (pcv). In Nrp1-null embryos (B; n=4), there were some Mash1-positive 





Figure 3.5: Ectopic sympathetic precursors in NRP1 mutants differentiate into neurons.  
Transverse cryosections of E11.5 wildtype and Nrp1-null embryos immunolabelled for Tuj1 
(blue), tyrosine hydroxylase (TH, red) and endomucin (Endm, green); half the section is shown. 
In wildtype (A), Tuj1-positive dorsal root ganglia (drg) formed properly in the same plane as a 
spinal nerve (spn). Tuj1- and TH-positive neurons were aggregated between the dorsal aorta 
(da) and the posterior cardinal vein (pcv), forming the primary sympathetic ganglia (box in A 
magnified in C,E; n=3). In Nrp1-null mutants (B), DRGs were misshapen and there were fewer 
sympathetic neurons in the primary sympathetic ganglia (arrows in B), with TH- and Tuj1-
positive ectopic neurons lateral to the pcv (box in B magnified in D,F; n=3). Scale bars: 100 µm. 
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3.2.2.2	  NRP1/SEMA3A	  and	  NRP2/SEMA3F	  signalling	  control	  sympathetic	  chain	  organisation	  To	  visualise	  sympathetic	  chains	   in	  wholemounts,	   the	  head	  and	   internal	  organs	   including	  liver,	   stomach,	   heart	   and	   lungs	   were	   dissected	   away	   from	   E13.5	   embryos	   and	   the	  remaining	   trunk	   immunolabelled	   with	   TH	   antibody	   and	   an	   HRP-­‐conjugated	   secondary	  antibody	  (Fig.	  3.6).	  Sympathetic	  chains	   in	  wildtype	  embryos	   lay	  either	  side	  of	   the	  dorsal	  aorta,	  and	  stretched	  from	  the	  anterior	  superior	  cervical	  ganglia	  towards	  the	  posterior	  end	  of	  the	  embryo	  (Fig.	  3.6A,	  long	  bracket).	  Individual	  ganglia	  were	  visible	  as	  grouped	  clusters	  of	   TH-­‐positive	   neurons	   in	   a	   string	   formation	   (Fig.	   3.6A,	   short	   bracket),	   with	   axons	  stretching	  the	  length	  of	  the	  string	  of	  ganglia,	  completing	  the	  chain	  structure.	  In	  Nrp1-­‐null	  embryos,	   the	   sympathetic	   chains	   were	   disorganised.	   The	   neuronal	   cell	   bodies	   were	  dispersed	  in	   loose	  clusters	   instead	  of	  tight	  ganglia	  (Fig.	  3.6B,F).	  Many	  sympathetic	  axons	  did	  not	  remain	  in	  the	  chain,	  but	  prematurely	  extended	  inwards	  towards	  the	  dorsal	  aorta.	  Sympathetic	  neurons	  were	  seen	  in	  ectopic	  locations	  distal	  to	  the	  dorsal	  aorta	  (Fig.	  3.6G),	  consistent	  with	  observations	  from	  earlier	  developmental	  stages	  (Figs.	  3.4B	  and	  3.5B),	  and	  particularly	   at	   forelimb	   level.	   This	   agrees	   with	   the	   high	   expression	   of	   SEMA3A	   in	   the	  forelimb	   (Schwarz	   et	   al.,	   2009b),	   as	   without	   NRP1/SEMA3A	   signalling	   the	   sympathetic	  NCC	   could	   stray	   into	   these	   areas.	   These	   characteristics	   were	   phenocopied	   in	   embryos	  lacking	   SEMA3A	   (Fig.	   3.6,	   compare	   B	   with	   C,	   and	   G	   with	   H),	   and	   were	   consistent	   with	  previous	  findings	  (Kawasaki	  et	  al.,	  2002).	  	  The	   sympathetic	  nervous	   system	  was	  affected	  mildly	   in	  embryos	   lacking	  NRP2,	  as	   some	  sympathetic	  axons	  extended	  from	  the	  chain	  prematurely	  and	  reached	  towards	  and	  around	  the	  dorsal	  aorta	  (Fig.	  3.6D,I).	  Similarly,	  in	  mice	  lacking	  SEMA3F,	  some	  axons	  were	  lying	  on	  top	  of	  and	  around	  the	  dorsal	  aorta	  (Fig.	  3.6E,J).	  However,	  in	  contrast	  to	  Nrp1-­‐	  or	  Sema3a-­‐null	   embryos,	   the	   sympathetic	   ganglia	   appeared	   well	   condensed.	   To	   verify	   that	   the	  sympathetic	  neurons	  were	  as	  condensed	  in	  mutants	  as	  in	  wildtypes,	  I	  quantified	  the	  area	  of	  ganglia	  and	  the	  distance	  between	  the	  ganglia	  in	  cryosections	  through	  the	  trunk	  of	  E14.5	  wildtype	   and	   Nrp2-­‐null	   mice	   immunolabelled	   with	   TH	   (Fig.	   3.7A-­‐D).	   There	   were	   large	  changes	   in	   ganglia	   area	   and	  distance	   at	  different	   anteroposterior	   levels	   in	   each	   embryo.	  Therefore	   I	   took	   measurements	   from	   two	   different	   levels:	   the	   anterior	   SCG	   level	   and	  further	   posteriorly	   in	   the	   trunk	   where	   the	   sympathetic	   chains	   are	   thinner,	   termed	  sympathetic	   chain	   level.	   There	   were	   no	   significant	   differences	   between	   wildtypes	   and	  
Nrp2-­‐null	   mutants	   in	   ganglia	   area	   (Fig.	   3.7E;	   mean	   SCG	   area:	   wildtypes	   0.034mm2	   ±	  0.002mm2	   versus	   NRP2	  mutants	   0.034mm2	   ±	   0.004mm2,	   P	   =	   0.974	   in	   a	   paired	   t-­‐test);	  mean	  chain	  area:	  wildtypes	  0.01mm2	  ±	  0.002mm2	  versus	  mutants	  0.012mm2	  ±	  0.002mm2,	  
P	   =	   0.465	   in	   a	   paired	   t-­‐test)	   or	   in	   distance	   between	   ganglia	   (Fig.	   3.7F;	   mean	   inter-­‐SCG	  distance	  wildtypes	  0.53mm	  ±	  0.006mm	  versus	  mutants	  0.57mm	  ±	  0.034mm,	  P	  =	  0.310	  in	  a	  paired	   t-­‐test;	   mean	   chain	   inter-­‐ganglia	   distance	   wildtypes	   0.44mm	   ±	   0.02mm	   versus	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mutants	   0.46mm	   ±	   0.03mm,	  P	   =	   0.507	   in	   a	   paired	   t-­‐test).	   Together,	   these	   observations	  suggested	  that	  NRP2	  is	  not	  essential	  for	  neuron	  cell	  body	  organisation	  in	  the	  sympathetic	  ganglia,	  but	  functions	  in	  sympathetic	  axon	  guidance.	  
3.2.2.3	  Signalling	  mechanism	  in	  NRP1	  controlled	  sympathetic	  nervous	  system	  development Mice	  lacking	  NRP1	  have	  severe	  cardiovascular	  defects,	  and	  my	  earlier	  work	  suggested	  that	  ectopic	  neurons	  are	  often	  placed	  proximal	  to	  blood	  vessels	  (Fig.	  3.5B).	  I	  therefore	  asked	  if	  the	  sympathetic	  phenotype	  in	  Nrp1-­‐null	  mutants	  was	  secondary	  to	  a	  defective	  vasculature	  or	   due	   to	   a	   cell-­‐autonomous	   defect	   in	   the	   sympathetic	   NCC	   lineage.	   I	   used	   transgenic	  mouse	  lines	  expressing	  CRE	  recombinase	  under	  the	  control	  of	  the	  endothelial-­‐specific	  Tie2	  promoter	  (Kisanuki	  et	  al.,	  2001)	  or	  the	  NC	  promoter	  Wnt1	  (Chai	  et	  al.,	  2000)	  crossed	  to	  a	  conditional	  Nrp1	   “floxed”	   line	   to	   target	  NRP1	   in	   these	  specific	   cell	   lineages.	  Mice	   lacking	  endothelial	  NRP1	  had	  no	  defects	   in	   sympathetic	   chain	   organisation	   (Fig.	   3.8B),	  whereas	  mice	  lacking	  NRP1	  in	  the	  NC	  lineage	  had	  defects	  that	  phenocopied	  the	  Nrp1-­‐null	  mice	  (Fig.	  3.8D);	  ganglia	  were	  dispersed,	  axons	  extended	  from	  the	  chain	  and	  neurons	  were	  scattered	  in	  ectopic	   locations.	  Consistent	  with	   the	   lack	  of	  phenotype	   in	  endothelial	  NRP1	  mutants,	  mice	  lacking	  the	  vascular	  NRP1	  ligand	  VEGF164,	  which	  also	  have	  a	  disrupted	  vasculature	  (Ruhrberg	  et	  al.,	  2002),	  had	  no	  defects	  in	  the	  sympathetic	  chain	  organisation	  (Fig.	  3.8C).	  	  Taken	   together,	   these	  results	  suggest	   that	  SEMA3A	  signals	   through	  NRP1	  on	  NC-­‐derived	  sympathetic	   precursors	   to	   regulate	   sympathetic	   NCC	   migration	   and	   placement,	   and	  subsequent	   development	   of	   the	   sympathetic	   nervous	   system,	   independently	   of	   blood	  vessels.	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Figure 3.6: Sympathetic chain is disorganised in mutants deficient in semaphorin or 
neuropilin signalling.  
E13.5 embryos with internal organs removed immunolabelled for TH and presented in ventral 
view to visualise the sympathetic chains. In wildtype (A), sympathetic chains (sc, long bracket) 
extend anteroposteriorly either side of the spinal cord, with individual sympathetic ganglia visible 
(sg, short bracket) and all axons remaining within the chain (n=10). Position of dorsal aorta 
(hashed red line), level of forelimb (fl) and anterior (a) and posterior (p) directions are indicated. 
In all Nrp1-null mutants (B; boxes in B magnified in F and G), axons extended prematurely 
across the midline (arrows in F) and ectopic neurons were visible (G; n=3). Sema3a-null 
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mutants (C; box in C magnified in H) phenocopied these defects, with misguided sympathetic 
axons and ectopic neurons, particularly at forelimb level (H; n=4). Nrp2-null mutants (D, box in 
D magnified in I) exhibited mild axon guidance defects, with sympathetic axons reaching 
towards and around the dorsal aorta (arrows in I; n=4). Sema3f-null mutants (E, box in E 





Figure 3.7: Sympathetic ganglia in embryos lacking NRP2 are not dispersed.  
Transverse sections through E14.5 wildtype (A,C) and Nrp2-null (B,D) embryo trunks were 
immunolabelled for TH to measure the cross section area of the paired ganglia (red dotted line 
in A) and distance between ganglia (red straight line in A) at anterior superior cervical ganglion 
level (SCG; A,B) and further posterior at the sympathetic chain level (C,D). There were no 
significant differences in area of ganglia at SCG or chain level (E) or distance between the two 
ganglia at SCG or chain level (F) between wildtypes and Nrp2 mutants (paired t-test, n=4 each). 




Figure 3.8: Defect in sympathetic chain from loss of NRP1 is cell autonomous and 
independent of vascular defects.  
E13.5 embryos with internal organs removed immunolabelled for TH presented in ventral view 
to visualise the sympathetic chains. The sympathetic chains were normal in embryos lacking 
endothelial NRP1 (B; n=4) or the VEGF164 isoform (C; n=3), as in wildtype (A; n=14). Embryos 
lacking NRP1 in NC-derived tissues (D) had disorganised sympathetic chains with ectopically 
placed sympathetic neurons distal to the chains at the forelimb (fl) and sympathetic axons 
extending out of the chain (n=5). Scale bar: 250µm. 
 88	  
3.2.2.4	  Ectopic	  sympathetic	  precursors	  in	  the	  absence	  of	  NRP1	  differentiate	  into	  sympathetic	  
neurons	  	  Even	   though	   abnormal	   blood	   vessel	   patterning	   does	   not	   account	   for	   sympathetic	   NCC	  displacement,	   the	   proximity	   of	   ectopic	   sympathetic	   neurons	   to	   blood	   vessels	   (Fig.	   3.5B)	  suggests	   they	   respond	   to	   blood	   vessel-­‐derived	   cues.	   The	   dorsal	   aorta	   releases	   BMPs,	  which	  have	  been	   implicated	   in	   induction	  of	   sympathetic	   differentiation	  or	   in	   survival	   of	  sympathetic	   NCCs	   (Morikawa	   et	   al.,	   2009;	   Shah	   et	   al.,	   1996).	   Many	   ectopic	   neurons	   in	  mutants	   with	   disrupted	   NRP1	   signalling	   are	   positioned	   far	   from	   the	   dorsal	   aorta	   (Figs.	  3.6B	  and	  3.8D),	  so	  would	  be	  unlikely	  to	  be	  affected	  by	  dorsal	  aorta-­‐derived	  BMP	  signals.	  To	  assess	  whether	  any	  misplaced	  NCCs	  die	  due	  to	  the	  lack	  of	  dorsal	  aorta-­‐derived	  signals,	  I	  immunolabelled	  sections	  through	  E10.5	  wildtype	  and	  Nrp1;Wnt1Cre	  mutant	  embryos	  with	  antibodies	  for	  MASH1	  and	  activated	  Caspase3	  (aCasp3),	  a	  marker	  for	  apoptosis	  (Fig.	  3.9A-­‐D).	  Consistent	  with	  previous	  findings	  in	  Nrp1-­‐null	  embryos	  (Figs.	  3.4B	  and	  3.5B),	  mutant	  embryos	   had	   dispersed	   primary	   sympathetic	   ganglia	   compared	   to	  wildtypes	   (Fig.	   3.9B)	  and	   ectopic	   MASH1-­‐positive	   sympathetic	   precursors	   (Fig.	   3.9B,D).	   No	   MASH1-­‐positive	  ectopic	   sympathetic	   precursors	   appeared	   to	   undergo	   apoptosis,	   as	   there	   was	   no	  MASH1/aCasp3	   colocalisation	   in	   sympathetic	   precursors	   (Fig.	   3.9B,D).	   Note	   that	  autofluorescent	  blood	  cells	  appeared	  yellow	  and	  were	  visible	  within	  the	  blood	  vessels	  of	  these	   sections;	   they	   should	   not	   be	   confused	   with	   apoptotic	   cells.	   At	   E11.5,	   MASH1	  immunolabelling	  of	  the	  sympathetic	  ganglia	  was	  reduced	  in	  intensity	  as	  most	  sympathetic	  precursors	   had	   differentiated	   into	   sympathetic	   neurons	   in	   wildtype	   embryos	   (Fig.	  3.10A,C).	  Similarly	   in	  Nrp1;Wnt1Cre	  mutant	  embryos,	   few	  sympathetic	  precursors	   in	   the	  ganglia	   expressed	   MASH1	   (Fig.	   3.10B,D),	   and	   few	   ectopically	   located	   sympathetic	  precursors	   remained	   MASH1-­‐positive	   at	   this	   stage	   (Fig.	   3.10B,D).	   None	   of	   the	   ectopic	  MASH1-­‐positive	  cells	  were	  co-­‐labelled	  with	  aCasp3	  (Fig.	  3.10D)	  so	  were	  not	  apoptotic.	  To	  confirm	   that	   ectopic	   sympathetic	   precursors	   differentiated	   properly,	   I	   immunolabelled	  cryosections	   through	   E10.5	   embryos	   for	   MASH1	   and	   TH	   (Fig.	   3.9E-­‐H).	   MASH1-­‐positive	  sympathetic	   precursors	   were	   beginning	   to	   differentiate	   and	   express	   TH	   in	   wildtype	  embryos	   (Fig.	   3.9E,G).	   In	   Nrp1;Wnt1cre	   mutants,	   some	   MASH1-­‐positive	   sympathetic	  precursors	  at	  the	  ganglia	  and	  in	  ectopic	  locations	  were	  also	  beginning	  to	  produce	  TH	  (Fig.	  3.9F,H).	  MASH1	  is	  a	  transcription	  factor	  and	  localises	  to	  the	  cell	  nucleus,	  whereas	  the	  TH	  enzyme	  localises	  to	  the	  cytoplasm,	  therefore	  cells	  co-­‐expressing	  the	  markers	  had	  red	  TH-­‐positive	   cytoplasm	   surrounding	   green	   MASH1-­‐positive	   nucleus.	   Blood	   cells	   were	   also	  autofluorescent	  in	  these	  sections.	  At	  E11.5,	  no	  MASH1-­‐positive	  sympathetic	  precursors	  in	  wildtype	  and	  very	  few	  in	  Nrp1;Wnt1cre	  mutant	  cryosections	  were	  apparent	  (Fig.	  3.10E-­‐H).	  Sympathetic	  neurons	  in	  the	  wildtype	  ganglia	  strongly	  expressed	  TH,	  and	  exhibited	  a	  tight	  ganglionic	   structure	   (Fig.	   3.10E,G).	   In	   mutants,	   sympathetic	   neurons	   in	   the	   ganglia	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Figure 3.9: Ectopic sympathetic NCCs are not apoptotic but begin to differentiate at 
E10.5.  
Transverse cryosections at forelimb level through E10.5 wildtype and Nrp1;Wnt1Cre mutant 
embryos. Immunolabelling with activated Caspase3 (aCasp3; red, A-D) and MASH1 (green, A-
D) revealed MASH1-positive cells aggregated into primary sympathetic ganglia located between 
the dorsal aorta (da) and the left and right posterior cardinal veins (pcv) in wildtype embryos 
(A,C; n=1); aCasp3 was localised to a few cells in the neural tube (nt) and limb (arrowheads, A). 
In Nrp1;Wnt1Cre mutants (B,D), MASH1-positive sympathetic anlagen were in dispersed 
primary sympathetic ganglia and misplaced distal to the posterior cardinal veins, and none of 
them were aCasp3-positive (n=1); aCasp3 was present in a few cells in the neural tube and 
limb (arrowheads, B). Immunolabelling for MASH1 (green, E-H) and TH (red, E-H) revealed 
some of the MASH1-positive sympathetic anlagen at the dorsal aorta in wildtypes expressed TH 
(E,G; n=1). In Nrp1;Wnt1Cre mutants (F,H), some MASH1-positive sympathetic anlagen at the 
primary ganglia expressed TH, and some MASH1-positive ectopically located sympathetic 
anlagen also expressed TH (n=1). MASH1 was localised to the nucleus, whereas TH was in the 




Figure 3.10: Ectopic sympathetic NCCs are not apoptotic but can differentiate into 
sympathetic neurons at E11.5.  
Transverse cryosections at forelimb level through E11.5 wildtype and Nrp1;Wnt1Cre mutant 
embryos. Immunolabelling for activated Caspase3 (aCasp3, red), MASH1 (green) and 
endomucin (Endm, blue; A-D) reveals few MASH1-positive sympathetic anlagen between the 
dorsal aorta (da) and the left and right posterior cardinal veins (pcv) in wildtype (A,C; n=1). 
aCasp3 was localised to cells in the gut (arrowheads, A). Nrp1;Wnt1Cre mutant (B,D) had few 
MASH1-positive sympathetic anlagen at the dorsal aorta and some anlagen misplaced distal to 
the posterior cardinal veins (D), none of which were aCasp3-positive (n=1). aCasp3 was 
localised to cells in the gut and many cells in the DRG (arrowheads, B). Immunolabelling for TH 
(red), MASH1 (green) and endomucin (blue; E-H) revealed TH-positive sympathetic ganglia at 
the dorsal aorta with no MASH1-positive anlagen in wildtypes (E,G; n=1). In Nrp1;Wnt1Cre 
mutants (F,H), loose TH-positive sympathetic ganglia were formed between the dorsal aorta 
and the posterior cardinal veins and TH-positive neurons were misplaced in ectopic locations 
distal to the posterior cardinal veins. There were also a few MASH1-positive sympathetic 
precursors in the mutant (H; n=1). nt, neural tube. Scale bar: 200µm.  	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3.2.2.5	  Sympathetic	  NCC	  placement	  is	  severely	  affected	  when	  NRP1	  and	  NRP2	  are	  lost	  I	  have	  shown	  that	  NRP2	  is	  expressed	  in	  the	  sympathetic	  nervous	  system	  (Figs.	  3.1	  and	  3.2)	  and	   functions	   in	   sympathetic	   axon	   guidance	   (Fig.	   3.6D).	   NRP2	   also	   guides	   early	   NCC	  segmental	  migration	   (Gammill	   et	   al.,	   2006),	   and	   I	   therefore	  wanted	   to	  assess	  whether	   it	  has	   a	   role	   in	   sympathetic	   NCC	   migration	   and	   sympathetic	   precursor	   placement.	   I	   also	  wanted	   to	   further	   investigate	   any	   interaction	   between	   NRP2	   and	   NRP1	   in	   early	  sympathetic	   development.	   Abolishing	   both	   Nrp1	   and	   Nrp2	   results	   in	   early	   embryonic	  lethality	   due	   to	   severe	   cardiovascular	   defects,	   presumably	   due	   to	   defective	   VEGF164	  signalling	  (Takashima	  et	  al.,	  2002).	  Hence,	  I	  utilised	  mice	  with	  a	  null	  allele	  for	  Nrp2	  as	  well	  as	   a	   mutated	   SEMA-­‐binding	   domain	   in	  Nrp1,	   which	   preserves	   VEGF-­‐binding	   domain	   of	  NRP1	  to	  allow	  development	  to	  birth	  (Gu	  et	  al.,	  2003).	  	  Assembling	   primary	   sympathetic	   chains	   were	   visualised	   by	   in	   situ	   hybridisation	  with	   a	  
Mash1	  RNA	  probe	  on	  wholemount	  E9.5	  mouse	  embryos	  (Fig.	  3.11).	  Viewed	   laterally,	   the	  
Mash1-­‐positive	  primary	  sympathetic	  ganglia	  in	  wildtype	  animals	  formed	  loosely	  arranged	  strands	  along	  the	  anteroposterior	  axis,	  either	  side	  of	  the	  notochord,	  below	  the	  neural	  tube	  (Fig.	   3.11A).	   Transverse	   cryosections	   at	   forelimb	   level	   through	   these	   embryos	   allowed	  visualisation	  of	  clustering	  of	  NC	  sympathetic	  precursors	  into	  primary	  sympathetic	  ganglia	  either	   side	  of	   the	  dorsal	   aorta,	   in	  between	   the	  dorsal	   aorta	   and	  posterior	   cardinal	   veins	  (Fig.	   3.11E).	   Mash1-­‐positive	   primary	   sympathetic	   ganglia	   in	   Nrp1Sema	   mutant	   embryos	  formed	   in	   the	   same	   location	   as	   in	   wildtype,	   but	   appeared	   less	   condensed	   (Fig.	   3.11B).	  Cryosections	  showed	  that	   the	  primary	  sympathetic	  ganglia	  were	   indeed	  more	  dispersed,	  and	  some	  sympathetic	  precursors	  were	  located	  further	  laterally	  to	  the	  posterior	  cardinal	  veins	   from	   the	  dorsal	   aorta	   (Fig.	   3.11F),	   consistent	  with	  previous	   observations	   in	  Nrp1-­‐null	  embryos	  (Figs.	  3.4B	  and	  3.5B).	  In	  embryos	  lacking	  NRP2,	  all	  sympathetic	  precursors	  were	  placed	  correctly	  adjacent	  to	  the	  dorsal	  aorta	  and	  well	  condensed	  as	  in	  wildtype	  (Fig.	  3.11C,G).	   Compound	   Nrp2/Nrp1sema	   homozygous	   mutants	   had	   more	   severely	   dispersed	  primary	  sympathetic	  ganglia	  than	  Nrp1sema-­‐null	  mutants	  that	  could	  barely	  be	  identified	  in	  the	  lateral	  wholemount	  view	  (Fig.	  3.11D).	  Transverse	  cryosections	  showed	  that	  individual	  
Mash1-­‐positive	   sympathetic	   precursors	  were	   so	   scattered	   that	   the	   primary	   sympathetic	  ganglia	  were	  barely	  visible	  (Fig.	  3.11H).	  Few	  sympathetic	  precursors	  could	  be	  seen	  at	  the	  dorsal	  aorta;	  instead	  many	  were	  spread	  in	  ectopic	  locations	  distal	  to	  the	  posterior	  cardinal	  vein	   (Fig.	   3.11H,	   arrowheads).	   Since	   the	   phenotype	   in	   the	   compound	   Nrp2/Nrp1sema	  mutant	  was	  more	  severe	  than	  in	  the	  Nrp1sema-­‐null	  mutant	  (Fig.	  3.11B,F),	  and	  the	  Nrp2-­‐null	  mutant	   had	   no	   phenotype	   at	   all,	   this	   suggests	   a	   genetic	   interaction	   between	   NRP1	   and	  NRP2	  in	  sympathetic	  development.	  	  There	  appeared	   to	  be	   increased	  numbers	  of	  Mash1-­‐positive	  NCCs	   in	   the	  gut	  of	  Nrp1sema-­null	   and	   compound	  Nrp2/Nrp1sema	  mutants	   (Fig.	   3.11F,H)	   compared	   to	   control	   or	  Nrp2-­‐
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Figure 3.11: Compound NRP1/NRP2 mutants have disrupted primary sympathetic 
ganglia.  
In situ hybridisation with a Mash1 probe on E9.5 embryos to visualise sympathetic NCCs in the 
developing primary sympathetic ganglia (psg); wholemount embryos were viewed laterally, 
anterior to the left, with the position of the developing heart indicated (lv – left ventricle) (A-D) 
and transverse cryosections at forelimb (fl) level were taken (E-H). In wholemount wildtype 
embryos (A), Mash1-positive NCCs formed loosely arranged chains of psg ventrally to the 
neural tube (nt) in an anteroposterior orientation; Mash1 was also expressed in the neural tube. 
In transverse sections (E), Mash1-positive psg were positioned in between the dorsal aorta (da) 
and the posterior cardinal veins (pcv; n=1). Mash1 was expressed in two areas of the neural 
tube and the gut (E). In wholemount Nrp1sema -null embryos, psg appeared less well condensed 
(B); in transverse sections, psg were dispersed and some Mash1-positive NCCs were 
misplaced distal to the pcv (arrowheads, F; n=2). There were increased numbers of Mash1-
positive cells in the gut (F). In wholemount Nrp2-null embryos, psg formed normally with no 
ectopically placed sympathetic NCCs (C,G; n=1). Compound Nrp1sema/Nrp2-null mutant had psg 
that were severely dispersed in wholemounts (D) and in transverse sections (H); more Mash1-
positive sympathetic NCCs were ectopically placed distal to the pcv, and also in the gut, than in 
Nrp1sema -null embryos (arrowheads, H; n=1). Scale bars: A-D – 200µm; E-F – 100µm.  
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3.2.2.6	  A	  ‘back-­up’	  role	  for	  NRP2	  in	  sympathetic	  precursor	  placement	  To	   assess	   the	   effects	   of	   the	   Nrp2	   and	   Nrp1sema	   mutations	   later	   in	   development,	   I	  immunolabelled	   transverse	   cryosections	   through	   E11.5	   embryos	   with	   TH,	   SMA	   and	  endomucin	  to	  visualise	  the	   location	  of	  differentiated	  sympathetic	  neurons	  relative	  to	  the	  SMA-­‐positive	   dorsal	   aorta	   and	   endomucin-­‐positive	   posterior	   cardinal	   veins	   (Fig.	   3.12).	  Control	  embryos	  with	  heterozygous	  mutations	  in	  both	  Nrp2	  and	  Nrp1Sema	  exhibited	  tightly	  aggregated	  TH-­‐positive	   sympathetic	   ganglia,	  positioned	   in	  between	   the	  dorsal	   aorta	   and	  the	   posterior	   cardinal	   veins,	   as	   in	   wildtypes	   (Fig.	   3.12A,E).	   Nrp2-­‐null	   embryos	   with	   a	  
Nrp1Sema	  heterozygous	  mutation	  had	  well	  formed	  and	  condensed	  sympathetic	  ganglia,	  but	  a	  few	  TH-­‐positive	  neurons	  were	  placed	  ectopically,	  distal	  to	  the	  dorsal	  aorta	  towards	  the	  limb	   (Fig.	   3.12B,F).	   Sympathetic	   ganglia	   in	   Nrp1Sema-­‐null	   embryos	   with	   a	   heterozygous	  
Nrp2	  mutation	  were	  less	  well	  condensed	  and	  had	  more	  TH-­‐positive	  sympathetic	  neurons	  mispositioned	  distal	   to	   the	  posterior	   cardinal	   vein,	   towards	   the	   limb	   (Fig.	  3.12C,G).	  This	  was	   similar	   to	   observations	   in	   Nrp1-­‐null	   embryos	   (Figs.	   3.4B	   and	   3.5B).	   TH-­‐positive	  sympathetic	   ganglia	   at	   the	   dorsal	   aorta	   in	   compound	  Nrp2/Nrp1Sema-­‐null	   mutants	   were	  scattered,	  and	  even	  more	  sympathetic	  neurons	  were	  placed	  ectopically	  toward	  the	  limbs	  distal	   to	   the	   posterior	   cardinal	   vein	   (Fig.	   3.12D,H).	   The	   finding	   that	   abolishing	   both	   the	  NRP1	  and	  NRP2	  signalling	  pathway	  had	  a	  worse	  effect	  on	  sympathetic	  neuron	  placement	  than	   the	   effect	   of	   abolishing	   either	   NRP1	   or	   NRP2	   signalling	   was	   consistent	   with	   the	  results	   from	   E9.5	  Mash1	   in	   situ	   hybridisations	   (Fig.	   3.11).	   This	   suggests	   that	   NRP1	   and	  NRP2	  signalling	  interact	  genetically.	  Since	  Nrp2-­‐null	  mutants	  did	  not	  have	  a	  phenotype,	  I	  suggest	  that	  NRP2	  provides	  a	  ‘back-­‐up’	  function	  for	  NRP1	  in	  sympathetic	  NC	  guidance.	  	  I	   next	   assessed	   the	   sympathetic	   phenotype	   in	   E13.5	  mice	   lacking	   both	  NRP1	   and	  NRP2	  signalling	   pathways	   in	   sympathetic	   neurons	   (Fig.	   3.13).	   I	   utilised	   the	   Nrp1;Wnt1Cre	  mutant	  mice	  to	  abolish	  NRP1	  in	  the	  NC	  lineage	  instead	  of	  using	  the	  Nrp1sema	  mutation	  	  to	  confirm	   the	   phenotype	   was	   due	   to	   a	   cell	   autonomous	   effect	   on	   sympathetic	   neurons.	  Compound	  Nrp1;Wnt1Cre/Nrp2-­‐null	  mutants	  had	  more	  ectopic	  neurons	  (arrowheads,	  Fig.	  3.13	   compare	   F	   and	   H)	   and	   more	   severely	   disrupted	   sympathetic	   chains	   than	   in	   the	  
Nrp1;Wnt1Cre	  mutant	   (Fig.	   3.13	   compare	  B,E	  with	  C,G).	  This	   is	   in	   support	   of	   the	   theory	  that	  NRP2	  compensates	  for	  the	  loss	  of	  NRP1,	  since	  Nrp2-­‐null	  mutants	  do	  not	  have	  defects	  in	  the	  sympathetic	  ganglia	  (Fig.	  3.7).	  There	  were	  also	  misguided	  axons	  and	  axons	  lying	  on	  top	  of	  the	  dorsal	  aorta	  (arrows	  Fig.	  3.13G),	  similar	  to	  the	  axon	  guidance	  defects	  in	  Nrp2-­‐null	  mutants	  (Fig.	  3.6D).	  I	   next	   investigated	   ligand	   mutants	   to	   explore	   whether	   embryos	   lacking	   SEMA3A	   and	  SEMA3F	  phenocopy	   embryos	   lacking	  NRP1	   and	  NRP2,	   given	   that	   SEMA3A	   is	   thought	   to	  signal	   through	   NRP1	   and	   SEMA3F	   through	   NRP2.	   As	   expected,	   compound	  
Sema3a/Sema3f-­‐null	  mutants	  (Fig.	  3.14C,F)	  also	  had	  more	  severely	  disrupted	  sympathetic	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Figure 3.12: Compound NRP mutants have severely disrupted sympathetic ganglia.  
Transverse cryosections through E11.5 control, Nrp1sema-null, Nrp2-null and compound 
Nrp1sema/Nrp2-null mutant embryos immunolabelled for TH (red), smooth muscle actin (SMA, 
blue) and endomucin (endm, green). Sympathetic ganglia (sg) in control embryos (A,E) were 
tightly packed bundles of TH-positive neurons, located between the dorsal aorta (da) and the 
posterior cardinal veins (pcv; n=1). A Nrp1sema heterozygous mutation on a homozygous Nrp2-
null background (B,F) resulted in a mild phenotype; TH-positive sympathetic ganglia were 
positioned at the correct location, with a few neurons in ectopic locations (arrowheads in B; 
n=1). Introducing a heterozygous Nrp2 mutation onto an Nrp1sema -null background (C,G) 
worsened this phenotype; more ectopic neurons were positioned lateral to the pcv (arrowheads 
in C; n=1). Double Nrp2/Nrp1sema knockout mutants (D,H), had dispersed ganglia and many TH-
positive sympathetic neurons were placed distally in the forelimb (arrowheads in D; n=1). nt, 




Figure 3.13: Sympathetic chains are disorganised in mutants lacking NRP1 and NRP2.  
E13.5 embryos with internal organs removed were subjected to immunolabelling with TH to 
visualise the sympathetic chains, as in wildtype (A; box magnified in D). In Nrp1;Wnt1Cre 
mutants (B, boxes magnified in E,F), ganglia were dispersed, with misguided axons under the 
dorsal aorta (E) and ectopic sympathetic neurons distal to the chains (arrowheads in F). In 
compound Nrp1;Wnt1Cre/Nrp2-null mutants (C, boxes magnified in G,H; n=3), ganglia were 
more dispersed (G) with misguided axons on top of the dorsal aorta (arrows in G) and many 





Figure 3.14: Sympathetic chains are disorganised in mutants lacking SEMA3A and 
SEMA3F.  
E13.5 embryos with internal organs removed and immunolabelled for TH. Sema3f-null mutants 
with a Sema3a heterozygous mutation (A, box magnified in D) had some sympathetic axons 
extending towards and around the dorsal aorta (arrows in D). Sema3a-null embryos with a 
heterozygous Sema3f mutation (B, box magnified in E) had dispersed sympathetic ganglia, 
axons extending across the midline (arrow in E) and ectopic neurons distal to the sympathetic 
chain. Compound Sema3a/Sema3f-null embryos (C, box magnified in F) had more severely 
disrupted sympathetic chains, with sympathetic ganglia less well condensed, axons extending in 
anteroposterior directions in ectopic locations, for example on top of the dorsal aorta (arrow in 




3.2.3	  NRP1	  controls	  postnatal	  sympathetic	  innervation	  of	  target	  organs	  Sympathetic	  axons	  from	  the	  stellate	  ganglia	  innervate	  the	  heart	  to	  modulate	  heart	  rate	  in	  response	  to	  stress.	  I	  next	  asked	  if	  the	  disorganisation	  observed	  in	  the	  sympathetic	  nervous	  system	   of	   embryos	   with	   disrupted	   NRP	   signalling	   persists	   into	   adulthood	   and	   affects	  target	  organ	  innervation.	  For	  the	  following	  analysis,	  I	  used	  Sema3a-­‐null	  mutants	  that	  have	  ablated	   signalling	   through	  NRP1,	   and	  Nrp1;Wnt1Cre	  mutants	   that	   have	   ablated	  NRP1	   in	  the	  NC	   lineage,	   since	  NRP1	   signalling	  on	  NCCs	  was	   shown	   to	  be	   critical	   for	   sympathetic	  development	  (Fig.	  3.8D).	  Additionally,	  these	  mice	  are	  viable	  into	  adulthood	  in	  contrast	  to	  
Nrp1-­‐null	  and	  Nrp1sema-­‐null	  mutants.	  	  Immunolabelling	   wholemount	   hearts	   from	   embryos	   at	   E17.5	   allowed	   visualisation	   of	  sympathetic	  axons	  lying	  on	  the	  epicardial	  surface.	  Consistent	  with	  previous	  observations	  (Ieda	  et	  al.,	  2007),	  SEMA3A-­‐deficient	  embryonic	  hearts	  had	  fewer	  axons	  on	  the	  epicardial	  surface	  of	  the	  heart	  compared	  to	  wildtype	  hearts	  (Fig.	  3.15A,B).	  This	  was	  also	  observed	  in	  embryonic	   hearts	   lacking	   NRP1	   in	   the	   NC	   lineage	   (Fig.	   3.15C,D).	   Previous	   observations	  showed	  that	  SEMA3A	  acts	  as	  a	  repulsive	  guidance	  molecule	  to	  maintain	  the	  epicardial-­‐to-­‐endocardial	   gradient	   of	   sympathetic	   fibres	   through	   the	   cardiac	   wall	   (Ieda	   et	   al.,	   2007).	  Because	  AP-­‐tagged	  SEMA3A	  bound	  NRP1	  in	  the	  subepicardial	   layer	  of	  the	  heart	  at	  E14.5	  (Fig.	  3.3A),	  these	  results	  suggest	  that	  the	  reduction	  in	  sympathetic	  fibres	  on	  the	  epicardial	  surface	  of	  hearts	  lacking	  SEMA3A	  or	  NRP1	  is	  because	  NRP1-­‐deficient	  fibres	  are	  more	  able	  to	  invade	  the	  endocardium.	  	  To	  test	  whether	  more	  sympathetic	  fibres	  invade	  the	  endocardium	  in	  hearts	  lacking	  NRP1	  in	  the	  NC	  lineage,	  I	  examined	  the	  pattern	  of	  sympathetic	  innervation	  in	  the	  cardiac	  wall	  in	  longitudinal	  cryosections	  through	  postnatal	  day	  (P)	  7	  wildtype	  and	  Nrp1;Wnt1Cre	  mutant	  mouse	  hearts	  immunolabelled	  for	  TH	  and	  endomucin	  (Fig.	  3.16,A-­‐D).	  Quantification	  of	  the	  number	  of	  sympathetic	  fibres	  per	  field	  in	  the	  outer	  epicardium	  and	  inner	  endocardium	  of	  wildtype	   and	   Nrp1;Wnt1Cre	   mutant	   mice	   revealed	   that	   the	   epicardial-­‐to-­‐endocardial	  gradient	   was	   less	   steep	   in	   mice	   lacking	   NRP1	   in	   the	   NC	   lineage	   compared	   to	   wildtype	  (compare	  red	   line	  to	  blue	   line	   in	  Fig.	  3.16E).	  There	  were	  fewer	  sympathetic	   fibres	  at	   the	  surface	  epicardium	   in	  Nrp1;Wnt1Cre	  mutant	  hearts	   than	  wildtype	  hearts	   (Fig.	  3.16A,C,E;	  wildtype	  mean	  number	  of	  fibres	  85	  ±	  14	  versus	  mutant	  mean	  80	  ±	  5),	  and	  more	  fibres	  in	  the	   endocardium	   of	  Nrp1;Wnt1Cre	   hearts	   compared	   to	   wildtype	   hearts	   (Fig.	   3.16B,D,E;	  wildtype	  mean	  number	  of	  fibres	  20	  ±	  1	  versus	  mutant	  mean	  38	  ±	  4).	  This	  resulted	  in	  a	  4.4-­‐fold	   difference	   in	   sympathetic	   fibres	   between	   epicardium	   and	   endocardium	   in	  wildtype	  hearts,	  compared	  to	  a	  2.1-­‐fold	  difference	  in	  Nrp1;Wnt1Cre	  mutant	  hearts,	  and	  represented	  a	  significant	  decrease	  in	  fold	  change	  (P	  =	  0.019	  in	  a	  two-­‐sample	  student’s	  t-­‐test,	  Fig.	  20F).	  Thus,	  the	  overall	  numbers	  of	  sympathetic	  fibres	  within	  the	  heart	  are	  unaltered,	  but	  many	  more	  sympathetic	  axons	  reached	  the	  endocardium	  in	  mice	  lacking	  NC-­‐derived	  NRP1	  than	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Figure 3.15: Fewer sympathetic nerve fibres on the epicardial surface in embryonic 
hearts lacking SEMA3A or NRP1 in the NC lineage.  
E17.5 wildtype, Sema3a-null or Nrp1;Wnt1Cre mutant hearts subjected to immunolabelling with 
TH, visualised from the base of the heart with the apex towards the bottom. Sympathetic nerve 
bundles were abundant on the epicardial surface of control hearts (A,C), with three to five 
bundles reaching towards the apex of each heart (n=6). Sema3a-null mutants (B) had fewer 
sympathetic nerve bundles on the epicardial surface, and only one bundle was seen reaching 
towards the apex (n=3). Nrp1;Wnt1Cre mutants (D) also had fewer sympathetic nerve bundles 
on the epicardial surface; none were seen reaching towards the apex (n=3). b, base; a, apex. 




Figure 3.16: Loss of NRP1 in NC alters the epicardial-to-endocardial distribution of 
sympathetic nerve fibres in postnatal hearts.  
Longitudinal sections of P7 hearts from wildtype and Nrp1;Wnt1Cre mutants were 
immunolabelled for TH (red) and endomucin (green). Nrp1;Wnt1Cre mutants had fewer 
sympathetic fibres on the heart epicardial surface than wildtype (A), and nerves in mutants were 
defasciculated. The number of sympathetic fibres per 0.02mm2 field in epicardial (A,C) and 
endocardial (arrowheads, B,D) tissue of the left ventricular wall were quantified (E,F); compared 
to wildtypes, mutant hearts had a reduced epicardial-to-endocardial sympathetic fibre gradient 
(E) and a significantly lower fold difference of sympathetic fibres between epicardium and 




Figure 3.17: Loss of NRP1 in NC reduces the number of sympathetic nerve fibres 
innervating the aorta.  
50µm vibratome sections of P7 aortas from wildtypes (A) and Nrp1;Wnt1Cre mutants (B) 
immunolabelled with TH (green) and SMA (red). Quantification of sympathetic fibres in contact 
with the dorsal aorta in each section (C) reveals significantly fewer sympathetic fibres on the 
dorsal aorta in mutants compared to wildtypes (n=3 each). * P < 0.05 in a two-sample student’s 
t-test. Scale bars: 100 µm.  	  
 106	  
3.2.4	  Investigating	  a	  function	  for	  SEMA3G	  in	  the	  sympathetic	  nervous	  system	  Preliminary	   studies	   showed	   that,	   despite	   the	   predominantly	   vascular	   embryonic	  expression	  of	  SEMA3G,	  Sema3g-­‐null	  mice	  have	  no	  defects	  in	  vascular	  patterning	  or	  smooth	  muscle	   actin	   coating	   (personal	   communication,	   Minoru	   Takemoto	   and	   Prof	   Christer	  Betsholtz).	   Similarly,	   no	   gross	   patterning	   defects	   were	   found	   in	   the	   PNS	   (personal	  communication,	  Minoru	   Takemoto	   and	   Prof	   Christer	   Betsholtz).	   A	   recent	   study	   claimed	  that	   SEMA3G	   has	   an	   autocrine	   destabilising	   effect	   on	   endothelial	   cells	   and	   a	   paracrine	  effect	   on	   smooth	  muscle	   cell	   outgrowth	   in	   vitro	   (Kutschera	   et	   al.,	   2011).	  However	  no	   in	  
vivo	  function	  for	  SEMA3G	  was	  declared	  from	  analysis	  of	  the	  Sema3g-­‐null	  mice.	  	  Major	  arteries	  are	  innervated	  by	  the	  sympathetic	  nervous	  system	  before	  birth,	  and	  these	  arteries	  express	  SEMA3G	  in	  the	  embryo	  (personal	  communication,	  Minoru	  Takemoto	  and	  Prof	  Christer	  Betsholtz).	  Taking	   into	  account	   in	   vitro	  work	   showing	   that	   SEMA3G	  repels	  sympathetic	   neurons	   (Taniguchi	   et	   al.,	   2005),	   these	   results	   make	   SEMA3G	   a	   likely	  candidate	  for	  a	  chemorepellant	  sympathetic	  axon	  guidance	  molecule.	  	  




Figure 3.18: Sema3g is expressed in arteries and sensory ganglia at E11.5.  
Visualisation of Sema3g expression using lacZ reporter in E11.5 Sema3g heterozygous 
mutants (A). Sema3g is expressed by major arteries, including the internal and external carotid 
arteries (ica, eca; B) and the dorsal aorta (da; E), and in the trigeminal ganglia (tg; B) and dorsal 
root ganglia (drg, C-E). Vibratome sections in D and E were taken at positions indicated in A. 




Figure 3.19: Sema3g expression in arteries and sensory ganglia is maintained at E12.5 
and E13.5.  
Visualisation of Sema3g expression using lacZ reporter in Sema3g heterozygous mutants at 
E12.5 (A-C) and E13.5 (D-F). At E12.5 Sema3g is expressed in major arteries, including the 
external carotid arteries (eca; A) dorsal aorta (da; C), and trigeminal ganglia (tg; A) and DRG 
(B,C). At E13.5, expression in external carotid arteries (D), dorsal aorta (F) and DRGs (E,F) is 
maintained. Scale bars: 1mm.  	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Figure 3.20: Loss of SEMA3G does not affect development of the sympathetic nervous 
system.  
E13.5 wildtype (A; n=5) and Sema3g-null mutants (B; n=4) with internal organs removed 
immunolabelled with TH revealed that the sympathetic chains developed normally, with no 




Figure 3.21: Loss of SEMA3G in absence of SEMA3A or SEMA3F does not exacerbate 
sympathetic nervous system defects.  
E13.5 control (A), Sema3g-null (B), Sema3a-null (C), compound Sema3a/Sema3g-null (D) and 
compound Sema3f/Sema3g-null (E) mutant embryos subjected to TH immunolabelling, viewed 
ventrally with internal organs removed. The phenotypes previously observed when SEMA3A is 
lost, including misplaced sympathetic neurons and disorganised ganglia (C), or the axon 
guidance defect observed when SEMA3F was lost, were not worsened by the concurrent loss of 




Figure 3.22: Loss of SEMA3G does not affect postnatal sympathetic innervation 
patterning of the heart or dorsal aorta.  
Longitudinal cryosections from P7 wildtype (A,B) and Sema3g-null (C,D) hearts were 
immunolabelled for TH (red) and endomucin (green), and the number of sympathetic fibres per 
0.02mm2 field in epicardial (A,C) and endocardial (arrowheads, B,D) tissue of the left ventricular 
wall was quantified. No difference in number of sympathetic fibres in epicardium or 
endocardium was found, resulting in no change in fold difference in sympathetic fibres between 
epicardium and endocardium (E; n=2 each). Vibratome sections of P7 dorsal aortas were cut 
from wildtypes (F) and Sema3g-null mutants (G), immunolabelled with TH (green) and SMA 
(red), and the number of sympathetic fibres on each section quantified. There was no difference 
between the numbers of sympathetic fibres on the aorta of mutant mice compared to wildtype 




The	  aim	  of	   the	  work	  described	  earlier	   in	  Chapter	  3	  was	   to	   investigate	   the	  roles	  of	  NRP1	  and	   NRP2	   and	   their	   SEMA3	   ligands	   in	   the	   development	   of	   the	   sympathetic	   nervous	  system.	  As	  discussed	  in	  Chapter	  1.1,	  a	  previous	  study	  in	  mice	  showed	  that	  loss	  of	  SEMA3A	  or	  NRP1	  disrupts	  sympathetic	  nervous	  system	  patterning,	  and	  it	  was	  suggested	  that	  these	  defects	  are	  caused	  once	  NCCs	  have	  differentiated	   into	  sympathetic	  neuronal	  progenitors	  (Kawasaki	   et	   al.,	   2002).	   I	   here	   show	   that	   the	   defects	   originate	   during	   sympathetic	   NCC	  migration	   (Figs.	  3.4	  and	  3.11)	   (Schwarz	  et	  al.,	  2009b).	   In	  agreement	  with	   the	  previously	  proposed	  idea	  that	  SEMA3A	  acts	  on	  sympathetic	  neurons	  through	  NRP1	  to	  guide	  axons	  in	  the	   sympathetic	   nervous	   system	   (Kawasaki	   et	   al.,	   2002),	   NRP1	   was	   expressed	   on	  sympathetic	  neurons	  (Figs.	  3.1	  and	  3.2)	  where	  it	  bound	  SEMA3A	  (Figs.	  3.3).	  I	  further	  show	  that	   the	   sympathetic	   nervous	   system	   defects	   observed	   in	   mice	   lacking	   NRP1	   are	   cell	  autonomous	  and	  are	  independent	  of	  vascular	  problems	  (Figs.	  3.6	  and	  3.8).	  	  	  Due	   to	   defective	   NCC	   migration,	   mice	   lacking	   NRP1	   have	   increased	   numbers	   of	   NCC	  entering	  the	  intersomitic	  furrow	  and	  the	  dermomyotome	  pathway	  (Schwarz	  et	  al.,	  2009b).	  I	  contributed	  to	  this	  study	  by	  showing	  that,	  due	  to	  this	  defective	  migration,	  sympathetic-­‐fated	   NCCs	   end	   up	   in	   ectopic	   locations	   (Figs.	   3.4	   and	   3.5)	   (Schwarz	   et	   al.,	   2009b).	   This	  finding	   is	   supported	   by	   previous	   work	   implicating	   NRP1/SEMA3A	   signalling	   in	   the	  migration	  of	  trunk	  NCCs	  in	  vitro	  (Eickholt	  et	  al.,	  1999),	  and	  in	  cranial	  NCC	  migration	  in	  vivo	  (McLennan	  and	  Kulesa,	  2007;	  Osborne	  et	  al.,	  2005).	  	  The	  technique	  used	  in	  the	  study	  that	  reported	   normal	   NCC	   migration	   in	   Nrp1-­‐null	   mice	   (Kawasaki	   et	   al.,	   2002)	   involved	   an	  antibody	   that	   also	   labelled	   blood	   vessels	   (Kubota	   et	   al.,	   1996),	   meaning	   that	   ectopic	  sympathetic	   NCCs	   might	   not	   have	   been	   identified	   because	   they	   migrate	   close	   to	   blood	  vessels.	   I	   now	   show	   that	   ectopically	   placed	   sympathetic	   NCCs	   in	   NRP1-­‐deficient	   mice	  survive	   to	   differentiate	   into	   sympathetic	   neurons	   (Figs.	   3.9	   and	   3.10),	   resulting	   in	   the	  previously	   described	   disorganisation	   of	   the	   sympathetic	   nervous	   system	   (Figs.	   3.6	   and	  3.8).	  	  Work	  using	  mice	  lacking	  the	  BMP	  receptor	  ALK3	  on	  NCCs	  previously	  showed	  that	  without	  BMPs	  derived	  from	  the	  dorsal	  aorta,	  sympathetic	  NCCs	  die	  at	  E10	  (Morikawa	  et	  al.,	  2009).	  In	  my	  work,	  most	  ectopic	  sympathetic	  NCCs	  in	  mice	  lacking	  NRP1	  were	  in	  close	  proximity	  to	   the	  posterior	  cardinal	  vein	  or	  other,	   smaller	  blood	  vessels	   (Fig.	  3.5).	  This	  observation	  raised	   the	  possibility	   that	  ectopically	  positioned	  NCCs	  may	   receive	   survival	   factors	   from	  blood	  vessels	  other	  than	  the	  dorsal	  aorta.	  A	  previous	  study	  showed	  that	  endothelial	  cells	  in	   bone	   express	   BMP4	   to	   stimulate	   bone	   formation	   (Goldman	   et	   al.,	   2009a),	   therefore	  endothelial	   cells	   other	   than	   those	   in	   the	  dorsal	   aorta	  might	   also	   express	  BMPs.	  BMP4	   is	  also	   required	   for	   limb	   development	   (Goldman	   et	   al.,	   2009b)	   and	   is	   expressed	   in	   the	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forelimb	  at	  E9.5,	  E10.5	  and	  E12	  (Selever	  et	  al.,	  2004).	  Consistent	  with	  the	  possibility	  that	  limb-­‐derived	  BMP4	  provides	  a	  survival	  factor	  for	  ectopic	  sympathetic	  neurons,	  they	  were	  particularly	  prevalent	   at	   the	   forelimb	   level	   compared	   to	  other	   anteroposterior	  positions	  (Fig.	  3.6).	  	  My	  work	  showing	  that	  ectopic	  NCCs	  can	  differentiate	  into	  sympathetic	  neurons	  supports	  the	   idea	  of	  NCC	   fate	  predetermination.	  Past	  experiments	  have	   led	   to	   the	  hypothesis	   that	  NCC	   fate	   is	   predetermined	   by	   time	   of	   delamination	   from	   the	   neural	   tube.	   For	   example,	  single	  cell	  tracing	  in	  zebrafish	  showed	  that	  the	  first	  NCCs	  to	  delaminate	  become	  neuroglial	  structures	   and	   NCCs	   delaminating	   later	   become	   melanocytes	   (Schilling	   and	   Kimmel,	  1994).	  More	  recently,	  timing	  of	  delamination	  was	  linked	  to	  previous	  dorsoventral	  location	  of	   NCCs	   in	   the	   mouse	   neural	   tube	   and	   correlated	   with	   expression	   of	   specific	   markers	  (Wilson	   et	   al.,	   2004).	   My	   observations	   show	   that	   sympathetic	   fate	   is	   not	   altered	   by	  mislocation	  of	  sympathetic	  NCCs,	  endorsing	  the	  hypothesis	  that	  NCC	  fate	  is	  predetermined	  at	   the	   time	   of	   delamination	   from	   the	   neural	   tube.	   To	   further	   substantiate	   the	   idea	   that	  sympathetic	  fate	  in	  NCCs	  is	  predetermined,	  sympathetic	  NCCs	  could	  be	  derived	  from	  chick	  embryo	  neural	   tube	   explants	   and	   inserted	   into	   the	  melanocyte-­‐fated	   stream	  of	   an	   older	  chick	   embryo,	   as	   in	   previous	   experiments	   with	   neural	   progenitor	   NCCs	   (Krispin	   et	   al.,	  2010).	  I	  would	  predict	  that	  the	  sympathetic	  NCCs	  would	  reach	  their	  sympathetic	  fate	  even	  in	  the	  melanocyte	  stream.	  	  Consistent	  with	  NRP2	  expression	  in	  differentiated	  sympathetic	  neurons	  (Figs.	  3.1	  and	  3.2)	  (Chen	  et	  al.,	  1997)	  and	  SEMA3F	  binding	  to	  sympathetic	  neurons	  (Fig.	  3.3),	  I	  demonstrated	  here	  using	  mouse	  mutants	  that	  SEMA3F/NRP2	  signalling	  plays	  a	  role	  in	  sympathetic	  axon	  guidance	   (Figs.	  3.6).	  This	   agrees	  with	   in	   vitro	  work	   showing	   that	   the	  normally	   repulsive	  effect	   of	   SEMA3F	   is	   lost	   in	   sympathetic	   axons	   from	   NRP2-­‐deficient	   mice	   (Giger	   et	   al.,	  2000).	  However,	   a	   previous	   study	   found	  no	  obvious	  defect	   in	   sympathetic	  patterning	  of	  mice	   lacking	   NRP2	   (Waimey	   et	   al.,	   2008).	   The	   authors	   of	   this	   previous	   study	   did	   not	  explicitly	  look	  at	  sympathetic	  axon	  guidance,	  and	  images	  showed	  the	  superior	  cervical	  and	  stellate	  ganglia	  at	  E13.5	  rather	  than	  the	  sympathetic	  chain.	  Perhaps	  it	  is	  warranted	  to	  look	  at	   axon	   extension	   from	   these	   ganglia	   later	   in	   development	   in	  mice	   lacking	   NRP2,	   since	  sympathetic	   innervation	   of	   the	   heart,	   which	   originates	   in	   the	   stellate	   ganglia,	   was	   not	  apparent	  at	  E13.5	   in	  my	   investigations	  (not	  shown).	  Alternatively,	   the	  axons	   innervating	  the	  carotid	  arteries	  extend	  anteriorly	  from	  the	  superior	  cervical	  ganglia	  into	  the	  cranium,	  and	  removal	  of	  the	  head	  to	  expose	  the	  ganglia	  may	  have	  resulted	  in	  accidental	  removal	  of	  misguided	  sympathetic	  axons	  in	  the	  previous	  study.	  Examination	  of	  other	  sympathetically	  innervated	  organs	  in	  mice	  lacking	  NRP2,	  such	  as	  the	  carotid	  arteries	  or	  the	  heart	  at	  later	  stages,	  would	  further	  establish	  the	  presence	  of	  the	  sympathetic	  axon	  guidance	  defect.	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As	  well	  as	  the	  sympathetic	  axon	  guidance	  function,	  I	  have	  also	  described	  a	  novel	  function	  for	   NRP2	   in	   early	   sympathetic	   nervous	   system	   development.	   NRP2	   can	   partially	  compensate	   for	   the	   loss	   of	   NRP1	   in	   sympathetic	   NC	  migration	   and	   placement,	   because	  when	  both	  NRP1	  and	  NRP2	  are	  lost,	  the	  sympathetic	  NCC	  migration	  defect	  is	  worse	  than	  when	  NRP1	  alone	  is	  lost	  (Fig.	  3.11	  and	  3.12).	  However,	  I	  could	  not	  find	  NRP2	  expression	  in	  sympathetic	  NC	  precursors	  (Figs	  3.1	  and	  3.2).	  To	  address	  whether	  NRP2	  is	  switched	  on	  in	  sympathetic	   NCCs	   when	   NRP1	   expression	   is	   lost,	   Nrp1-­‐null	   embryos	   at	   E9.5	   could	   be	  immunolabelled	  with	  NRP2	  and	  the	  NC	  marker	  p75.	  Alternatively,	  a	  subset	  of	  sympathetic	  NCCs	  might	  express	  NRP2,	  but	  went	  undetected	  since	  I	  did	  not	  look	  at	  contiguous	  sections.	  It	   has	   been	   previously	   shown	   that	   NRP2-­‐positive	   NCCs	   migrate	   through	   the	   anterior	  somite	  (Gammill	  et	  al.,	  2006;	  Schwarz	  et	  al.,	  2009a).	  Therefore,	  NRP2-­‐positive	  sympathetic	  NCCs	   might	   exist	   in	   the	   primary	   sympathetic	   ganglia	   at	   the	   axial	   level	   of	   the	   anterior	  somite.	   To	   investigate	   whether	   there	   are	   NRP2-­‐positive	   sympathetic	   NCCs,	   contiguous	  sections	   through	   two	  complete	   somites	   should	  be	  double	   immunolabelled	   for	  NRP2	  and	  the	   NCC	   marker	   p75	   and	   examined	   for	   potential	   NRP2-­‐positive	   NCCs	   en	   route	   to	   the	  dorsal	  aorta.	  	  Recent	   work	   provides	   evidence	   for	   the	   unconventional	   ability	   of	   SEMA3A	   to	   signal	  through	  NRP2	  in	  specific	  cases	  of	  axon	  guidance	  (Cariboni	  et	  al.,	  2011).	  In	  agreement,	  the	  AP-­‐binding	  assay	  I	  carried	  out	  showed	  that	  SEMA3A	  bound	  lung	  tissue	  even	  in	  the	  absence	  of	   SEMA-­‐binding	  NRP1	   (Fig.	   3.3).	   Together,	   these	   observations	   raise	   the	   possibility	   that	  SEMA3A	  might	   signal	   through	  NRP2	   in	   the	   absence	   of	   NRP1	   to	   help	   guide	   sympathetic	  NCCs,	  which	  might	  provide	  an	  alternative	  explanation	  for	  why	  the	   loss	  of	  NRP2	  worsens	  the	   NCC	   migration	   phenotype	   in	   the	   absence	   of	   NRP1.	   This	   could	   be	   investigated	   by	  reacting	   AP-­‐tagged	   SEMA3A	   with	   sections	   from	   E9.5	   embryos	   lacking	   NRP1.	   Once	  confirmed,	  perhaps	  by	  testing	  if	  AP-­‐tagged	  SEMA3A	  binding	  in	  lung	  tissue	  is	  abolished	  in	  embryos	  lacking	  NRP2	  and	  SEMA-­‐binding	  NRP1,	  this	  may	  further	  substantiate	  evidence	  of	  SEMA3A	  binding	  NRP2.	  	  By	  analysing	  postnatal	  mice	  lacking	  NRP1	  in	  the	  NC	  lineage,	  I	  confirmed	  and	  extended	  the	  finding	  that	  SEMA3A	  contributes	  to	  sympathetic	  patterning	  in	  the	  postnatal	  heart	  (Ieda	  et	  al.,	   2007)	   by	   showing	   that	   SEMA3A	   signals	   through	   NRP1	   on	   sympathetic	   neurons	   to	  regulate	   innervation	  of	   the	  cardiac	  wall	   (Fig.	  3.16).	  Mice	   lacking	  NRP1	   in	   the	  NC	   lineage	  are	  viable	  so	  the	  defects	  observed	  in	  sympathetic	  patterning	  do	  not	  affect	  survival.	  	  In	  collaboration	  with	   John	  Gomes	  and	  Prof	  Andrew	  Tinker	  at	  University	  College	  London,	  we	  have	  now	  begun	  heart	   function	   studies	  on	  mice	   lacking	  NRP1	   in	   the	  NC	   lineage	  at	  6	  months	  of	  age.	  Telemetry	  on	   live	  mice	  and	  ECG	  on	  mice	  under	  anaesthesia	  were	  used	  to	  follow	   resting	  heart	   rates	   and	  analyse	   them	  by	  measurement	  of	   the	   time	   lapse	  between	  the	  R	  points	  of	  two	  adjacent	  ECG	  curves,	  known	  as	  RR	  values.	  It	  was	  found	  that	  heart	  rates	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of	   mutants	   were	   on	   average	   decreased	   compared	   to	   control	   heart	   rates	   (personal	  communication,	   data	   not	   shown).	   Since	   the	   sympathetic	   nervous	   system	   is	   thought	   to	  increase	  heart	  rate	  (Cao	  et	  al.,	  2000a),	  the	  reduced	  heart	  rate	  in	  the	  Nrp1;Wnt1Cre	  mutant	  mice	  may	  be	  due	   to	  a	   reduction	   in	   functional	   cardiac	   sympathetic	   innervation.	  Defective	  sympathetic	  activity	  causes	  arrhythmias	  in	  dogs	  (Yanowitz	  et	  al.,	  1966),	  and	  interestingly,	  the	   most	   consistent	   defects	   observed	   in	   Nrp1;Wnt1Cre	   mutant	   mice	   were	   arrhythmias	  (personal	   communication,	   data	   not	   shown).	   	   Further	   examination	   is	   required	   to	  substantiate	  thesis	  findings,	  for	  example	  telemetry	  studies	  on	  live	  mice	  during	  exercise,	  to	  see	  if	  their	  heart	  rates	  respond	  abnormally	  to	  physiological	  stimuli.	  	  In	  addition,	   I	   found	   that	   the	   sympathetic	   innervation	  of	   the	  dorsal	   aorta	   is	  misguided	   in	  
Nrp1;Wnt1Cre	  mutant	  mice,	  resulting	  in	  fewer	  axons	  in	  contact	  with	  the	  dorsal	  aorta	  (Fig.	  3.17).	  Stimulation	  of	  sympathetic	  ganglia	  that	  innervate	  the	  dorsal	  aorta	  in	  the	  dog	  alters	  blood	  pressure	  (Gerova	  et	  al.,	  1973),	  suggesting	  that	  the	  defects	  in	  Nrp1;Wnt1Cre	  mutant	  mice	   may	   cause	   problems	   in	   modulation	   of	   blood	   pressure.	   This	   could	   be	   tested	  experimentally	   by	   taking	  measurements	   of	   blood	   pressure	   in	   the	  mice	   before	   and	   after	  exercise	  to	  assess	  whether	  the	  mutant	  mice	  can	  sufficiently	  alter	  blood	  pressure.	  	  The	   defects	   in	   sympathetic	   heart	   innervation	   in	   mice	   lacking	   NRP1	   in	   the	   NC	   lineage	  appeared	   mild	   compared	   to	   other	   published	   reports	   of	   mutant	   mice	   with	   defects	   in	  sympathetic	  innervation.	  For	  example,	  in	  mice	  with	  defective	  NGF	  signalling,	  sympathetic	  innervation	  of	   the	  heart	   is	   almost	   entirely	   lacking	   (Glebova	   and	  Ginty,	   2004).	  Defects	   in	  sympathetic	  innervation	  were	  also	  present	  in	  the	  salivary	  glands	  and	  eyes	  of	  NGF	  mutant	  mice;	   however,	   the	   trachea	   maintained	   normal	   sympathetic	   innervation	   (Glebova	   and	  Ginty,	   2004).	   This	   raises	   the	   possibility	   that	   a	   range	   of	   different	   guidance	   molecules	  specific	  to	  the	  target	  structure	  may	  cooperate	  to	  pattern	  the	  sympathetic	  nervous	  system.	  It	  would	  be	   interesting	   to	   compare	   innervation	  of	   other	   vascular	   sympathetic	   targets	   in	  
Nrp1;Wnt1Cre	  or	   Sema3a-­‐null	  mutant	  mice,	   such	   as	   the	   carotid	   arteries,	   to	   assess	   their	  sympathetic	  innervation	  defects.	  Comparison	  with	  sympathetic	  innervation	  of	  organs	  such	  as	   the	   trachea	   and	   salivary	   glands	   would	   also	   be	   interesting	   to	   assess	   whether	   non-­‐vascular	  structures	  are	  also	  affected	  by	  the	  loss	  of	  NRP1	  signalling.	  A	   recent	   study	   suggested	   that	   SEMA3G	   is	   a	   vascular-­‐acting	   molecule	   that	   increases	  migration	  of	  smooth	  muscle	  cells	  (Kutschera	  et	  al.,	  2011).	  However,	  the	  vascular	  system	  is	  normal	   in	  embryos	   lacking	  SEMA3G	  (personal	  communication,	  Prof	  Christer	  Betsholtz	  &	  Minoru	   Takemoto).	   The	   arterial	   expression	   of	   SEMA3G	   in	   development	   and	   its	   in	   vitro	  ability	   to	   bind	   NRP2	   and	   repel	   sympathetic	   axons	   (Taniguchi	   et	   al.,	   2005)	   led	   me	   to	  hypothesise	   that	   SEMA3G	   might	   guide	   sympathetic	   axons	   to	   their	   arterial	   targets.	  However,	  I	  found	  no	  function	  for	  SEMA3G	  in	  regulating	  sympathetic	  chain	  organisation	  or	  later	   sympathetic	   innervation	   of	   the	   heart	   or	   aorta	   (Figs.	   3.20	   and	   3.22).	   Partially	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overlapping	   expression	   patterns	   of	   SEMA3G	   and	   SEMA3F	   in	   the	   postnatal	  mouse	   brain	  have	   been	   suggested	   to	   indicate	   functional	   compensation	   between	   these	   two	   signalling	  molecules	  (Matsuda	  et	  al.,	  2010).	  Since	  neither	  SEMA3F	  nor	  SEMA3A	  compensate	  for	  the	  loss	   of	   SEMA3G	   in	   embryonic	   sympathetic	   patterning	   (Fig.	   3.21),	   I	   searched	   the	  mouse	  genome	  with	  BLAST	  to	   find	  genes	  similar	   to	  SEMA3G	  that	  might	  encode	  a	  compensating	  class	   3	   semaphorin.	   This	   proved	   unsuccessful,	   however,	   as	   the	   nearest	   homologues	   to	  SEMA3G	   that	   I	   found	   were	   all	   previously	   identified	   semaphorins.	   Whether	   SEMA3A	  compensates	   for	   the	   loss	   of	   SEMA3G	   in	   sympathetic	   innervation	   of	   the	   postnatal	   heart	  remains	  to	  be	  investigated	  using	  compound	  Sema3a/Sema3g-­‐null	  mice.	  	  Decreased	  expression	   in	  adulthood	   (Taniguchi	  et	  al.,	  2005)	   suggests	   that	   the	   function	  of	  SEMA3G	   is	   likely	   to	   be	   developmental.	   Even	   though	   patterning	   of	   the	   PNS	   is	   grossly	  normal	   in	   mice	   lacking	   SEMA3G	   (personal	   communication,	   Prof	   Christer	   Betsholtz	   &	  Minoru	  Takemoto),	  the	  developmental	  expression	  of	  SEMA3G	  in	  the	  sensory	  ganglia	  might	  be	  significant	  to	  its	  adult	  function.	  Using	  an	  AP-­‐tagged	  SEMA3G	  construct	  to	  visualise	  the	  localisation	   of	   bound	   SEMA3G	   might	   shed	   more	   light	   on	   potential	   sites	   of	   action	   of	  SEMA3G	  outside	  the	  vascular	  and	  nervous	  systems	  to	  identify	  an	  essential	  role	  in	  an	  as	  yet	  unidentified	  organ	  system.	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4.	  HSPGS	  IN	  VEGF-­A	  SIGNALLING	  IN	  THE	  DEVELOPING	  BRAIN	  
4.1	  Introduction	  
In	  the	  second	  part	  of	  this	  thesis,	  I	  studied	  the	  role	  HSPGs	  play	  in	  VEGF164-­‐driven	  vascular	  and	   neuronal	   patterning	   in	   the	   developing	   mouse	   brain.	   Early	   in	   vitro	   work	   into	   the	  binding	  affinities	  of	  VEGF-­‐A	  isoforms	  to	  their	  receptors	  suggested	  that	  heparin	  promotes	  VEGF165	  binding	  to	  VEGFR1	  and	  VEGFR2	  (Gitay-­‐Goren	  et	  al.,	  1992;	  Tessler	  et	  al.,	  1994),	  as	  well	  as	  to	  NRP1	  (Soker	  et	  al.,	  1998).	  Consistent	  with	  this,	  cell	  surface	  HS	  produced	  by	  pericytes	   can	   activate	   VEGFR2	   in	   trans	   to	  mediate	   VEGF165-­‐stimulated	   angiogenesis	   in	  
vitro	   (Jakobsson	   et	   al.,	   2006).	   2-­‐O-­‐	   and	   6-­‐O-­‐sulphated	   HS	   in	   particular	   have	   been	  implicated	   in	   VEGF165	   mitogenic	   activity	   and	   endothelial	   tube	   formation	   in	   vitro	  (Ashikari-­‐Hada	   et	   al.,	   2005;	   Chen	   et	   al.,	   2005;	   Robinson	   et	   al.,	   2006).	   I	   here	   aimed	   to	  investigate	   whether	   HSPGs	   have	   a	   role	   in	   presenting	   VEGF165	   to	   its	   receptors,	   as	  suggested	  by	  these	  studies.	  I	  also	  tested	  whether	  HSPGs	  are	  required	  to	  retain	  VEGF164	  in	  the	  ECM	  to	  maintain	  the	  VEGF-­‐A	  gradients	  required	  for	  blood	  vessel	  branching,	  as	  loss	  of	  heparin-­‐binding	  VEGF164	  results	  in	  vascular	  branching	  defects	  in	  the	  mouse	  brain	  due	  to	  the	  loss	  of	  VEGF-­‐A	  gradients	  (Gerhardt	  et	  al.,	  2003;	  Ruhrberg	  et	  al.,	  2002).	  	  The	  migration	   path	   followed	   by	   the	   cell	   bodies	   of	   FBM	   neurons	   is	   guided	   by	   VEGF164	  signalling	  through	  NRP1	  (Schwarz	  et	  al.,	  2004).	  A	  co-­‐receptor	  for	  this	  signalling	  pathway	  has	   not	   yet	   been	   found.	   Since	  VEGF164	   and	  NRP1	  both	   bind	  HS,	   I	   investigated	  whether	  HSPGs	  are	  required	  in	  FBM	  neuronal	  migration.	  	  
	  
4.2	  Results	  
4.2.1	  HSPGs	  in	  VEGF-­A	  driven	  vascular	  patterning	  in	  the	  brain	  
4.2.1.1	  Expression	  of	  HSPGs	  in	  the	  hindbrain	  Initially,	   I	   confirmed	   the	   expression	   of	   HSPGs	   in	   the	   developing	   hindbrain	   using	   an	  antibody	  specific	  for	  HSPGs,	  10E4	  (David	  et	  al.,	  1992),	  as	  previously	  described	  (Stenzel	  et	  al.,	   2009).	   At	   E11.5,	   HSPGs	   were	   expressed	   in	   the	   developing	   subventricular	   vascular	  plexus	  (Fig.	  4.1A,D),	  indicated	  by	  co-­‐expression	  with	  isolectin	  B4	  (IB4),	  a	  marker	  of	  blood	  vessels	   and	  macrophages	   (Fig.	   4.1C,F).	  Macrophages	  were	   not	   positive	   for	   10E4.	   HSPGs	  were	  present	  on	  neural	  progenitor	  cells	  (Fig.	  4.1A-­‐F).	  	  To	  identify	  the	  expression	  of	  genes	  for	  HSPG	  biosynthetic	  enzymes	  or	  for	  the	  core	  protein	  of	  HSPG,	  an	  Affymetrix	  GeneChip	  microarray	  was	  carried	  out	  on	  RNA	  from	  E11.5	  mouse	  hindbrains,	   which	   is	   the	   age	   at	   which	   sprouting	   angiogenesis	   is	   occurring.	   The	   results	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were	   normalised	   to	   gapdh,	   a	   housekeeping	   gene	   due	   to	   its	   stable	   and	   constitutive	  expression	   in	  most	   cells,	   and	  presented	  as	   relative	   intensity	  of	   fluorescent	   signal,	  which	  was	  indicative	  of	  gene	  expression	  (Fig.	  4.2).	  The	  signal	  obtained	  for	  expression	  of	  the	  Pu1	  gene	  was	  used	  as	  a	  negative	  control	  to	  identify	  the	  level	  of	  background	  noise;	  three	  of	  the	  six	  hindbrains	  used	  were	  Pu1-­‐null,	  but	  showed	  an	  ‘expression’	  of	  5,	  so	  expression	  of	   less	  than	   5	  was	   considered	   background	  noise.	  Most	   of	   the	  HSPG	  biosynthetic	   enzymes	  were	  expressed	   in	   the	  hindbrain.	  Both	  Ext1	  and	  Ext2	   enzymes	  were	  expressed	  at	  a	  high	   level,	  along	  with	  Ndst1,	  whereas	  Hsepi,	  the	  gene	  encoding	  C5-­‐epimerase,	  and	  Ndst2	  were	  slightly	  lower.	  Of	   the	   sulphotransferase	   enzymes,	  Hs2st	   and	  Hs6st1	  were	   both	   highly	   expressed,	  and	  Hs6st2	  and	  Hs6st3	  were	  expressed	  at	  a	  lower	  level.	  The	  former	  had	  a	  large	  error	  bar,	  suggesting	  variability	  in	  expression.	  Hs3st1	  expression	  was	  not	  detected	  in	  the	  hindbrain.	  HS3ST1	  functions	   in	  blood	  coagulation	  (Atha	  et	  al.,	  1985)	  and	  there	  are	  no	  reports	  of	   its	  expression	   any	   earlier	   than	   E16	   (Yabe	   et	   al.,	   2005).	   It	   is	   therefore	   unlikely	   that	   this	  enzyme	   functions	   in	  VEGF164	  signalling.	   	   I	   also	   looked	  at	  genes	   for	  HSPG	  core	  proteins.	  
Syndecan-­1	  and	  -­3	  were	  highly	  expressed	  and	  syndecan-­2	  and	  -­4	  were	  expressed	  at	  a	  lower	  level.	  Expression	  of	  glypican-­1,	  -­2,	  -­3	  and	  -­6	  was	  high,	  whereas	  glypican-­4	  expression	  was	  lower,	  and	  glypican-­5	  expression	  was	  not	  detected.	  Of	  the	  ECM	  HSPGs,	  perlecan	  expression	  was	  low	  and	  agrin	  expression	  was	  very	  high.	  Previously,	  expression	  studies	  were	  carried	  out	  on	  three	  of	  the	  sulphotransferase	  enzymes	  by	  Joaquim	  Vieira.	  He	  carried	  out	  a	  β-­‐galactosidase	  assay	  on	  E10.5	  embryos	  containing	  a	  




Figure 4.1: HSPGs are expressed in blood vessels and neural progenitors of the 
hindbrain at E11.5.  
Immunolabelling of E11.5 hindbrains with HSPG marker 10E4 (green in A, higher magnification 
in D) and endothelial marker isolectin4 (IB4; red in B, higher magnification in E) to visualise 
HSPG expression (merged image in C, higher magnification in F). HSPGs were expressed in 




Figure 4.2: HSPG-related genes are expressed in the E11.5 mouse hindbrain.  
Graph of expression of HSPG-related genes in E11.5 hindbrains from GeneChip microarray, 
normalised to gapdh. Hashed red line indicates background noise. Most HSPG biosynthetic 
enzymes were expressed at a high level, including Ext1, Ext2, Ndst1, Ndst2, Hs2st, and Hs6st1. 
The others were also expressed, including C5-epimerase, Hs6st2 and Hs6st3. Hs3st was not 
expressed above background noise. Most HSPG proteins were also highly expressed, including 
syndecan1 and 3, glypican1, 2, 3 and 6, and agrin. Glypican5 was not expressed above 
background noise.  	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4.2.1.2	   Previous	   investigations	   into	   vessel	   branching	   of	   mice	   lacking	   sulphotransferase	  
enzymes	  Previous	   analysis	   of	   blood	   vessel	   patterning	   in	   the	   hindbrain	   subventricular	   plexus	   of	  embryos	  lacking	  these	  enzymes	  revealed	  that	  removal	  of	  HS2ST	  or	  HS6ST1	  or	  both	  did	  not	  perturb	   vessel	   branching	   (J.	   Vieira	   &	   C.	   Ruhrberg,	   unpublished	   data).	   Embryos	   lacking	  HS6ST2	  had	  a	  15%	  decrease	  in	  branching	  of	  the	  subventricular	  vascular	  plexus	  (J.	  Vieira	  &	  C.	  Ruhrberg,	  unpublished	  data).	  These	  samples	  were	  sent	  from	  Dr	  Koji	  Kimata	  at	  the	  Aichi	  Medical	  University	  in	  Japan	  as	  fixed,	  severed	  heads	  of	  embryos,	  from	  which	  the	  hindbrains	  were	  then	  dissected.	  To	  obtain	  clear	  immunolabelling	  with	  PECAM,	  hindbrains	  need	  to	  be	  dissected	   prior	   to	   fixing.	   The	   quality	   of	   the	   immunolabelling	   was	   variable	   between	  hindbrains	  and	  it	  was	  difficult	  to	  accurately	  quantify	  the	  number	  of	  vessel	  branchpoints	  in	  the	  hindbrain.	  The	  laboratory	  supplying	  these	  mice	  then	  closed	  down,	  so	  to	  obtain	  further	  embryos,	  we	  obtained	  a	  mouse	  lacking	  HS6ST2	  from	  Lexicon	  Pharmaceuticals	  Inc.	  
4.2.1.3	  Genetic	  analysis	  of	  the	  Hs6st2	  mutant	  mouse	  	  Like	  the	  Hs2st	  and	  Hs6st1	  knockout	  mice,	  the	  Lexicon	  Pharmaceuticals	  Hs6st2	  mouse	  had	  a	  lacZ/Neo	  cassette	   inserted	   into	  exon	  1	  of	   the	  gene.	  To	  confirm	  the	  efficacy	  of	   the	  Hs6st2	  gene	  knockout,	  I	  carried	  out	  quantitative	  (q)-­‐PCR	  on	  RNA	  extracted	  from	  the	  hindbrains	  of	  E12.5	  embryos	  null	  for	  Hs6st1	  or	  Hs6st2	  (Fig.	  4.3A,B).	  Expression	  was	  normalised	  to	  18s,	  a	  housekeeping	  gene	  encoding	  a	  ribosomal	  RNA	  subunit	  present	  in	  every	  cell,	  and	  presented	  as	  fold	  change	  in	  expression	  from	  wildtype.	  Consistent	  with	  previous	  findings	  (Pratt	  et	  al.,	  2006),	  the	  Hs6st1-­‐null	  mutant	  had	  a	  0.05-­‐fold	  decrease	  from	  wildtype	  (Fig.	  4.3A),	  and	  was	  therefore	   an	   efficient	   knockout.	   The	  Hs6st2	  mutation	  was	   not	   as	   effective	   as	   the	  Hs6st1	  mutation.	  Homozygous	  Hs6st2	  mutants	  had	  a	  0.24-­‐	  or	  0.29-­‐fold	  change	  in	  expression	  from	  wildtype	   in	   the	   presence	   or	   absence	   of	   HS6ST1,	   respectively	   (Fig.	   4.3B),	   meaning	   the	  primers	   still	   detected	   HS6ST2	   RNA.	   The	   reasons	   for	   this	   are	   not	   yet	   clear	   and	  warrant	  further	   investigation.	   The	   presence	   of	   HS6ST2	   protein	   could	   be	   tested	   for	   by	  immunoblotting	  with	  HS6ST2	  antibody,	  or	  simply	  immunolabelling	  of	  knockout	  embryos	  with	   the	  antibody.	  To	   test	   for	   the	  presence	  of	  a	   functional	  enzyme,	  HS	  could	  be	  purified	  from	  fibroblasts	  from	  Hs6st2-­‐null	  embryos	  and	  their	  structure	  assessed	  to	  check	  for	  any	  6-­‐
O-­‐sulphation,	  as	  described	  previously	  for	  the	  Hs2st	  mutant	  mouse	  (Merry	  et	  al.,	  2001).	  	  I	  used	  the	  q-­‐PCR	  to	  address	  whether	  there	  was	  compensatory	  upregulation	  of	  the	  other	  6-­‐
O-­‐sulphation	  enzymes	  in	  the	  absence	  of	  HS6ST2	  by	  quantifying	  the	  expression	  of	  Hs6st3	  as	  well	  as	  Hs6st1	   in	  embryos	   lacking	  HS6ST1	  or	  HS6ST2	  or	  both.	  Expression	  of	  Hs6st1	  was	  not	   affected	   by	   the	   loss	   of	  Hs6st2,	   as	   there	   was	   no	   difference	   in	   fold	   change	   of	  Hs6st1	  expression	   in	   the	   presence	   or	   absence	   of	   HS6ST2	   (Fig.	   4.3A).	  Hs6st3	   expression	   levels	  were	  highly	  variable,	  but	  no	  significant	  difference	  was	  found	  in	  the	  fold	  change	  of	  Hs6st3	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expression	  in	  the	  presence	  or	  absence	  of	  HS6ST1	  or	  HS6ST2	  (Fig.	  4.3C).	  Therefore,	  other	  
Hs6st	  genes	  are	  not	  upregulated	  in	  embryos	  lacking	  HS6ST2.	  	  The	  raw	  data	  from	  the	  qPCR	  in	  wildtype	  hindbrain	  samples	  suggested	  that	  the	  expression	  of	  Hs6st1	  relative	  to	  18s	  is	  5-­‐fold	  higher	  than	  Hs6st2,	  which	  in	  turn	  is	  10-­‐fold	  higher	  than	  




Figure 4.3: q-PCR reveals Hs6st2 mRNA is produced in homozygous Hs6st2 mutant.  
Quantification of Hs6st1 (A), Hs6st2 (B) and Hs6st3 (C) mRNA levels by q-PCR in E12.5 
compound Hs6st1 and Hs6st2 mutant hindbrains, normalised to 18s and shown as fold change 
from wildtype. Hs6st1 expression did not change from wildtype when Hs6st2 was lost. In 
compound Hs6st1/Hs6st2-null hindbrains, Hs6st1 expression was negligible. Hs6st2 was 
expressed in homozygous Hs6st2 mutant hindbrains in the presence and absence of Hs6st1. 
Hs6st3 expression was not affected by loss of Hs6st2 or Hs6st1 or both, and was highly 
variable. For controls, n=3; Hs6st1+/+Hs6st2-/-, n=4; Hs6st1-/-Hs6st2-/-, n=4. Error bars 
represent standard error of the mean. Raw data: wildtype relative expression of Hs6st1 is 5.25, 
Hs6st2 is 0.98 and Hs6st3 is 0.08. 	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4.2.1.4	  Knockdown	  of	  6-­O-­sulphated	  HSPGs	  does	  not	  affect	  vascular	  patterning	  I	   immunolabelled	   hindbrains	   from	   E12.5	   wildtype	   and	   Hs6st2-­‐null	   embryos	   with	   the	  endothelial	   marker	   PECAM	   (Fig.	   4.4A-­‐D),	   and	   quantified	   the	   number	   of	   vessel	  branchpoints	   in	   a	   0.2mm2	   field	   of	   the	   subventricular	   vascular	   plexus	   (Fig.	   4.4E).	  Hindbrains	   from	  mice	   lacking	  HS6ST2	  exhibited	  a	   small	  but	  non-­‐significant	   reduction	   in	  average	  number	  of	  vessel	  branchpoints	   compared	   to	   control	  hindbrains,	  which	   included	  wildtypes	   and	  heterozygous	  Hs6st2	  mutants	   (Fig.	   4.4E;	  wildtypes	  60	  branchpoints	  ±	  4.3	  versus	  mutant	  53	  ±	  4.2).	  There	  was	  high	  variability	   in	  branchpoints	   in	  HS6ST2-­‐deficient	  hindbrains,	   ranging	   between	   46	   and	   62	   vessel	   branchpoints	   per	   field.	   Since	   the	  Hs6st2	  gene	  is	  X-­‐linked,	  I	  separated	  male	  and	  female	  embryos	  by	  genotyping	  for	  the	  presence	  of	  the	   Sex-­determining	   Region	   Y	   (SRY)	   gene	   and	   analysed	   embryos	   for	   vessel	   branching	   to	  address	  whether	   it	  was	   affected	   by	   gender	   (Fig.	   4.4A-­‐D).	   Small	   differences	   between	   the	  controls	  and	  mutants	  were	  seen	  in	  both	  males	  and	  females	  (Fig.	  4.4F;	  male	  controls	  69	  ±	  0	  versus	  male	  mutants	  60	  ±	  2.4;	  female	  controls	  57	  ±	  2.4	  versus	  female	  mutants	  46	  ±	  0.4).	  The	  difference	  in	  males	  was	  slightly	  less	  than	  the	  difference	  in	  females,	  suggesting	  that	  in	  the	   absence	   of	   HS6ST2	   the	   vasculature	   was	   more	   severely	   affected	   in	   females	   than	   in	  males.	  These	  samples	  were	  from	  a	  single	  litter	  and	  statistical	  analysis	  of	  vessel	  branching	  in	  male	  and	  female	  hindbrains	  could	  not	  be	  carried	  out	  because	  the	  n	  numbers	  were	  too	  low.	  	  HSPG	  biosynthetic	  enzymes	  may	  compensate	  for	  each	  other	  in	  knockout	  mutant	  animals,	  for	  example	  mice	  lacking	  HS2ST	  have	  increased	  N-­	  and	  6-­‐O-­‐sulphation	  of	  HS	  chains	  (Merry	  et	  al.,	  2001).	  Therefore,	  HS6ST1	  or	  HS6ST3	  might	  compensate	  for	  the	  loss	  when	  Hs6st2	  is	  knocked	   out.	   Compensation	   by	  HS6ST3	   is	   unlikely	   since	   it	  was	   expressed	   at	   a	   very	   low	  level	  in	  wildtype	  hindbrains	  (Fig.	  4.2)	  and	  was	  not	  upregulated	  in	  the	  absence	  of	  HS6ST2	  (Fig.	  4.3C).	  Hs6st1	  was	  highly	  expressed	  in	  the	  hindbrain	  (Fig.	  4.2)	  and	  although	  it	  was	  not	  upregulated	  in	  the	  absence	  of	  HS6ST2	  (Fig.	  4.3A),	  might	  functionally	  compensate	  for	  it.	  To	  address	   this,	   I	   analysed	   the	   subventricular	   vascular	   plexus	   in	   embryos	   lacking	   both	  HS6ST1	  and	  HS6ST2.	  To	  simplify	   the	  analysis,	  wildtypes	  and	  heterozygous	  mutants	   (e.g.	  pooled	   Hs6st1+/+Hs6st2+/+	   with	   Hs6st1+/-­Hs6st2+/+)	   were	   pooled	   into	   the	   ‘control’	   group.	  Similarly,	  embryos	  homozygous	  for	  Hs6st1	  and	  wildtype	  or	  heterozygous	  for	  Hs6st2	  were	  pooled	   (Hs6st1-­/-­Hs6st2+/+	  with	  Hs6st1-­/-­Hs6st2+/-­),	   and	   vice	   versa.	   An	   initial	   investigation	  using	   final	   samples	   sent	   from	   Japan	   immunolabelled	   with	   IB4	   suggested	   that	   the	  subventricular	   plexus	   of	   embryos	   lacking	   both	   HS6ST1	   and	   HS6ST2	   (Fig.	   4.5C;	  
Hs6st1/Hs6st2	   mutant	   40	   branchpoints	   ±	   3.3;	   n=1)	   had	   fewer	   vessel	   branches	   than	  embryos	  lacking	  either	  HS6ST1	  or	  HS6ST2	  (Fig.	  4.5A,B;	  Hs6st1	  mutant	  49	  branchpoints	  ±	  2.0	  and	  Hs6st2	  mutants	  48	  branchpoints	  ±	  2.5;	  n=1	  and	  n=2,	  respectively).	  However,	  these	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hindbrains	  were	  from	  a	  single	  litter	  with	  no	  control	  heterozygous	  or	  wildtype	  embryos	  so	  comparison	  to	  controls	  could	  not	  be	  carried	  out.	  	  Using	  the	  new	  Hs6st2-­‐null	  mouse	  line	  crossed	  with	  the	  Hs6st1-­‐null	  mouse	  already	  used	  in	  the	   lab,	   I	   found	   that	   at	  E12.5	   (Fig.	   4.6),	   vessel	  branching	   in	   the	   subventricular	  plexus	  of	  male	  Hs6st2-­null	  or	  compound	  Hs6st1/Hs6st2-­‐null	  mutants	  was	  not	  reduced	  compared	  to	  controls	   (Fig.	   4.6E;	   male	   controls	   55	   ±	   7.8,	   male	   Hs6st2	   mutants	   55	   ±	   1.9,	   male	  
Hs6st1/Hs6st2	  mutants	  52	  ±	  0).	  Surprisingly,	  and	  in	  contrast	  to	  previous	  suggestions	  (Fig.	  4.4),	  there	  was	  a	  small	  but	  non-­‐significant	  increase	  in	  vessel	  branching	  in	  female	  Hs6st1-­null,	  Hs6st2-­null	   and	   compound	  Hs6st1/Hs6st2-­null	   mutants	   compared	   to	   controls	   (Fig.	  4.6E;	  female	  controls	  46	  ±	  1.8,	  female	  Hs6st1	  mutants	  50	  ±	  3.0,	  female	  Hs6st2	  mutants	  54	  ±	  5.3,	   female	  Hs6st1/Hs6st2	   mutant	   59	   ±	   0).	   These	   results	   confirmed	   that	   there	   were	   no	  significant	  differences	   in	  hindbrain	  vessel	  branching	  between	  males	  and	   females	  and	  no	  dependence	   of	   changes	   in	   vascular	   branching	   on	   gender,	   therefore	   I	   pooled	   males	   and	  females	   to	   increase	   n	   numbers.	   The	   resultant	   graph	   and	   statistical	   analysis	   confirmed	  there	   was	   no	   decrease	   in	   vascular	   branching	   in	   the	   absence	   of	   HS6ST1	   and	   HS6ST2	  compared	  to	  control	  (Fig.	  4.6F;	  controls	  49	  ±	  3.4,	  Hs6st1	  mutants	  50	  ±	  3.1,	  Hs6st2	  mutants	  56	  ±	  2.1,	  Hs6st1/Hs6st2	  mutants	  55	  ±	  3.4).	  	  The	  visual	  inspection	  of	  the	  E12.5	  hindbrains	  suggested	  a	  developmental	  delay	  in	  animals	  lacking	   both	   HS6ST1	   and	   HS6ST2.	   Vibratome	   sections	   through	   E12.75	   compound	  
Hs6st1/Hs6st2-­null	   hindbrains	   revealed	   that	   they	   were	   thinner	   than	   controls	   and	  resembled	   E12.5	   hindbrains	   (Fig.	   4.7A,B).	   This	   0.25-­‐day	   developmental	   delay	   was	   also	  apparent	   when	   analysing	   FBM	   somata	   migration,	   as	   fewer	   neurons	   had	   migrated	   at	  E12.75	   in	   compound	  Hs6st1/Hs6st2-­null	   hindbrains	   compared	   to	   littermate	   controls,	   as	  discussed	   later	   in	   the	   chapter	   (Fig.	   4.13).	   At	   E12.75,	   compound	   Hs6st1/Hs6st2-­null	  mutants	   had	   no	   significant	   difference	   in	   vessel	   branching	   compared	   to	   control	   (Fig.	  4.7C,F,G;	   controls	   69	  branchpoints	   ±	   4.1	   versus	  Hs6st1/Hs6st2	  mutants	   72	  ±	   1.2).	   There	  was	  a	  small,	  but	  non-­‐significant	  increase	  in	  subventricular	  vessel	  branching	  in	  Hs6st1-­null	  and	   Hs6st2-­null	   mutants	   compared	   to	   control	   (Fig.	   4.7C-­‐E,G;	   Hs6st1	   mutants	   82	   ±	   5.3,	  




Figure 4.4: Loss of HS6ST2 results in no significant decrease in subventricular vessel 
plexus branching.  
Immunolabelling of E12.5 wildtype (A,C) and Hs6st2-null (B,D) hindbrains with endothelial 
marker PECAM and quantification of blood vessel branches per 0.2mm2 field revealed a small 
but non-significant decrease in vessel branching in mutants compared to controls (E; controls 
n=3, mutants n=4). Separation of female controls (A) and mutants (B) from male controls (C) 
and mutants (D) revealed female control hindbrains had fewer branchpoints than male controls 
(F). Both females and males had small but non-significant reductions in vessel branching in 
mutants compared to controls (F, male control n=1, female controls n=2, male mutants n=2, 
female mutants n=2). ‘Control’ groups included wildtype and heterozygous Hs6st2 mutants. 




Figure 4.5: Hindbrain vasculature appears altered in absence of both HS6ST1 and 
HS6ST2.  
Hindbrains from Hs6st1-null (A; n=1), Hs6st2-null (B; n=2) or compound Hs6st1/Hs6st2-null (C; 
n=1) E11.5 embryos subjected to immunolabelling with IB4 to visualise the vasculature, 
revealing slight decrease in vascular complexity in the compound mutant compared to either 




Figure 4.6: Loss of 6-O-sulphation does not affect subventricular vascular branching.  
Immunolabelling of hindbrains from E12.5 wildtype (A), Hs6st1-null (B), Hs6st2-null (C) and 
compound Hs6st1/Hs6st2-null embryos (D) with endothelial marker IB4 for quantification of 
vessel branchpoints in 0.2mm2 field. In males, the number of vessel branchpoints in control, 
Hs6st2-null and Hs6st1/Hs6st2-null hindbrains remained similar (E; n=2, n=7 and n=1, 
respectively). In females, the number of vessel branchpoints in control, Hs6st1-null, Hs6st2-null 
and Hs6st1/Hs6st2-null hindbrains increased slightly in this order (E, n=3, n=3, n=4 and n=1, 
respectively). When males and females were pooled (F), Hs6st2-null or compound 
Hs6st1/Hs6st2-null mutants had slightly higher numbers of branchpoints (n=11 and n=2, 
respectively) than controls or Hs6st1-null hindbrains (n=5 and n=3, respectively). The difference 




Figure 4.7: Loss of 6-O-sulphation does not affect vascular patterning but causes a 
developmental delay.  
Immunolabelling E12.75 hindbrains with IB4 revealed a developmental delay, shown in 
transverse sections of wildtype (A) and compound Hs6st1/Hs6st2-null mutant (B) hindbrains. 
Hindbrain was thinner in mutant than in wildtype, as if it was 0.25 days younger. High 
magnification images of control (C), Hs6st1-null (D), Hs6st2-null (E) and compound 
Hs6st1/Hs6st2-null hindbrains (F) allow quantification of vessel branchpoints (G). No decrease 
in vessel branching was observed in any of the mutants compared to controls. A slight non-
significant increase was observed in Hs6st1-null mutants compared to controls. (Controls, n=4; 
Hs6st1 mutants, n=2; Hs6st2 mutants, n=5; compound mutants, n=3). Scale bars: A,B – 
500µm; C-F – 100µm.  	  
 131	  




Figure 4.8: E14.5 embryos lacking HS6ST1 and HS6ST2 are oedematous.  
Wholemount wildtype (A) and compound Hs6st1/Hs6st2-null (B) embryos shown laterally to 
visualise differences in gross development. Mutant mice exhibit oedema of the trunk and head 
and blood spots on the skin (arrowheads, B). They were developmentally delayed in 
comparison to wildtype, indicated by less well-developed digits and smaller eyes (n=2). Scale 
bar: 1 mm. 	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4.2.1.6	  Endothelial	  cell	  HSPGs	  are	  not	  required	  for	  blood	  vessel	  branching	  I	  next	  investigated	  vascular	  patterning	  in	  embryonic	  brains	  deficient	  in	  HSPG	  synthesis	  in	  specific	  cell	  types.	  I	  first	  deleted	  the	  conditional	  null	  Ext	  “floxed”	  gene	  with	  CRE	  under	  the	  control	  of	  the	  endothelial	  cell	  specific	  Tie2	  promoter	  (hereafter	  referred	  to	  as	  Ext;Tie2Cre	  mutant)	  to	  abolish	  HSPG	  production	  in	  endothelial	  cells.	  To	  assess	  whether	  the	  knockout	  was	   successful,	   I	   immunolabelled	   E11.5	   hindbrains	   with	   the	   HSPG	   antibody	   10E4.	   In	  wildtype	  hindbrains,	  HSPGs	  were	  visible	  on	  the	  vasculature	  and	  in	  the	  neural	  progenitor	  cell	   layer	   (Fig.	   4.9A),	   consistent	   with	   earlier	   observations	   (Fig.	   4.1).	   In	   contrast,	   HSPGs	  were	  no	  longer	  visible	  on	  the	  vasculature	  in	  Ext;Tie2Cre	  mutant	  hindbrains,	  but	  were	  still	  present	   in	   neural	   progenitor	   cells	   (Fig.	   4.9B),	   indicating	   that	   the	   endothelium-­‐specific	  knockout	   was	   efficient.	   I	   quantified	   the	   blood	   vessel	   branchpoints	   in	   hindbrains	  immunolabelled	  with	  PECAM	  (Fig.	  4.9C,D),	  and	  found	  no	  decrease	  in	  subventricular	  vessel	  branching	   when	   HSPG	   production	   was	   abolished	   in	   endothelial	   cells	   compared	   to	  wildtypes	  (Fig.	  4.9E;	  controls	  57	  branchpoints	  ±	  2.7	  versus	  mutants	  63	  ±	  2.9).	  The	  findings	  were	   consistent	   with	   previous	   work	   (J.	   Vieira	   &	   C.	   Ruhrberg,	   unpublished	   data)	   and	  suggest	   that	   HSPGs	   produced	   by	   endothelial	   cells	   are	   not	   essential	   for	   blood	   vessel	  branching.	   Perhaps	   HSPGs	   produced	   by	   neural	   cells	   or	   pericytes	   could	   act	   in	   trans	   in	  VEGF164-­‐driven	   blood	   vessel	   branching,	   as	   pericyte-­‐derived	   HSPGs	   can	   potentiate	  VEGF165/VEGFR2	  signals	  in	  vitro	  (Jakobsson	  et	  al.,	  2006).	  	  
4.2.1.7	  Neural	  progenitor	  cell	  HSPGs	  are	  not	  required	  for	  blood	  vessel	  branching	  To	   address	   whether	   neural	   cells	   produce	   HSPGs	   required	   for	   blood	   vessel	   branching,	   I	  ablated	  the	  conditional	  null	  Ext	  “floxed”	  gene	  with	  CRE	  under	  control	  of	  the	  neural-­‐specific	  
Nestin8	  promoter	  (hereafter	  referred	  to	  as	  Ext;Nes8Cre	  mutant).	  Ext;Nes8Cre	  mutant	  mice	  had	   severe	   head	   malformations:	   forebrains	   protruded	   from	   the	   skull	   (Fig.	   4.10B),	  midbrain-­‐hindbrain	  patterning	  was	  disrupted	  and	  hindbrains	  were	  truncated	  (Fig.	  4.10D).	  These	  characteristics	  were	  consistent	  with	  previous	  observations	  in	  a	  similar	  mutant,	  and	  are	   indicative	   of	   problems	   in	   FGF8	   signalling	   (Inatani	   et	   al.,	   2003).	   In	   addition,	   the	   tails	  had	  not	   grown	   sufficiently	   and	   the	   forelimbs	   exhibited	   syndactyly	   (Fig.	   4.10B),	  which	   is	  also	   seen	   in	   mouse	   mutants	   with	   disrupted	   BMP	   signalling	   (Wang	   et	   al.,	   2004).	  Immunolabelling	   for	   PECAM	   revealed	   that	   the	   hindbrain	   vasculature	   in	   Ext;Nes8Cre	  mutants	  was	  morphologically	  different,	  as	  vessels	  were	  elongated	  and	  stretched	  laterally	  away	  from	  the	  midline	  (Fig.	  4.10E,F).	  Despite	  this,	  quantification	  of	  vessel	  branchpoints	  in	  the	  hindbrains	   indicated	  that	  there	  was	  no	  difference	  in	  branching	  of	  mutants	  compared	  to	   wildtypes	   (Fig.	   4.10E,F,I;	   controls	   66	   branchpoints	   ±	   3.4	   versus	   mutants	   67	   ±	   9.8),	  suggesting	   that	   the	   altered	  morphology	  of	   the	   vasculature	  was	  most	   likely	   secondary	   to	  the	  altered	  brain	  morphology.	  To	  examine	  the	  vasculature	  in	  an	  area	  with	  unaffected	  brain	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morphology,	   I	  also	  quantified	  vessel	  branchpoints	  at	   the	  cervical	  spinal	  cord,	  adjacent	  to	  the	   border	   of	   the	   hindbrain	   (Fig.	   4.10G,H,J).	   Again,	   no	   significant	   decrease	   in	   branching	  was	   found	   between	   mutants	   and	   wildtypes	   (Fig.	   4.10J;	   controls	   58	   branchpoints	   ±	   3.2	  versus	  mutants	  49	  ±	  5.5).	  These	  results	  suggested	  that	  HSPGs	  produced	  by	  neural	  cells	  are	  not	   required	   for	   sprouting	   angiogenesis	   in	   the	   hindbrain.	   The	   possibility	   remains	   that	  HSPGs	   produced	   by	   pericytes	   could	   be	   rescuing	   the	   blood	   vessel	   branching	   phenotype	  when	  endothelial	  or	  neural	  HSPGs	  are	  lost.	  	  
4.2.1.8	   Mice	   lacking	   HSPGs	   in	   endothelial	   cells	   and	   neural	   progenitors	   exhibit	   embryonic	  




Figure 4.9: Vessel branching is not affected in the absence of HSPGs in the endothelium.  
Immunolabelling E11.5 hindbrains with 10E4 and IB4 allowed visualisation of the vasculature 
and localisation of HSPGs. In wildtype hindbrains (A), HSPGs are present on the endothelium 
and in the neural progenitor cell layer. HSPGs were not present on the endothelium of 
Ext;Tie2Cre mutant hindbrains, but were still present in the neural progenitor cell layer (B). 
Immunolabelling E12.5 hindbrains with PECAM allowed quantification of vessel branchpoints in 
wildtype (C) and Ext;Tie2Cre mutants (D). No difference in number of branchpoints was 
observed in mutants (n=3) compared to wildtype (E; n=4). Scale bars: A,B – 100µm; C,D – 
100µm.  	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Figure 4.10: Embryos lacking neural-specific HSPGs have severe morphological defects 
but normal vascular branching.  
E12.5 embryos lacking neural progenitor-derived EXT exhibit many morphological defects, 
including malformed brains that protrude from the head, syndactyly and small tails, compared to 
wildtype (A,B). Dissected hindbrains (C-F) and cervical spinal cords (G,H) were immunolabelled 
with PECAM to visualise the vasculature. Hindbrains in Ext;Nes8Cre mutants were truncated 
(red brackets in C compared with D) with no clear midbrain/hindbrain boundary, resulting in 
altered vessel morphology. Quantification of vessel branching in control and Ext;Nes8Cre 
mutant hindbrains (E,F) and spinal cords (G,H) revealed no significant difference (n=3 each). 
Scale bars: A,B – 1mm; C,D – 500µm; E,H – 100µm.  	  
 137	  
4.2.2	  HSPGs	  in	  VEGF164-­driven	  facial	  branchiomotor	  neuron	  migration	  
4.2.2.1	   Cytoplasmic	   domain	   of	   NRP1	   is	   not	   essential	   for	   VEGF164-­driven	   FBM	   neuronal	  
migration	  In	   most	   SEMA-­‐activated	   NRP1	   signalling	   pathways,	   a	   co-­‐receptor	   is	   required	   for	   signal	  transduction	  (Feiner	  et	  al.,	  1997;	  Schwarz	  et	  al.,	  2008b;	  Takahashi	  et	  al.,	  1999).	  In	  analogy,	  a	  co-­‐receptor	  is	  thought	  to	  be	  used	  for	  VEGF164/NRP1	  signalling.	  However,	  unpublished	  observations	   suggest	   that	   VEGF164/NRP1-­‐mediated	   migration	   of	   FBM	   somata	   in	   the	  hindbrain	   does	   not	   essentially	   require	   plexins	   or	   either	   of	   the	   VEGF	   tyrosine	   kinase	  receptors	   (Q.	   Schwarz	   &	   C.	   Ruhrberg,	   unpublished	   data).	   Quenten	   Schwarz	   therefore	  generated	  a	  mouse	  that	  retains	  the	  transmembrane	  and	  ligand-­‐binding	  domains	  of	  NRP1,	  whilst	   the	   cytoplasmic	   domain	   is	   abolished	   (hereafter	   referred	   to	   as	   Nrpcyto	  mutant),	   to	  investigate	  if	  the	  intracellular	  domain	  of	  NRP1	  itself	  could	  transduce	  signals.	  




Figure 4.11: The cytoplasmic domain of NRP1 is not required for FBM somata migration.  
In situ hybridisation with Isl1 probe to visualise migrating FBM neuronal cell bodies in hindbrains 
from E12.5 wildtype, Nrp2-null, NrpCyto-null or compound NrpCyto/Nrp2-null embryos. FBM 
somata migrated in two streams on either side of the midline at r4 on ventricular side (A) to form 
facial nuclei at r6 on pial side (B) of hindbrains in wildtype embryos (A,B; n=7). No defects in 
FBM somata migration were observed in NrpCyto mutants (C,D; n=2). Nrp2-null mutants (E,F; 
n=5) had variable migration defects with a few somata segregated from the migratory stream. 
The compound NrpCyto/Nrp2-null mutant (G,H; n=1) phenocopied the Nrp2-null mutants. 
Hindbrains viewed from the ventricular side (v) and the pial side (p). Scale bar: 200µm.  	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4.2.2.2	  6-­O-­sulphated	  HSPGs	  are	  involved	  in	  VEGF164-­driven	  FBM	  neuronal	  migration	  HSPGs	  have	  been	  proposed	  to	  act	  as	  co-­‐receptors	  for	  VEGF164	  to	  facilitate	  binding	  to	  its	  tyrosine	  kinase	  receptors	  and	  NRP1	  in	  vascular	  development	  (for	  example	  (Gitay-­‐Goren	  et	  al.,	   1992)),	   but	   not	   for	   signal	   transduction.	   I	   therefore	   asked	   if	   HSPGs	   could	   act	   as	   co-­‐receptors	  for	  VEGF164/NRP1	  signalling	  in	  FBM	  soma	  migration	  in	  the	  hindbrain.	  Initially,	  I	  assessed	  whether	  6-­‐O-­‐sulphated	  HSPGs	  are	  required	  for	  this	  migration,	  since	  they	  have	  been	  implicated	  in	  VEGF164	  signalling	  in	  the	  vasculature	  of	  zebrafish	  (Chen	  et	  al.,	  2005).	  Quenten	  Schwarz	  previously	   showed	   that	   there	  was	  no	  migration	  defect	   in	  mice	   lacking	  HS6ST1	   (Q.	   Schwarz	  &	   C.	   Ruhrberg,	   unpublished	   data).	   I	   analysed	  mice	   lacking	  HS6ST2	  using	   Isl1	   in	   situ	   hybridisation	   and	   found	   that	   FBM	   somata	   in	   Hs6st2-­‐null	   embryos	  underwent	  normal	   tangential	  migration,	   and	   formed	   rounded	   facial	  motor	  nuclei	   on	   the	  pial	  side	  of	   the	  hindbrain	  (Fig.	  4.12C,D),	  as	   in	  wildtype	  (Fig.	  4.12A,B).	  To	  assess	  whether	  there	  was	  compensation	  between	  the	  6-­‐O-­‐sulphotransferases,	  I	  next	  analysed	  FBM	  somata	  migration	  in	  mice	  lacking	  both	  HS6ST1	  and	  HS6ST2.	  In	  7/7	  compound	  Hs6st1/Hs6st2-­‐null	  mutants	  analysed,	  a	  developmental	  delay	  was	  observed,	  consistent	  with	  previous	  findings	  (Figs.	  4.7	  and	  4.8),	  and	  the	  hindbrains	  appeared	  thinner	  compared	  to	  single	  mutants	  and	  controls	   (not	   shown).	   I	   found	   defects	   in	   FBM	   somata	   migration	   in	   compound	  
Hs6st1/Hs6st2-­‐null	   mutants,	   but	   the	   phenotype	   was	   variable	   (Fig.	   4.13).	   2/7	   had	   no	  defects	  in	  FBM	  soma	  migration	  (Fig.	  4.13C,D).	  4/7	  had	  mild	  migration	  defects,	  with	  ectopic	  migratory	  FBM	  neurons	   (Fig.	  4.13E)	  or	   separation	  of	  FBM	  neurons	   into	  distinct	   streams	  (Fig.	   4.13G),	   similar	   to	   but	   less	   severe	   than	  Nrp1	   (Schwarz	   et	   al.,	   2004)	   and	   Vegf120/120	  mutants	  (Fig.	  1.9B-­‐E).	  Both	  of	  these	  types	  of	  defects	  resulted	  in	  misshapen	  facial	  nuclei	  on	  the	  pial	  side	  (Fig.	  4.13F,H).	  1/7	  had	  severe	  migration	  defects;	  FBM	  neurons	  were	  born	  in	  incorrect	  locations,	  migrated	  randomly	  and	  crossed	  at	  the	  midline	  instead	  of	  remaining	  in	  distinct	  bilateral	  populations	  (Fig.	  4.13I).	  This	  resulted	  in	  severely	  misshapen	  facial	  nuclei	  (Fig.	   4.13J).	   These	   hindbrains	   also	   had	   severe	   morphological	   defects,	   and	   rhombomere	  boundaries	  were	  disrupted	  (Fig.	  4.13I,J).	  Prior	  to	  dissection,	  I	  noticed	  that	  this	  embryo	  had	  head	  malformations	  resembling	  the	  E12.5	  Ext;Nes8Cre	  mutants	  (not	  shown).	  Therefore,	  it	  is	  not	   clear	   if	   the	  observed	  FBM	  migration	  defects	  were	  a	  direct	   consequence	  of	   altered	  VEGF164/NRP1	  signalling,	  or	  an	  indirect	  consequence	  of	  abnormal	  brain	  architecture.	  	  
4.2.2.3	  2-­O-­sulphated	  HSPGs	  are	  required	  for	  VEGF164-­driven	  FBM	  neuronal	  migration	  Because	   Hs2st	   is	   expressed	   in	   r4	   of	   the	   E10.5	   hindbrain,	   at	   the	   site	   of	   origin	   of	   FBM	  neurons	   (J.	   Vieira	   &	   C.	   Ruhrberg),	   I	   next	   assessed	   whether	   2-­‐O-­‐sulphated	   HSPGs	   are	  required	   by	   migrating	   FBM	   neurons.	   Isl1	   in	   situ	   hybridisation	   revealed	   a	   prominent	  migration	   defect	   in	   Hs2st-­‐null	   embryos	   at	   E12.5	   (Fig.	   4.14C,D).	   Migrating	   FBM	   somata	  separated	  into	  two	  distinct	  streams	  (Fig.	  4.14C),	  resulting	  in	  misshapen	  facial	  motor	  nuclei	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forming	   at	   r6	   (Fig.	   4.14D)	   instead	   of	   rounded	   nuclei	   as	   in	   wildtype	   (Fig.	   4.14B).	   The	  distance	   between	   the	   trigeminal	   nuclei	   and	   the	   facial	   nuclei	  was	   significantly	   shorter	   in	  these	  mutants	   (brackets	   in	   Fig.	   4.14B,D;	  wildtype	  633µm	  ±	  4.7	   versus	  mutant	   485µm	  ±	  10.1,	   P	   =	   0.007),	   as	   reported	   for	   mice	   lacking	   VEGF164	   (Schwarz	   et	   al.,	   2004).	   The	  phenotype	  was	  maintained	  at	  E14.5	   in	  Hs2st-­‐null	  embryos,	  when	  one	  of	   the	   facial	  motor	  nuclei	   was	   substantially	   smaller	   than	   in	   wildtype,	   and	   the	   other	   more	   dispersed	   and	  misshapen	   compared	   to	   wildtype	   (Fig.	   4.14E,F).	   Facial	   nuclei	   in	   control	   hindbrains	  increase	   in	   size	   from	  E12.5	   to	  E14.5	   (Fig.	   4.14B,E).	  At	  E14.5,	  mutants	  had	   smaller	   facial	  nuclei	   compared	   to	   mutants	   at	   E12.5,	   which	   have	   large	   misshapen	   facial	   nuclei	   (Fig.	  4.14D,F),	   raising	   the	   possibility	   that	   FBM	   neuronal	   cell	   bodies	   that	   are	   ectopically	  positioned	   at	   E12.5	   may	   be	   lost	   by	   apoptosis	   rather	   than	   form	   the	   facial	   nuclei.	   The	  phenotypes	   in	   these	   Hs2st-­‐null	   mice	   at	   E12.5	   and	   E14.5	   are	   consistent	   with	   those	  described	   for	  mice	   lacking	  NRP1	  or	  VEGF164	  (Fig.	  1.9B-­‐E)	   (Schwarz	  et	  al.,	  2004).	  Taken	  together,	  these	  results	  are	  indicative	  of	  an	  essential	  requirement	  for	  2-­‐O-­‐sulphated	  HSPGs	  in	  VEGF164-­‐driven	  FBM	  neuron	  migration.	  	  





Figure 4.12: FBM somata migrate normally in the absence of HS6ST2.  
In situ hybridisation with Isl1 probe to visualise migrating FBM neuronal cell bodies in hindbrains 
from E12.5 wildtype (A,B) and Hs6st2-null mutant (C,D) embryos. FBM neuronal cell bodies in 
4/4 mutant hindbrains migrated in single streams (C) to form correctly shaped facial nuclei (D), 




Figure 4.13: FBM somata migration is affected with varying penetrance when both 
HS6ST1 and HS6ST2 are lost.  
In situ hybridisation with Isl1 probe to visualise migrating FBM neuronal cell bodies in E12.75 
hindbrains from wildtype (A,B) and four compound Hs6st1/Hs6st2-null mutant (C-J) embryos 
with varying phenotypes. FBM somata in wildtypes had mostly migrated from r4 on ventricular 
side (A), and had formed facial nuclei at r6 on pial side (B) of the hindbrain. 2/7 had normal 
FBM neuron migration (C,D), 4/7 had mild defects in FBM soma migration, such as misplaced 
clusters of neurons (arrowhead in E) or duplicate streams of cell bodies (arrow in G). Only 1/7 
had severe defects in FBM soma migration, including crossing at the midline (I) and misshapen 




Figure 4.14: Defects in FBM soma migration in the absence of HS2ST.  
In situ hybridisation with Isl1 probe to highlight migratory FBM neuronal cell bodies in E12.5 
wildtype (A,B) and Hs2st-null (C,D) embryos. FBM cell bodies in 3/3 mutants were misguided 
(C) and formed multiple facial nuclei (D). Distances between trigeminal nuclei (Vn) and facial 
nuclei (VIIn) were shorter in 3/3 mutants compared to wildtype (compare brackets in B and D; * 
P > 0.05 in a 2-tailed paired t-test). At E14.5, 3/4 Hs2st-null mutants displayed misshapen 




Figure 4.15: Loss of Syndecan4 does not affect FBM neuron migration.  
In situ hybridisation with Isl1 probe to visualise migrating FBM somata in E12.5 wildtype (A,B) 
and Syndecan4-null mutant (C,D). FBM neuronal cell bodies in mutants migrated normally (C) 
and formed rounded facial nuclei (D; n=2), as in wildtype (B; n=2). v, ventricular side; p, pial 





As	   I	  discussed	   in	  Chapter	  1.2,	   substantial	   in	  vitro	   evidence	   for	  HSPGs	  acting	   in	  VEGF164	  signalling	  exists,	  but	  there	  remains	  a	  distinct	   lack	  of	   in	  vivo	  evidence.	   I	  have	  investigated	  whether	  specific	  HS	  chain	  patterns	  are	  required	  for	  VEGF164-­‐driven	  vascular	  or	  neuronal	  patterning	  using	  mice	  lacking	  specific	  HSPG-­‐modifying	  enzymes.	  	  The	  microarray	  analysis	  showed	  that	  Vegfa	  expression	  was	  high	  in	  the	  hindbrain	  (Fig.	  4.2),	  in	   accordance	  with	   its	   roles	   in	   vascular	   and	  neuronal	   patterning	   (Ruhrberg	   et	   al.,	   2002;	  Schwarz	  et	  al.,	  2004).	  Consistent	  with	  the	  possibility	  that	  HSPGs	  are	  involved	  in	  hindbrain	  development,	  most	  HSPG	  core	  proteins	  and	  their	  biosynthetic	  enzymes	  were	  expressed	  in	  the	   hindbrain	   at	   E11.5	   (Fig.	   4.2).	  Ndst1	   and	  Hsepi	  were	   expressed	   at	   a	   high	   level	   in	   the	  hindbrain	  and	  have	  been	  previously	  studied.	  Mice	  lacking	  NDST1	  have	  structurally	  altered	  HS	   chains	   with	   reductions	   in	   N-­‐sulphation,	   epimerisation,	   2-­‐O-­‐sulphation	   and	   6-­‐O-­‐sulphation	  (Abramsson	  et	  al.,	  2007),	  however	  my	  examination	  of	  the	  published	  images	  of	  pericyte	  recruitment	  in	  these	  mice	  revealed	  no	  apparent	  reduction	  in	  hindbrain	  vascular	  branching.	   In	   the	   same	   study,	  mice	   lacking	  C5-­‐epimerase	  had	   reduced	  HS	   epimerisation	  and	  2-­‐O-­‐sulphation	  but	   increased	  6-­‐O-­‐sulphation	   (Abramsson	   et	   al.,	   2007),	   but	   again	  no	  obvious	   reduction	   in	   vascular	   branching.	  Ndst2	   was	   also	   expressed	   at	   a	   high	   level,	   but	  
Ndst2-­‐null	  mice	  have	  no	  embryonic	  growth	  defects	  or	  structural	  HS	  defects	   (Forsberg	  et	  al.,	   1999),	   so	   are	   unlikely	   to	   have	   VEGF164	   signalling	   defects.	   Whether	   other	   HSPG	  modifying	  enzymes,	  such	  as	  EXT1,	  EXT2,	  HS2ST,	  HS6ST1	  or	  HS6ST2,	  function	  in	  VEGF164	  signalling	  in	  vivo	  had	  not	  been	  investigated	  prior	  to	  this	  study.	  	  2-­‐O-­‐sulphated	   HS	   is	   essential	   for	   VEGF164-­‐driven	   migration	   of	   the	   FBM	   neurons	   (Fig.	  4.14),	   and	   6-­‐O-­‐sulphated	   HS	   is	   also	   involved	   (Fig.	   4.13).	   The	   fine	   structure	   of	   HS	   is	  therefore	   important	   for	   VEGF164	   signalling	   through	   neuronal	   NRP1	   in	   FBM	   neuronal	  patterning.	   2-­‐O-­‐sulphation	   of	   HS,	   along	   with	   N-­sulphation,	   forms	   the	   modification	  backbone	   upon	   which	   6-­‐O-­‐	   and	   3-­‐O-­‐sulphation	   then	   occurs	   (Gallagher,	   2001)	   and	   2-­‐O-­‐sulphated	   HS	   chains	   are	   a	   component	   of	   all	   HSPGs.	   It	   might	   be	   apprehended	   that	   2-­‐O-­‐sulphation	  would	  be	  essential	  in	  the	  signalling	  of	  HS-­‐binding	  growth	  factors,	  whereas	  the	  less	   common	   6-­‐O-­‐sulphation	   would	   be	   non-­‐essentially	   required.	   However	   previous	  observations	   in	   embryos	   lacking	   HS2ST	   state	   that,	   despite	   defects	   in	   kidney	  morphogenesis,	   the	   CNS	   and	   the	   skeleton,	   the	   PNS	   and	   cardiovascular	   system	   develop	  normally,	  and	   it	  was	   therefore	  suggested	  that	  N-­	  and	  6-­‐O-­‐sulphation	  compensate	  (Merry	  and	  Wilson,	  2002).	  Further	  investigation	  is	  needed	  to	  elucidate	  whether	  the	  2-­‐O-­‐	  and	  6-­‐O-­‐sulphated	  HSPGs	  are	  required	  as	  VEGF164	  co-­‐receptors	  for	  NRP1	  on	  the	  FBM	  neurons	  or	  to	  retain	  VEGF164	  in	  the	  environment	  and	  present	   it	   to	   its	  receptors.	  Disruption	  of	  FBM	  somata	  migration	  in	  mice	  lacking	  HSPGs	  specifically	  in	  motor	  neurons	  would	  demonstrate	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that	   HSPGs	   are	   required	   as	   co-­‐receptors.	   However,	   there	   is	   currently	   no	   genetic	  mouse	  model	  that	  is	  sufficient	  to	  study	  this	  question.	  	  In	   contrast,	  HS2ST	  and	  HS6ST1	   (J.	   Vieira	  &	  C.	  Ruhrberg,	   unpublished	  data)	   and	  HS6ST2	  (Fig.	   4.4)	   were	   not	   essential	   for	   VEGF164-­‐driven	   sprouting	   angiogenesis	   in	   the	  subventricular	  vessel	  plexus.	  This	  corroborates	  with	  observations	  in	  mice	  lacking	  NDST1	  and	  C5-­‐epimerase	  (Abramsson	  et	  al.,	  2007),	  and	  suggests	   that	   the	   fine	  structure	  of	  HS	   is	  not	   important	   in	   this	   VEGF164	   signalling	   pathway.	   Moreover,	   functional	   compensation	  between	  HS6ST1	  and	  HS6ST2	  does	  not	  occur	  to	  rescue	  vessel	  branching	  (Figs.	  4.6	  and	  4.7)	  and	   Hs6st3	   is	   not	   upregulated	   to	   compensate	   (Fig.	   4.3).	   The	   reason	   for	   the	   difference	  between	   the	   requirement	   for	   HSPGs	   in	   VEGF164	   signalling	   in	   vascular	   and	   neuronal	  patterning	   may	   lie	   with	   the	   receptors.	   VEGFR1	   and	   VEGFR2	   tyrosine	   kinases	   act	   in	  VEGF164-­‐driven	  vascular	  patterning	  and	  not	  in	  FBM	  neuronal	  patterning	  (Q.	  Schwarz	  &	  C.	  Ruhrberg,	  unpublished	  data).	  NRP1	  is	  required	  in	  both	  cases:	  as	  a	  co-­‐receptor	  for	  VEGFR2	  in	   VEGF164-­‐driven	   angiogenesis,	   and	   as	   a	   VEGF164-­‐binding	   receptor	   in	   FBM	   neuronal	  migration.	  Since	  the	  cytoplasmic	  domain	  of	  NRP1	  is	  not	  required	  (Fig.	  4.11),	  an	  unknown,	  but	  probably	  HS-­‐binding,	   co-­‐receptor	   is	   required	   for	   signal	   transduction	   in	   FBM	  neuron	  migration.	  	  As	  previously	  described,	  the	  Lexicon	  Pharmaceuticals	  Hs6st2	  mutant	  mouse	  still	  produced	  a	   low	   level	   of	   Hs6st2	   mRNA	   (Fig.	   4.3).	   This	   may	   account	   for	   the	   discrepancies	   in	   the	  analysis	  of	  vessel	  branching	  between	  this	  and	   the	  Hs6st2	  mutant	  mouse	   from	  Japan	   that	  was	  used	  for	  preliminary	  studies	  (J.	  Vieira	  &	  C.	  Ruhrberg,	  unpublished	  data).	  I	  found	  that	  mice	   lacking	   HS6ST1	   and	   HS6ST2	   had	   a	   developmental	   delay	   of	   0.25	   days,	   and	   mice	  lacking	   only	   HS6ST2	  were	   also	   slightly	   delayed.	   The	   delay	  would	   have	   been	   difficult	   to	  assess	  in	  the	  preliminary	  experiments	  since	  only	  the	  heads	  of	  the	  embryos	  were	  sent	  from	  Japan	  and	  staging	  according	  to	  limb	  development	  was	  not	  possible.	  The	  decrease	  in	  vessel	  branching	  in	  E12.5	  mice	  lacking	  HS6ST2	  previously	  (J.	  Vieira	  &	  C.	  Ruhrberg,	  unpublished	  data)	  and	  the	  non-­‐significant	  decrease	  I	  found	  (Fig.	  4.4)	  could	  therefore	  be	  due	  to	  a	  small	  developmental	   delay.	   At	   E12.75,	   vascular	   remodelling	   occurs	   in	   the	   hindbrain,	   which	  could	   account	   for	   the	   slightly	   increased	   branching	   in	   the	   delayed	   HS6ST1/HS6ST2	  embryos	   compared	   to	   control	   hindbrains.	   This	   would	   require	   further	   investigation	   in	  wildtype	   animals	   by	   performing	   a	   time-­‐course	   of	   subventricular	   vessel	   remodelling.	   On	  the	  other	  hand,	  the	  developmental	  delay	  and	  the	  striking	  oedema	  in	  mice	  lacking	  HS6ST1	  and	  HS6ST2	  suggest	   that	   the	  Lexicon	  Hs6st2	  knockout	   is	  at	   least	  a	  severe	  and	   functional	  knockdown.	  	  My	   findings	   indicate	   that	  HS	  produced	   in	  endothelial	   cells	  or	  neural	  progenitors	  are	  not	  essential	  for	  VEGF164-­‐driven	  sprouting	  angiogenesis	  in	  the	  brain	  (Figs.	  4.9	  and	  4.10).	  The	  efficiency	   of	   the	   tissue-­‐specific	   HSPG	   knockouts	   was	   verified,	   so	   the	   lack	   of	   phenotype	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cannot	  be	  explained	  by	  inefficient	  knockdown.	  However,	  functional	  compensation	  of	  HSPG	  production	   between	   the	   two	   cell	   types	   could	   not	   be	   addressed,	   as	   the	   double	  endothelial/neural	   CRE	   knockout	   was	   embryonic	   lethal	   for	   reasons	   that	   are	   not	   yet	  understood.	   Alternatively,	   the	   lack	   of	   vascular	   defects	   may	   be	   due	   to	   pericyte	   derived	  HSPGs.	  Pericytes	  can	  produce	  cell-­‐surface	  HS	  that	  act	  in	  trans	  through	  VEGFR2	  to	  mediate	  VEGF164-­‐driven	  angiogenesis	  (Jakobsson	  et	  al.,	  2006),	  and	  HSPGs	  are	  required	  for	  proper	  pericyte	  recruitment	  and	  coverage	  of	  new	  vessels	  (Abramsson	  et	  al.,	  2007).	  A	  recent	  study	  showed	   that	   abolishing	   HSPG	   production	   specifically	   in	   pericytes	   does	   not	   lead	   to	   a	  reduction	   in	  vessel	  branching	   in	   the	  CNS,	  but	   that	  pericyte	  recruitment	   is	  affected	   in	   the	  peripheral	  vasculature	  of	  the	  skin	  that	  leads	  to	  increased	  regression	  of	  vessels	  (Stenzel	  et	  al.,	   2009).	   It	   is	   therefore	   unlikely	   that	   pericytes	   produce	   HSPGs	   that	   are	   required	   for	  VEGF164-­‐driven	   vessel	   sprouting	   in	   vivo,	   but	   this	   could	   be	   further	   investigated	   by	  implementation	   of	   a	   double	   pericyte/endothelial	   HSPG	   knockout,	   for	   example	   using	  
Pdgfrb-­Cre	  (Foo	  et	  al.,	  2006).	  Perhaps	  HSPGs	  need	  to	  be	  ablated	  from	  all	  cell	  types	  in	  the	  brain	  to	  produce	  an	  angiogenesis	  defect.	  Alternatively,	  HSPGs	  are	  simply	  not	  required	  for	  VEGF-­‐A	  driven	  developmental	  angiogenesis.	  	  Vessels	   in	   the	   hindbrains	   of	   mice	   lacking	   HS-­‐binding	   VEGF164	   are	   markedly	   less	  branched,	  larger	  in	  diameter	  and	  have	  bulbous	  vessel	  endings	  (Ruhrberg	  et	  al.,	  2002).	  This	  is	  caused	  by	  loss	  of	  the	  VEGF-­‐A	  gradient,	  which	  is	  normally	  created	  by	  retention	  of	  VEGF	  isoforms	  by	  matrix	  components.	  Although	  VEGF164	  binds	  HS	  (Houck	  et	  al.,	  1992),	   it	  has	  never	   been	   conclusively	   proven	   that	   HSPGs	   are	   the	   molecules	   that	   bind	   VEGF164	   and	  retain	   it	   in	   gradients	   in	   vivo.	   None	   of	   the	   HSPG	   enzyme	   knockout	   mice	   I	   analysed	   had	  phenotypes	   resembling	   the	   vasculature	   when	   heparin-­‐binding	   VEGF-­‐A	   is	   lost,	   which	  implies	  that	  either	  the	  loss	  of	  HSPGs	  is	  compensated	  for	  by	  another	  matrix	  component,	  or	  that	  HSPGs	  are	  not	  the	  matrix	  component	  required	  for	  the	  VEGF-­‐A	  gradients.	  Embryonic	  stem	  cells	  harvested	  from	  mice	  lacking	  EXT1	  produce	  no	  HS	  but	  exhibit	  a	  stimulated	  level	  of	   chondroitin	   sulphate	   production	   (Lin	   et	   al.,	   2000).	   This	   suggests	   that	   chondroitin	  sulphate,	   another	   glycosaminoglycan	   structurally	   similar	   to	  HS,	  may	   compensate	   for	   the	  loss	  of	  HS.	  A	   family	  of	  chondroitin	  sulphate	  proteoglycans	  called	   lecticans	  are	  one	  of	   the	  main	  components	  of	  the	  ECM	  in	  the	  CNS	  (Yamaguchi,	  2000).	  This	  raises	  the	  possibility	  that	  chondroitin	   sulphate	   proteoglycans	   may	   be	   expressed	   by	   neural	   progenitors	   as	   an	  alternative	   to	   HSPGs	   in	   VEGF164	   retention	   in	   vivo.	   To	   assess	   the	   likelihood	   of	   this	  possibility,	  expression	  studies	  of	  chondroitin	  sulphate-­‐modified	  proteins	  in	  the	  developing	  brain	  could	  be	  carried	  out,	   for	  example	  using	  previously	  described	  antibodies	  (Akatsu	  et	  al.,	   2010).	   An	   example	   of	   a	   suitable	   chondroitin	   sulphate	   proteoglycan	   is	   NG2,	  which	   is	  found	   on	   pericytes	   and	   neural	   progenitor	   subsets	   and	   binds	   a	   wide	   range	   of	   proteins,	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making	  it	  suitable	  for	  a	  role	  in	  VEGF164	  retention	  for	  angiogenesis	  (for	  review	  (Stallcup,	  2002).	  	  Early	   in	   vitro	   research	   into	   VEGF-­‐A	   binding	   to	   its	   receptors	   showed	   that	   iodinated	  VEGF165	  binds	  VEGFR2	  only	   in	   the	  presence	  of	  heparin	  and	  that	  binding	   is	   inhibited	  by	  unlabelled	  VEGF165	  (Tessler	  et	  al.,	  1994).	  Subsequent	  work	  showed	  that	  VEGFR2	  binding	  by	  iodinated	  VEGF121	  was	  competed	  for	  by	  unlabelled	  VEGF165	  in	  the	  absence	  of	  heparin	  (Gitay-­‐Goren	   et	   al.,	   1996).	   The	   authors	   suggested	   that	   iodination	   and	   oxidation	   damage	  VEGF165	   and	   thereby	   change	   its	   VEGFR2-­‐binding	   ability,	   which	   is	   restored	   by	   heparin	  (Neufeld	   et	   al.,	   1999).	   Consistent	   with	   this	   idea,	   glypican1	   binds	   VEGF165	   with	   high	  affinity	   and	   acts	   as	   a	   chaperone	   to	   restore	   the	   VEGFR2-­‐binding	   ability	   of	   oxidised	  VEGF165	   (Gengrinovitch	   et	   al.,	   1999).	   More	   recently,	   it	   was	   shown	   that	   mice	   lacking	  glypican1	  are	  born	  with	  no	  defects	  in	  appearance,	  size	  and	  lifespan,	  suggesting	  no	  defects	  in	   vascular	   development	   (Jen	   et	   al.,	   2009).	   Taken	   together,	   these	   results	   raise	   the	  possibility	   that	   HSPGs	   are	   required	   in	   VEGF165-­‐driven	   angiogenesis	   only	   in	   situations	  when	   VEGF165	   has	   undergone	   oxidative	   stress,	   such	   as	   hypoxia,	   wound	   repair	   or	  inflammation,	  and	  not	  in	  developmental	  angiogenesis.	  	  Despite	   the	   lack	   of	   vascular	   phenotypes,	  mice	  without	   HS6ST1	   and	   HS6ST2	   had	   severe	  oedema	   that	   might	   suggest	   a	   lymphatic	   defect	   (Fig.	   4.8),	   and	   was	   also	   indicative	   of	  knockdown	  of	  HS6ST1	  and	  HS6ST2	  being	  effective.	  The	  oedematous	  bodies	  were	  similar	  to	  those	  of	  mice	  lacking	  VEGF-­‐C,	  which	  have	  apparently	  normal	  blood	  vessel	  development	  (Karkkainen	   et	   al.,	   2004).	   This	   raises	   the	   possibility	   that	   HSPG	   is	   essential	   for	   VEGF-­‐C	  guided	   lymphangiogenesis.	   In	   support	   of	   this	   idea,	   VEGF-­‐C	   binds	   to	   NRP1	   and	   NRP2	   in	  
vitro	  in	  an	  interaction	  that	  is	  enhanced	  by	  the	  presence	  of	  heparin	  (Karpanen	  et	  al.,	  2006).	  
In	  vivo,	  NRP2	  and	  VEGFR3	  interact	  to	  mediate	  the	  VEGF-­‐C	  signalling	  required	  for	  the	  initial	  steps	  in	  lymphatic	  vascular	  development	  (Xu	  et	  al.,	  2010).	  In	  zebrafish,	  lymphangioblasts	  derive	  from	  caudal	  vein	  endothelial	  cells	  and	  bud	  off	  to	  form	  lymphatic	  vessels	  (Hogan	  et	  al.,	   2009).	   The	   disorganisation	   in	   the	   caudal	   vein	   of	   the	   zebrafish	   injected	   with	  Hs6st2	  morpholino	  (Chen	  et	  al.,	  2005)	  might	  also	  be	  due	  to	  lymphangioblasts	  not	  budding	  off	  to	  form	   lymphatic	  vessels	   and	  causing	  oedema	  as	  opposed	   to	  blood	  vasculature	  defects,	   as	  suggested.	  Alternatively,	   the	  oedema	  could	  be	   secondary	   to	   vascular	   stability	  defects,	   as	  previously	   observed	   when	   HSPG	   production	   was	   abolished	   in	   pericytes	   (Stenzel	   et	   al.,	  2009).	   To	   address	  whether	   pericytes	   are	   affected	   in	  mice	   lacking	   HS6ST1	   and	   HS6ST2,	  pericyte	   coverage	   in	   the	   hindbrain	   vasculature	   at	   E12.5	   could	   be	   assessed	   using	  immunolabelling	   with	   a	   pericyte	  marker	   and	   IB4.	   Investigation	   into	   whether	   lymphatic	  structure	  is	  affected	  in	  the	  mice	  lacking	  HS6ST1	  and	  HS6ST2	  is	  also	  required,	  which	  could	  be	  attempted	  by	  immunolabelling	  for	  lymphatic	  markers	  such	  as	  PROX-­‐1	  or	  LYV-­‐1.	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Genes	  expressed	  at	  high	  levels	  in	  the	  microarray	  may	  be	  suitable	  candidates	  for	  the	  HSPG	  involved	   in	   neural	   patterning	   in	   the	   hindbrain.	   I	   have	   shown	   that	   syndecan4	   is	   not	  involved	  in	  VEGF164-­‐driven	  FBM	  neuronal	  migration	  (Fig.	  4.15),	  but	  there	  are	  many	  other	  candidates	   (Fig.	   4.2).	  Of	   these,	   glypican-­‐2	   is	   known	   for	   its	   expression	  on	   the	  developing	  axons	   and	   growth	   cones	   (Ivins	   et	   al.,	   1997),	   which	   explains	   its	   high	   expression	   in	   the	  hindbrain	  but	  provides	  no	  specific	  evidence	  for	  NRP1	  or	  VEGF164	  interaction.	  Agrin,	  also	  expressed	  at	  high	  levels	  in	  the	  developing	  hindbrain,	  is	  required	  for	  synaptogenesis	  in	  the	  CNS	  (Hilgenberg	  et	  al.,	  2002;	  Smith	  and	  Hilgenberg,	  2002).	  Recently,	  perlecan	  was	  found	  to	   bind	   NRP1	   (Muthusamy	   et	   al.,	   2010)	   and	   had	   been	   implicated	   in	   VEGF-­‐A	   guided	  endothelial	  cell	  migration	  and	  proliferation	  (Zoeller	  et	  al.,	  2009).	  Perlecan	  may	  therefore	  be	   an	   ideal	   candidate	   for	   the	   HSPG	   essential	   for	   VEGF164/NRP1	   guided	   FBM	   neuron	  migration,	  and	  examination	  of	  mice	  lacking	  perlecan	  would	  clarify	  this.	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5.	  FINAL	  CONCLUSIONS	  AND	  FUTURE	  WORK	  
5.1	  Neuropilins	  in	  the	  developing	  sympathetic	  nervous	  system	  In	   the	  work	  described	   in	  Chapter	  3,	   I	   investigated	  how	  NRP1	  and	  NRP2	  and	   their	  SEMA	  ligands	   control	   the	   early	   steps	   in	   the	   development	   of	   the	   sympathetic	   nervous	   system	  from	  sympathetic	  NCCs	  in	  the	  mouse.	  I	  found	  that	  the	  previously	  described	  disruption	  of	  the	   sympathetic	   nervous	   system	  when	  NRP1	   signalling	   is	   lost	   is	   in	   fact	   due	   to	   defective	  sympathetic	  NCC	  migration	  and	  aggregation	  at	  the	  dorsal	  aorta.	  My	  findings	  are	  consistent	  with	  early	  in	  vitro	  work	  (Eickholt	  et	  al.,	  1999),	  but	  contrast	  with	  the	  study	  that	  described	  the	  sympathetic	  nervous	  system	  phenotype	  in	  Nrp1-­‐null	  mice	  (Kawasaki	  et	  al.,	  2002).	  The	  abnormal	  migration	  of	  NCCs	  results	  in	  ectopically	  placed	  sympathetic	  precursors,	  the	  fate	  of	   which	   is	   unaffected	   since	   they	   are	   able	   to	   differentiate	   into	   sympathetic	   neurons,	  presumably	   supported	   by	   expression	   of	   survival	   factors	   in	   their	   abnormal	   location.	   I	  further	   showed	   that	   the	   defects	   in	   Nrp1-­‐deficient	   mice	   are	   independent	   of	   vascular	  abnormalities	  and	  are	  NC	  cell	  autonomous.	  	  Consistent	  with	  previous	  work	  showing	  that	  SEMA3F/NRP2	  repels	  sympathetic	  axons	   in	  
vitro	   (Giger	   et	   al.,	   2000),	   my	   findings	   indicate	   that	   NRP2	   signalling	   guides	   sympathetic	  axons	   in	   vivo.	   I	   also	   show	   a	   novel	   ‘back-­‐up’	   role	   for	   NRP2/SEMA3F	   signalling	   in	  sympathetic	  NCC	  migration	  when	  NRP1	   signalling	   is	   lost.	   Future	  work	   on	   expression	   of	  NRP1	  and	  NRP2	   in	  ectopic	  NCCs	  would	  answer	  questions	  on	  the	  mechanism	  behind	  this	  suggestion.	  For	  example,	  is	  NRP2	  switched	  on	  in	  a	  subset	  of	  NCCs	  in	  the	  absence	  of	  NRP1?	  Or	  is	  NRP2	  is	  expressed	  at	  a	  low	  level	  in	  a	  subset	  of	  NCCs	  which	  are	  unaffected	  when	  NRP1	  is	  lost?	  It	  would	  also	  be	  interesting	  to	  carry	  out	  sympathetic	  NCC	  migration	  studies	  in	  the	  SEMA	  ligand	  knockout	  mice,	  since	  there	  is	  a	  possibility	  that	  SEMA3A	  may	  signal	  through	  NRP2	  in	  the	  absence	  of	  NRP1.	  If	  this	  were	  the	  case,	  then	  removal	  of	  SEMA3A	  would	  result	  in	  a	  more	  severe	  sympathetic	  NCC	  migration	  phenotype	  than	  removal	  of	  NRP1.	  	  I	  investigated	  the	  pattern	  of	  sympathetic	  innervation	  in	  postnatal	  mice	  lacking	  NRP1	  in	  the	  NC	  lineage.	  I	  found	  that,	  consistent	  with	  previous	  findings	  in	  mice	  lacking	  SEMA3A	  (Ieda	  et	  al.,	  2007),	  the	  distribution	  of	  sympathetic	  fibres	  in	  the	  cardiac	  wall	  of	  mutants	  is	  altered.	  I	  would	  like	  to	  continue	  with	  ECG	  tracing	  in	  live	  mice	  lacking	  NRP1	  in	  the	  NC	  lineage,	  and	  determine	  whether	   they	   are	   able	   to	   respond	   properly	   to	   situations	   such	   as	   exercise	   or	  other	  stress	  stimuli.	  Further,	  without	  NRP1	  in	  the	  NC	  lineage,	  the	  sympathetic	  innervation	  of	   the	   postnatal	   dorsal	   aorta	   was	   disrupted.	   To	   determine	   whether	   blood	   pressure	   is	  affected,	  studies	  could	  be	  carried	  out	  in	  these	  mutant	  mice	  in	  the	  future.	  I	  would	  also	  like	  to	   investigate	  whether	  SEMA3A/NRP1	  signalling	   is	  a	  specific	  controller	  of	   innervation	  of	  vascular	   sympathetic	   targets	   by	   examining	   innervation	   of	   the	   carotid	   arteries	   versus	  innervation	  of	  the	  trachea	  and	  salivary	  glands	  in	  mice	  lacking	  NRP1	  in	  the	  NC	  lineage.	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Finally,	   I	   confirmed	   that	   SEMA3G	   is	   expressed	   in	  major	   arteries	   during	   development	   as	  previously	  described	  (Kutschera	  et	  al.,	  2011;	  Taniguchi	  et	  al.,	  2005).	  Despite	  this,	  I	  found	  no	   evidence	   that	   SEMA3G	   is	   involved	   in	   sympathetic	   development	   or	   in	   postnatal	  sympathetic	   axon	   guidance	   in	   the	   heart	   or	   dorsal	   aorta.	   The	   lack	   of	   sympathetic	   axon	  guidance	  function	  could	  be	  confirmed	  by	  also	  looking	  at	  the	  carotid	  arteries,	  trachea	  and	  salivary	  glands	  in	  mice	  lacking	  SEMA3G.	  However,	  based	  on	  my	  findings	  and	  that	  SEMA3G	  has	  been	  shown	  to	  act	  on	  smooth	  muscle	  cells	  (Kutschera	  et	  al.,	  2011),	  I	  speculate	  that	  its	  
in	  vivo	  function	  may	  be	  vascular.	  	  
5.2	  HSPGs	  in	  VEGF164-­driven	  vascular	  and	  neuronal	  patterning	  The	  aim	  of	   the	  work	  described	   in	  Chapter	  4	  was	  to	  decipher	   the	  role	   that	  HSPGs	  play	   in	  VEGF164-­‐driven	  vascular	  and	  neuronal	  patterning	  in	  the	  developing	  hindbrain.	  I	  found	  no	  evidence	   that	   endothelial	   or	   neuronal	   HSPGs,	   or	   2-­‐O-­‐	   or	   6-­‐O-­‐sulphated	   HSPGs,	   are	  essential	  for	  VEGF164-­‐driven	  vessel	  branching	  in	  the	  mouse	  hindbrain.	  This	  suggests	  that	  HSPGs	   are	  not	   required	   for	   the	  presentation	  of	  VEGF164	   to	   its	   receptors	   on	   endothelial	  cells	  to	  mediate	  sprouting	  angiogenesis.	  However,	  since	  HSPGs	  produced	  by	  pericytes	  can	  act	   on	   endothelial	   VEGFR2	   in	   trans	   to	   stimulate	   angiogenesis	   (Jakobsson	   et	   al.,	   2006),	   I	  would	   propose	   an	   investigation	   into	   vascular	   branching	   defects	   in	   embryos	   deficient	   in	  endothelial	   and	  pericyte	  HSPGs	  before	   I	   conclude	   that	   they	   are	  not	   absolutely	   essential.	  Since	   HSPG-­‐modifying	   enzymes	   have	   been	   suggested	   to	   compensate	   for	   each	   other,	   it	  would	  also	  be	  an	  idea	  to	  attempt	  a	  triple	  Hs6st1/Hs6st2/Hs2st	  knockout	  to	  assess	  whether	  vascular	  branching	  is	  affected	  in	  the	  absence	  of	  all	  2-­‐O-­‐	  and	  most	  6-­‐O-­‐sulphation.	  	  My	   results	   also	   suggest	   that	   HSPGs	   are	   not	   the	   matrix	   molecules	   essential	   for	   the	  formation	   of	   VEGF-­‐A	   gradients	   in	   the	   ECM	   that	   are	   required	   for	   vessel	   branching,	   since	  none	  of	  the	  mouse	  mutants	  phenocopied	  mice	  lacking	  heparin-­‐binding	  VEGF-­‐A	  (Ruhrberg	  et	   al.,	   2002).	   Chondroitin	   sulphates	   are	   structurally	   similar	   and	   expressed	   in	   the	   ECM	  (Yamaguchi,	  2000),	  and	  therefore	  may	  be	  the	  alternative	  VEGF-­‐A	  binding	  matrix	  molecule	  responsible	   for	  retaining	   it	   in	  the	  ECM.	  In	  the	  microarray,	  neurocan	  and	  versican,	   two	  of	  the	   lectican	   family	   of	   chondroitin	   sulphates,	   were	   expressed	   at	   high	   levels	   in	   the	  hindbrains,	   suggesting	   that	   they	   might	   be	   candidates.	   Future	   investigations	   into	   mice	  lacking	   the	  enzymes	  essential	   for	  chondroitin	  sulphate	  modifications	  would	  add	  support	  to	  this	  suggestion.	  	  In	  stark	  contrast,	  I	  found	  that	  HSPGs	  are	  essential	  for	  VEGF164/NRP1	  guided	  migration	  of	  FBM	   neuronal	   cell	   bodies,	   and	   the	   pattern	   of	   HS	   sulphation	   is	   important.	   Previous	  unpublished	  investigations	  have	  shown	  that	  VEGFR1	  and	  VEGFR2	  are	  not	  involved	  in	  this	  process,	   and	   I	   here	   show	   that	   NRP1	   itself	   does	   not	   signal	   intracellularly	   in	   this	   system.	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